Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
01/2010 | Recent  |  14:  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions January recently filed with US Patent Office 01/10

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
01/28/2010 > patent applications in patent subcategories. recently filed with US Patent Office

20100022438 - Method of separating carbon nanotubes: A method of separating carbon nanotubes having substantially the same diameter including the steps of: providing a sample of carbon nanotubes; separating individual nanotubes within the sample, and mixing with a solution comprising fibrous protein fibrils so that at least some individual nanotubes form a complex with the protein fibrils,... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100022439 - Nanostructures with high load of active agents: The present invention provides an improved method of loading silica nanostructures with an active agent, comprising exposing a mixture comprising a liquid medium containing an active agent and silica nanostructures to reduced air pressure for a time period, and then returning the mixture to atmospheric air pressure at the end... Agent: Patent Docket Administrator Lowenstein Sandler PC

20100022440 - Vh4 codon signature for multiple sclerosis: The present invention provides for the diagnosis and prediction of multiple sclerosis (MS) in subject utilizing a unique a codon signature in VH4 expressing B cells that has now been associated with MS and not with any other autoimmune disease.... Agent: Fulbright & Jaworski L.L.P.

20100022441 - N-terminal polysialylation: The present invention relates to a composition comprising a population of polysaccharide derivatives of a protein, wherein the protein is insulin or an insulin-like protein and the polysaccharide is anionic and comprises between 2 and 125 saccharide units, and wherein the population consists of substantially only N-terminal derivatives of the... Agent: Morrison & Foerster LLP

20100022442 - Compositions and methods for increasing serum antioxidant concentrations, decreasing serum triglyceride levels, inhibiting insulin-receptor signaling activity, increasing serum ghrelin levels, and decreasing serum tnf-alpha levels: Compositions and methods are provided for increasing serum antioxidant levels, decreasing serum levels of oxidative chemical species, inhibiting insulin-receptor signaling activity, decreasing triglycerides levels, increasing serum ghrelin levels, and decreasing serum TNF-alpha levels. Compositions provided comprise a mixture of zinc-charged, fragmented proteins derived, for example, from serum or milk. Compositions... Agent: Knobbe Martens Olson & Bear LLP

20100022444 - Combination therapy for modulation of activity and development of cells and tissues: The invention as disclosed herein provides methods and compositions for modulation of development and activities of cells and tissues in a subject in need of treatment thereof. The inventive methods and compositions involve the use of a combination therapy that comprises at least two active compositions, the first active composition... Agent: Law Offices Of Khalilian Sira, LLC

20100022443 - Derivatisation of erythropoietin (epo): The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the... Agent: Morrison & Foerster LLP

20100022445 - Biologically active peptides: e

20100022447 - Composition for treating cancer and use thereof: The present invention provides a cyclic peptide containing RRXR motif. The present invention also provides a composition comprising the said cyclic peptide and a pharmaceutical acceptable carrier. The present invention further provides a method for treating cancer.... Agent: Wpat, PC Intellectual Property Attorneys

20100022446 - Use of peptides in combination with surgical intervention for the treatment of obesity: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100022450 - Octreotide implant having a release agent: Methods, formulations and kits are described that allow for the controlled release of octreotide, e.g., octreotide acetate, in a subject.... Agent: Foley And Lardner LLP Suite 500

20100022448 - Peptides: An internally-constrained cyclic oligopeptide comprising a ring of at least six amino acids for specifically binding to a target ligand, wherein the ring comprises a plurality of amino acid domains, each domain comprising at least two epitope-forming amino acids, and two or more associating functional groups positioned so that they... Agent: Cermak Kenealy Vaidya & Nakajima LLP

20100022449 - Receptor-avid exogenous optical contrast and therapeutic agents: Cyanine and indocyanine dye compounds and bioconjugates are disclosed. The present invention includes several cyanine and indocyanine dyes, including bioconjugates of the same, with a variety of bis- and tetrakis (carboxylic acid) homologues. The compounds of the invention may be conjugated to bioactive peptides, carbohydrates, hormones, drugs, or other bioactive... Agent: Thompson Hine L.L.P. Intellectual Property Group

20100022456 - Dimeric prolactin receptor ligands: The patent application relates to antagonistic dimers of prolactin molecules and their use in treating cancer.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100022452 - Nanobodies for the treatment of aggregation-mediated disorders: The present invention relates to improved Nanobodies™ against von Willebrand Factor (vWF), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host... Agent: Wolf Greenfield & Sacks, P.C.

20100022453 - Nogo receptor 1 and fibroblast growth factor interactions: Compositions and methods useful in promoting neuronal growth, synaptic transmission, or neuronal regeneration are described, including, for example, a polypeptide comprising a fragment of NgR1, wherein the NgR1 fragment has reduced FGF2 binding as compared to wild-type NgR1. Also described are chimeric polypeptides comprising the NgR1 fragment and compositions comprising... Agent: Fish & Richardson P.C.

20100022454 - Peptides with high affinity for the prolactin receptor: The present invention is concerned with peptides binding to the prolactin receptor, wherein said peptides have an improved binding via binding site 1 (BS1) to the prolactin receptor. In one embodiment, said improved binding is achieved by mutation of positions 61, 71 and 73.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100022455 - Therapeutic agents comprising elastin-like peptides: The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20100022451 - Use of infant formula with reduced protein content: A method of continuously reducing the circulating level of insulin like growth factor 1 (IGF-1) in the first few months of the life of an infant comprises administering to the 5 infant a nutritional composition comprising proteins in an amount such that the composition contains less than 2.25 g of... Agent: K&l Gates LLP

20100022457 - Sustained release glp-1 receptor modulators: The present invention provides novel pharmaceutical compositions comprising a human glucagon-like peptide-1 (GLP-1)-receptor modulator as an active ingredient in a sustained release formulation.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100022458 - Methods for treating acute acoustic trauma: The current invention provides methods and compositions for treating sensorineural hearing loss including but not limited to acute acoustic trauma (AAT). The composition includes compounds which function as free radical traps such as phenyl butyl nitrone (PBN), free radical scavengers, such as edaravone, resveratrol, ebselen and iron chelator and compounds... Agent: Mcafee & Taft Tenth Floor, Two Leadership Square

20100022459 - Peptides directed for diagnosis and treatment of amyloid-associated diseases: Peptides having at least 2 amino acids and no more than 15 amino acids are provided. The peptides comprise amino acid sequence X—Y or Y—X, wherein X is an aromatic amino acid and Y is any amino acid other than glycine. Also provided are pharmaceutical compositions and kits including such... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100022460 - C-phenyl glycitol compound: p

20100022461 - Novel derivatives of cyclic compound and the use thereof: Disclosed is tonovel cyclic derivatives having potent inhibiting effect on melanin formation and skin hyper-pigmentation activity with no adverse response to skin. They can be used as the therapeutics for treating and preventing the skin disease caused by over-reproduced melanin.... Agent: Sughrue Mion, PLLC

20100022462 - Appetite suppressant and colon cleansing composition: The present invention provides low calorie, high potency, sugar free compositions and methods for making and using the same. In one embodiment, the composition of the present invention can be used to reduce daily food intake and facilitate detoxification and weight loss.... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20100022463 - Feed additive for laying hen and feed containing the same: A feed additive for laying hens comprising lactobionic acid or a lactobionic acid salt and a feed characterized by containing a feed additive for laying hens comprising lactobionic acid or a lactobionic acid salt and a feed. Namely, a feed additive for laying hens, which is excellent in effect of... Agent: Sughrue-265550

20100022464 - Functional food composition that is rich in phenolic compounds and use of said composition: The invention relates to a functional food composition rich in phenolic compounds, obtained from the combination of citric and olive species extracts, comprising: between 5 and 25% of oleuropein; between 0.1 and 1% of verbascoside, between 0.1 and 1% of hydroxytyrosol, between 1 and 5% of neohesperidin; between 1 and... Agent: Merchant & Gould PC

20100022465 - Method of treating blepharitis: The present invention relates to a method for treating non-infectious, inflammatory chronic posterior blepharitis in a subject. The present invention also relates to a method for treating chronic posterior blepharitis in a subject for over two weeks. The method comprises identifying a subject in need thereof, and topically administering to... Agent: Howery LLP

20100022466 - Thermally-targeted delivery of medicaments including doxorubicin: Elastin-like polypeptide (ELP) serves as a vector for thermally-targeted delivery of therapeutics, including cytotoxic chemotherapeutic drugs such as doxorubicin. Examples of an ELP-based delivery vehicle can comprise: (1) a cell penetrating peptide, such as a Tat protein, (2) ELP, and (3) the lysosomally degradable glycylphenylalanylleucylglycine (GFLG) spacer and a cysteine... Agent: Stites & Harbison PLLC

20100022619 - Compositions and their uses directed to ptpr alpha: Disclosed herein are compounds, compositions and methods for modulating the expression of PTPR.alpha. in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Also provided are... Agent: Mcdermott Will & Emery

20100022621 - Construction and use of transfection enhancer elements: Nucleic acids comprising a nucleic acid moiety and two or more transfection enhancer elements (TEE's) according to the general formula (I): Hydrophobic moiety—pH-responsive hydrophilic moiety, wherein said pH sensitive hydrophilic moiety of said TEE is independently a weak acid having a pka of between 4 and 6.5 or is a... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20100022622 - Dbait and its standalone uses thereof: The invention relates to compositions and methods for interfering with the DNA repair of double strand breaks (DSBs). The invention discloses double-stranded nucleic acid molecules that act as baits and hijack the holocomplex of enzymes responsible of DNA DSB sensing, signaling and/or repair pathways, in particular the non-homologous end joining... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100022620 - Epitope reduction therapy: The present invention provides the use of an inhibitor of glycolipid biosynthesis in the manufacture of a medicament for the treatment of a glycolipid-mediated autoimmune disease.... Agent: Nixon & Vanderhye, PC

20100022618 - Long interfering nucleic acid duplexes targeting multiple rna targets: Long interfering nucleic acid (iNA) duplexes, which are at least 30 nucleotides in length, which have at least one nick or nucleotide gap in the antisense or the sense strands or in both the sense and antisense strands. These long iNA duplexes do not induce an interferon response when transfected... Agent: Paul G. Lunn

20100022623 - Methods and compositions for the treatment of eye disorders with increased intraocular pressure: The present invention relates to methods and compositions that decrease intraocular pressure (IOP) of the eye. The compositions of the invention comprise short interfering nucleic acid molecules (siNA) including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of... Agent: King & Spalding

20100022624 - Methods of treating smooth muscle cell disorders: The present invention provides methods of detecting cells showing smooth muscle differentiation. The present invention further provides methods of detecting tumor cells. The present invention further provides compositions and methods for treating smooth muscle cell disorders.... Agent: Bozicevic, Field & Francis LLP

20100022625 - Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use: Provided herein is a crystallized ternary structure of aldose reductase (AR) bound to NADPH and γ-glutamyl-S-(1,2-dicarboxyethyl)cysteinylglycine (DCEG). Also provided are specific inhibitors of glutathione-aldehyde binding to aldose reductase which are designed via at least computer modeling of the ternary AR:NADPH:DCEG structure and methods of designing and of screening the inhibitors... Agent: Benjamin Aaron Adler Adler & Associates

20100022628 - Alternative oxidase and uses thereof: The invention relates to a method for combating disorders affecting the mitochondrial oxidative phosphorylation system by allotopic expression of the cyanide-insensitive alternative oxidase (AOX) in human cells. The successful expression of AOX in human cells and in Drosophila has been shown to confer spectacular cyanide-resistance to mitochondrial substrate oxidation, alleviate... Agent: Marshall, Gerstein & Borun LLP

20100022626 - Modulators of cell migration and methods of identifying same: The present invention relates to a method of measuring cell migration, the method comprising (a) contacting a cell with a plurality of polystyrene non-fluorescent beads so as to generate a migratory track; and (b) analyzing at least one morphometric parameter of said migratory track, the morphomotric parameter being indicative of... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100022627 - Predictive biomarkers for chronic allograft nephropathy: The invention relates to the analysis and identification of genes that are modulated in transplant rejection. This alteration of gene expression provides a molecular signature to accurately detect transplant rejection.... Agent: Novartis Corporate Intellectual Property

20100022467 - Anti-cancer phosphonate analogs: The invention is related to phosphorus substituted anti-cancer compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Viksnins Harris & Padys Pllp

20100022468 - Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection: The present invention provides nucleoside cyclic phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as pre-cursors to... Agent: Merck And Co., Inc

20100022469 - Anthelminthic formulations: The present invention relates to veterinary or pharmaceutical antiparasitic formulations which may comprise a macrocyclic lactone, one or more alcohol cosolvents and an oil wherein the crystallization of the macrocyclic lactone is minimalized. This invention also provides for, inter alia, antiparasitic formulations for the treating, controlling and preventing of endo-... Agent: Judy Jarecki-black, Ph.d, J.d. Merial Ltd.

20100022472 - Liquid, eye-instillable preparations comprising sodium hyaluronate: A liquid, eye-instillable preparation comprises a viscosity-enhancing agent comprised of one or both of sodium hyaluronate and chondroitin sulphate, a preservative comprised of polyhexanide, and one or more carriers in which the agent and the preservative are dispersed.... Agent: Calfee Halter & Griswold, LLP

20100022470 - Method for treating allergic diseases: The present invention relates to use of polysaccharides obtained from Dendrobium for treating an allergic disease or for reducing airway-remodeling caused by inflammation.... Agent: Ipc Intellectual Property Connections, Inc.

20100022471 - Oral moisturizer for alleviating dry mouth: An oral moisturizer is disclosed to provide relief from dry mouth. The moisturizer may be provided in different flavors that are palatable, with clinical benefits such as anti-nausea, appetite stimulant, etc., in addition to relief from the deteriorating dental effects of dry mouth. One disclosed oral moisturizer includes glycerin, xylitol,... Agent: Miller, Matthias & Hull

20100022473 - Use of lipid conjugates in the treatment of diseases associated with vasculature: wherein L is a lipid or a phospholipid, Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol, Y is either nothing or a spacer group ranging in length from 2 to 30 atoms, X is a physiologically acceptable monomer, dimer, oligomer, or polymer, wherein X is a glycosaminoglycan; and... Agent: Pearl Cohen Zedek Latzer, LLP

20100022474 - Polymer controlled induced viscosity fiber system and uses thereof: The present invention relates generally to a method of blunting the postprandial glycemic response in a human by feeding an induced viscosity fiber system. The invention also relates to an induced viscosity fiber system and the liquid products that incorporate the induced viscosity fiber system. Further, the invention relates to... Agent: Ross Products Division Of Abbott Laboratories Department 108140-ds/1

20100022475 - Novel triazolopyrimidine derivatives: The present invention relates to novel triazolopyrimidine derivatives of formula I as active ingredients which have microbiocidal activity, in particular fungicidal activity(I): wherein the substituents are as defined in claim 1. Characterizing feature is the cyclic silyl group.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100022476 - Pyrazolylamino substituted quinazoles for the treatment of cancer: The invention provided a compound of formula: (I) for use in the treatment of disease, in particular proliferative diseases such as cancer and for use in the preparation of medicaments for use in the treatment of proliferative diseases; the invention also processes for the preparation of such compounds, as well... Agent: Astrazeneca R&d Boston

20100022477 - Fused aromatic ptp-1b inhibitors: The invention encompasses the novel class of compounds represented by the formula below, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown (Formula I) above and methods of treating or preventing PTP-1B mediated diseases, including diabetes.... Agent: Merck And Co., Inc

20100022478 - Chiral compounds substituted with phosphonate acid ester functions or phosphonic acid functions: The present invention relates to novel compounds that contain PNA units substituted with phosphonic acid ester functions or phosphonic acid functions, and have at least one chiral center. The compounds may be used for the treatment of viral diseases, such as AIDS.... Agent: Frommer Lawrence & Haug

20100022479 - Cellular gradient polymer composites: The invention relates to a foamed polymer composite product incorporating several fillers and/or fibres and several pores characterized by the fact that it shows two distinct gradients, namely a filler and/or fibre density gradient and a pore density gradient. The polymer composite according to the invention may advantageously be used... Agent: Nixon & Vanderhye, PC

20100022480 - Solid oral dosage form containing an enhancer: The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to enhance intestinal delivery of the bisphosphonate to the underlying circulation. Preferably, the enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain... Agent: Myers Bigel Sibley & Sajovec

20100022481 - Drug carriers, their synthesis, and methods of use thereof: Drug carriers, methods of synthesizing, and methods of use thereof are provided.... Agent: Dann, Dorfman, Herrell & Skillman

20100022482 - Asmase inhibitors: u

20100022483 - Substituted tetracycline compounds: The present invention pertains, at least in part, to methods of treating a microorganism-associated infection in a subject comprising administering to said subject an effective amount of a tetracycline compound.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100022484 - 4-chromenonyl-1,4-dihydropyridines and their use: The present application relates to novel 4-chromenonyl-1,4-dihydropyridines, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100022486 - Compounds: e

20100022485 - Formulations comprising a vitamin and the use thereof to make fortified feed and personal care formulations: The invention relates to aqueous formulations comprising alkoxylated castor oils with 15-25 ethyleneoxy units and a vitamin, preferably a fat-soluble vitamin, as well as to the use of such formulations in the process to administer the vitamin to an animal, or to make personal care formulations comprising the vitamin.... Agent: Akzo Nobel Inc.

20100022487 - Method, device, and kit for maintaining physiological levels of steroid hormone in a subject: A method, device, or kit is provided which maintain a substantially physiological cyclic pre-menopausal level of one or more steroid hormones in a mammalian subject in need thereof. The method, device, or kit includes providing to the subject at least one treatment regimen including replacement therapy for the one or... Agent: Searete LLC Clarence T. Tegreene

20100022488 - Method, device, and kit for maintaining physiological levels of steroid hormone in a subject: A method, device, or kit is provided which maintain a substantially physiological cyclic pre-menopausal level of one or more steroid hormones in a mammalian subject in need thereof. The method, device, or kit includes providing to the subject at least one treatment regimen including replacement therapy for the one or... Agent: Searete LLC Clarence T. Tegreene

20100022489 - Method, device, and kit for maintaining physiological levels of steroid hormone in a subject: A method, device, or kit is provided which maintain a substantially physiological level of one or more steroid hormones in a mammalian subject in need thereof. The method, device, or kit includes providing to the subject at least one treatment regimen including replacement therapy for the one or more steroid... Agent: Searete LLC Clarence T. Tegreene

20100022491 - 4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7yl compounds for modulation of b2-adrenoreceptor activity: The present invention provides compounds of formula (I) (A chemical formula should be inserted here—please see paper copy enclosed herewith) wherein Ra, Rb, R1, R2, R3, R4, R5, R6 and R29 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100022492 - Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set: The invention provides for a therapeutic causing contraction of a mucosal tissue whereby various diseases relating to mucosal tissues can be easily, safely and treated with minimal invasiveness, a method of treating various diseases relating to mucosal tissues with the use of the therapeutic causing contraction of a mucosal tissue,... Agent: Frommer Lawrence & Haug

20100022490 - Zilpaterol enantiomer compositions and methods of making and using such compositions: This invention is directed generally to zilpaterol enantiomer compositions and, in particular, to compositions comprising the 6R,7R zilpaterol enantiomer. This invention is also directed to processes for making such compositions; methods for using such compositions to, for example, increase the rate of weight gain, improve feed efficiency, and/or increase carcass... Agent: Traskbritt, P.C.

20100022493 - Use of mometasone furoate for treating airway passage and lung disease: The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20100022494 - Method, device, and kit for maintaining physiological levels of steroid hormone in a subject: A method, device, or kit is provided which maintain a substantially physiological level of one or more steroid hormones in a mammalian subject in need thereof. The method, device, or kit includes providing to the subject at least one treatment regimen including replacement therapy for the one or more steroid... Agent: Searete LLC Clarence T. Tegreene

20100022496 - Galenical form for the administration of active ingredients by transmucous means: A galenical form for the administration transmucously of at least one active ingredient, characterized in that the active ingredient is in a stable and complete dissolved state in a hydroalcoholic solution that includes at least 20% by mass of alcohol so as to allow rapid absorption of the active ingredient... Agent: Young & Thompson

20100022497 - Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on apoe allelic profile of a mammalian subject: A method for treating cardiovascular disease in a mammalian subject includes providing to the subject at least one treatment regimen including at least one estrogen receptor modulator, wherein the at least one treatment regimen is determined based on the APOE allelic profile in the subject, and based on the steroid... Agent: Searete LLC Clarence T. Tegreene

20100022495 - Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis: Endoplasmic reticulum stress has been found to be associated with the genetic disease tuberous sclerosis. Tuberous sclerosis is cause by defects in the two genes, TSC1 and TSC2. Agents that modulate ER stress may be used to treat tuberous sclerosis and other hamartomatous diseases. In particular, 4-phenyl butyric acid (PBA)... Agent: Edwards Angell Palmer & Dodge LLP

20100022498 - Steroids as agonists for fxr: d

20100022499 - Heterocyclic compounds, combinatorial libraries thereof and methods of selecting drug leads: Heterocyclic compounds having a relatively flexible backbone are used to create combinatorial libraries that permit screening for lead compounds and selection of drug candidates for a variety of uses in human and veterinary medicine as well as in agriculture. The compounds of the library generally differ in ring size and... Agent: Winston & Strawn LLP Patent Department

20100022500 - Macrocyclic lactams and pharmaceutical use thereof: wherein R1, R2, R3, U, V, W, X, Y, Z and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use... Agent: Foley And Lardner LLP Suite 500

20100022501 - Injectable or orally deliverable formulations of azetidine derivatives: The invention concerns injectable or orally deliverable binary or ternary formulations of azetidine derivatives. The azetidine derivatives used in the inventive pharmaceutical compositions can be represented by the general formulae (Ia) or (Ib), wherein Ar is an aromatic or heteroaromatic group optionally substituted by one or more among (C1-C4)alkyl, halogen,... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100022504 - Methods for treating latent tuberculosis: A method for treating individuals affected with latent tuberculosis comprising a step of administering an effective amount of one or more carbapenem compounds to the said individuals.... Agent: Young & Thompson

20100022506 - Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors: or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L1, M and R11 are as defined herein. The compounds of Formula (I) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa,... Agent: Louis J. Wille Bristol-myers Squibb Company

20100022505 - Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof: Ra, Rb and Rc are defined as in claim 1, their tautomers, their stereoisomers, their mixtures and their salts, in particular their physiologically acceptable salts with inorganic or organic acids and bases, which have valuable pharmacological properties, in particular an inhibitory action on the signal transduction mediated by tyrosine kinases,... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100022503 - Aminopyrazole kinase inhibitors: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. The formula (I) compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100022502 - Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Inc.

20100022507 - Aminopyrimidines useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Inc.

20100022509 - Inhibitors of mshc and homologs thereof, and methods of identifying same: The present invention utilizes three families of bacterial enzymes, which play a key role in mycothiol biosynthesis. The three families are bacterial cysteine:glucosaminyl inositol ligases (MshC) with catalytic ligase activity for ligation of glucosaminyl inositol and cysteine, bacterial acetyl-CoA:Cys-GlcN-Ins acetyltransferases (MshD) with catalytic activity for addition of an acetyl group... Agent: Dla Piper LLP (us)

20100022508 - Antiviral compounds: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Gilead Sciences Inc

20100022510 - Crystalline forms: The present invention is directed to a crystalline form the pharmaceutical compound 11-piperazin-1-yldibenzo[b,f][1,4]thiazepine as well as compositions, preparations, and pharmaceutical uses thereof.... Agent: Pepper Hamilton LLP

20100022511 - Stabilized atypical antipsychotic formulation: A pharmaceutical composition that contains an atypical antipsychotic drug and succinic acid, fumaric acid or a mixture of succinic acid and fumaric acid.... Agent: Hedman & Costigan P.C.

20100022512 - Compositions of chk1 inhibitors and cyclodextrin: Compositions containing at least one Chk1 inhibitor and at lease one cyclodextrin are disclosed. Also disclosed are methods of treating a cancer or potentiating a cancer treatment with a composition comprising at least one Chk1 inhibitor and at least one cyclodextrin.... Agent: Eli Lilly & Company

20100022513 - Organic compounds: m

20100022515 - Compounds and compositions as modulators of gpr119 activity: The invention provides compounds, pharmaceutical compositions comprising compound of following formula (I), and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119 (G protein-coupled receptor 119) such as obesity, diabetes and hyperlipidemia.... Agent: Genomics Institute Of The Novartis Research Foundation

20100022514 - Heterocycle compounds and methods of use thereof: The invention relates to the use of compounds in the treatment of deacetylase-associated diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100022516 - 4,5-disubstituted-2-aryl pyrimidines: wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I and II bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to... Agent: Edwards Angell Palmer & Dodge LLP

20100022517 - Ophthalmic formulation of rho kinase inhibitor compound: The present invention relates to an aqueous pharmaceutical formulation comprising at least one inhibitor of Rho-associated protein kinase (ROCK). The aqueous pharmaceutical formulation comprises 0.01-0.4% w/v of ROCK inhibitor(s), a non-ionic surfactant in an amount of 0.01-2% w/v, and a tonicity agent to maintain a tonicity between 220-360 mOsm/kG, at... Agent: Howery LLP

20100022518 - Novel heterocyclyl compounds: e

20100022519 - Heterocyclic-substituted piperidine compounds and the uses thereof: The invention relates to Heterocyclic-Substituted Piperidine Compounds, compositions comprising an effective amount of a Heterocyclic-Substituted Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Heterocyclic-Substituted Piperidine Compound.... Agent: Dechert LLP

20100022520 - Malonyl-coa acetyltransferase inhibitors against antibiotic resistant bactertia: Compounds characterized by thiolactone or thiomorpholino cores display useful antibiotic and radioprotective properties. The latter properties are believed to arise from an ability of the compounds to inhibit proteins involved in apoptosis.... Agent: Foley And Lardner LLP Suite 500

20100022521 - Compounds: The present invention relates to new mGluR1 and mGluR5 receptor subtype preferring ligands of formula (I) wherein X represents a group selected from SO, SO2; Y represents a group selected from (CH2)n, NH, NHCH2; n is an integer of 0 to 1; Z is H or monosubstituted by alkyl, nitro,... Agent: Fish & Richardson P.C.

20100022522 - Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.... Agent: Fish & Richardson PC

20100022523 - 3-aminobenzamide compounds and vanilloid receptor subtype 1 (vr1) inhibitors: The present invention relates to a novel 3-aminobenzamide compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R1 is a C1-6 alkyl group which may be substituted, R2 is a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group... Agent: Leydig Voit & Mayer, Ltd

20100022524 - Tricyclic tetrahydroquinoline antibacterial agents: The invention includes tetrahydroquinoline and related compounds of formula I, and pharmaceutical compositions thereof, that exhibit useful antibacterial activity against a wide range of human and veterinary pathogens.... Agent: Pfizer Inc Mary J Hosley

20100022525 - Arginine derivatives with np-i antagonistic activity: The present invention is a compound of formula (I) or formula (II) which are suitable as NP-1 antagonists.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100022526 - Pyridazine derivatives, processes for their preparation and their use as fungicides: The present invention relates to compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in claim 1, which are useful as fungicides.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100022527 - Biphenyl substituted spirotetronic acids and their use for the treatment of retroviral diseases: The present invention relates to novel substituted spirotetronic acids (I) in which R1 and R2, together with the carbon atom to which they are bonded, form a group of the formula (1), (2), (3) or (4), whereby * represents the carbon atom to which R1 and R2 are bonded, to... Agent: Morrison & Foerster LLP

20100022528 - Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use: Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits... Agent: Darby & Darby P.C.

20100022529 - Amidophenoxyindazoles useful as inhibitors of c-met: The present invention provides amidophenoxyindazole compounds useful in the treatment of cancer.... Agent: Eli Lilly & Company

20100022530 - Tetrahydrobenzoisoxazole and tetrahydroindazole derivatives as modulators of the mitotic motor protein: Compounds of the formula (I) in which A1, A2, R1, X1, X2, X3, Y, R2, Cy and n have meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20100022533 - Compositions and methods for inducing cell dedifferentiation: The present invention provides compounds, compositions and methods for dedifferentiating lineage committed mammalian cells into stem cells. The present invention also provides methods of inducing dedifferentiation of lineage committed mammalian cells into stem cells, which can be further differentiated into various lineage committed cells. Methods of identifying additional compounds useful... Agent: Townsend And Townsend And Crew, LLP

20100022531 - Novel compounds as p2x7 modulators and uses thereof: Compounds are disclosed that have a formula represented by the following (1), the compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.... Agent: Klauber & Jackson

20100022532 - Use of a kinase inhibitor for the treatment of particular resistant tumors: The invention provides low molecular weight compounds, namely 1H-thieno[2,3-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find... Agent: Scully Scott Murphy & Presser, PC

20100022534 - 2-benzimidazolyl-6-morpholino-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders: The invention concerns pyrimidine derivatives of Formula (I) wherein each of p, R1, R2, q, R3, r, R4, s, t, X1 and Q1 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in a method for producing an anti-proliferative... Agent: Astrazeneca R&d Boston

20100022535 - 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors: 2-pyridyl-substituted imidazoles which are used advantageously in the treatment of diseases mediated by ALK 5 or ALK 4 inhibitors or both.... Agent: The Nath Law Group

20100022536 - Inhibitors of cytosolic phospholipase a2: p

20100022538 - 5-fluoro pyrimidine derivatives: This present disclosure is related to the field of 5-fluoro pyrimidines and their derivatives and to the use of these compounds as fungicides.... Agent: Dow Agrosciences LLC

20100022537 - I-pheny 1-3,4-dihydropyrimidin-2(1h)-one derivatives and their use: This invention relates to novel heterocyclic derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.... Agent: Edwards Angell Palmer & Dodge LLP

20100022539 - Isoxazole compounds as histamine h3 modulators: Certain isoxazole compounds are histamine H3 modulators useful in the treatment of histamine H3 receptor mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20100022540 - Triazole derivatives ii: Novel triazole derivatives of the formula (I) in which R1—R6 and Y have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.... Agent: Millen, White, Zelano & Branigan, P.C.

20100022541 - Chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors: The invention relates to new compounds having heptose synthesis inhibitory properties, of formula (I) or a pharmaceutically acceptable salt, or prodrug thereof, wherein A is an aryl or heterocycle, optionally substituted by one or several identical or different R such as H, C1-C10 alkyl, C1-C10 alkyl-OR1, C1-C10 alkyl-NR1R1, alkoxy, hydroxy,... Agent: Nixon & Vanderhye, PC

20100022542 - Compounds exhibiting thrombopoietin receptor agonism: e

20100022544 - Cyclically substituted 3,5-dicyano-2-thiopyridines and use thereof: The present application relates to novel 4-cycloalkyl- and 4-heterocycloalkyl-3,5-dicyano-2-thio-pyridine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of hypertension and other cardiovascular... Agent: Edwards Angell Palmer & Dodge LLP

20100022543 - Cycloalkylidene and heterocycloalkylidene inhibitor compounds: The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.... Agent: Harness, Dickey, & Pierce, P.l.c

20100022545 - Metabotropic glutamate receptor isoxazole ligands and their use as potentiators - 286: e

20100022546 - Adamantyl diamide derivatives and uses of same:

20100022547 - Compounds and methods for treating mammalian gastrointestinal parasitic infections: One aspect of the present invention relates to compounds, and pharmaceutically acceptable salts and prodrugs thereof, that are useful as inhibitors of IMPDH. The invention also provides pharmaceutical compositions comprising the compounds of the invention which selectively inhibit parasitic IMPDH. In certain embodiments, the present invention relates to selective inhibition... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100022548 - Use of n-heterocyclylmethylbenzamides in therapeutics: e

20100022549 - Alpha-helix mimetic with functionalized pyridazine: The synthesis of new α-helix scaffolds mimicking i, i+3 or i+4, i+7 residues, was accomplished. The common pyridazine heterocycle originates from the easily available dimethyl pyridazine-3,6-dicarboxylate building block. These scaffolds may be thought of as synthetic counterparts of amphiphilic α-helices having a hydrophilic face along one side and a hydrophobic... Agent: Townsend And Townsend And Crew, LLP

20100022550 - Tetrahydrocarbazole derivatives useful as androgen receptor modulators: The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly frailty, osteoporosis, osteopenia, and male... Agent: Eli Lilly & Company

20100022551 - Trimetazidine for use in the treatment of fibromyalgia syndrome and related conditions: The present invention provides a method for treating certain rheumatic conditions such as fibromyalgia syndrome, chronic fatigue syndrome, myofascial pain syndrome, and Gulf War syndrome, among others, by administration of trimetazidine, along with related compositions and kits.... Agent: Frommer Lawrence & Haug

20100022552 - Kmup-1 capable of treating hypertension: A method for treating a spontaneous hypertension or a cardiomyocyte hypertrophy is provided. The method comprises a step of administering to a mammal a therapeutically effective amount of a compound of 7-[2-[4-(2-chlorobenzene)piperazinyl]ethyl]-1,3-dimethyl xanthine.... Agent: Volpe And Koenig, P.C.

20100022553 - Therapeutic combination comprising an aurora kinase inhibitor and imatinib: The present invention provides a therapeutic combination comprising (a) a compound 1 of formula (A) as set forth in the specification and (b) a BCR-ABL kinase inhibitor selected from the group consisting of Imatinib, Dasatinib, Nilotinib, Bosutinib and Inno-406, wherein the active ingredients are present in each case in free... Agent: Scully Scott Murphy & Presser, PC

20100022554 - Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia: e

20100022555 - Novel derivatives: The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100022556 - Therapeutic combinations comprising a long acting dihydropyridine calcium-channel blocker and a statin: A medicament comprising (±)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl methyl ester (manidipine) or a physiologically acceptable salt and a statin or a physiologically acceptable salt.... Agent: Ladas & Parry LLP

20100022557 - Radioprotector compounds and related methods: The invention relates to radioprotectors of formula (I), processes for their preparation and their use in protecting biological materials from radiation damage. In diagnostic and therapeutic radiology, particularly in cancer radiotherapy, the radioprotectors of the present invention may be used to protect certain normal tissues or structures from radiation damage.... Agent: Sughrue Mion, PLLC

20100022558 - Treatment of insomnia: The invention relates to the use of Flibanserin for the preparation of medicaments useful for the treatment of Insomnia.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100022559 - Bisoximes as fungicides: The invention relates to the novel use of bisoximes, some of which are known, for controlling unwanted microorganisms, and to processes for their preparation, and also to novel bisoximes, to processes for their preparation and to their use for controlling unwanted microorganisms and insects in crop protection and in the... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100022560 - Thiophene pyrazolopyrimidine compounds: The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and the use of such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.... Agent: Eli Lilly & Company

20100022561 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Wilson, Sonsini, Goodrich & Rosati

20100022563 - Phosphodiesterase inhibitor treatment: Methods and compositions are disclosed for the treatment of diseases or conditions produced by or associated with low cyclic nucleotide levels. The compositions comprise phosphodiesterase inhibitors and are formulated for intranasal and pulmonary administration.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100022562 - Use of plant growth regulators to reduce abscisic acid related plant leaf yellowing: The present invention describes methods for maintaining ABA-induced drought tolerance while reducing ABA-induced leaf yellowing through the combination of ABA with selected plant growth regulators. The present invention also describes a method of using selected ABA analogs to reduce water use with minimal leaf yellowing.... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100022564 - Purine and deazapurine derivatives as pharmaceutical compounds: The invention provides a compound of the formula (I) or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR5; J1-J2 is N═C(R6), (R7)C═N, (R8)N—C(O), (R8)2C—C(O), N═N or (R7)C═C(R6); E is a monocyclic carbocyclic or heterocyclic group of 5 or 6 ring members, the heterocyclic group containing up... Agent: Heslin Rothenberg Farley & Mesiti PC

20100022565 - Pharmaceutical compositions: Provided is a pharmaceutical composition comprising a calcilytic agent which, when administered orally to a subject induces a rapid and short-lasting absorption of the calcilytic agent and/or a rapid and short-lasting release of the parathyroid hormone.... Agent: Novartis Corporate Intellectual Property

20100022566 - Quinazoline derivatives and pharmaceutical compositions thereof: The present invention relates to novel quinazoline derivatives with less skin irritation and an excellent action of strongly suppressing scratching behavior, and pharmaceutical compositions containing a quinazoline derivative as an active ingredient. The present invention is directed to the quinazoline derivatives represented by the general formula [1] or pharmaceutically acceptable... Agent: Darby & Darby P.C.

20100022567 - Compositions containing pufa and/or uridine and methods of use thereof: This invention provides methods of enhancing brain development; increasing or enhancing intelligence; increasing or enhancing synthesis and levels of phospholipids, synapses, synaptic proteins, and synaptic membranes by a neural cell or brain cell, comprising contacting a subject or a pregnant or nursing mother thereof with a composition comprising an omega-3... Agent: Pearl Cohen Zedek Latzer, LLP

20100022568 - Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis: This present invention relates to the use of an endothelin receptor antagonist for the preparation of a medicament for the treatment of early stage idiopathic pulmonary fibrosis.... Agent: Hoxie & Associates LLC

20100022569 - Inhibitors of tyrosine kinases: The present invention relates to the use of pyrimidylaminobenzamide compounds for the preparation of a drug for the treatment of diseases that respond to modulation of Ephrin receptor kinase, especially EphB4, activity, especially for the curative and/or prophylactic treatment of proliferative diseases, and to a method of treating diseases that... Agent: Dilworth & Barrese, LLP

20100022570 - Novel microbiocides: Compounds of the formula (I) in which the substituents are as defined in claim 1 are suitable for use as microbiocides. Formula (I), wherein X is oxygen or sulfur; A is a 5- or 6-membered heterocyclic ring containing one to three heteroatoms, each independently selected from oxygen, nitrogen and sulphur,... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100022573 - Inhibitors of akt activity: The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in... Agent: Merck And Co., Inc

20100022572 - Novel spiro compound and medicine comprising the same: e

20100022571 - Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors: The present invention relates to phosphodiesterase (PDE) type IV selective inhibitors. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type IV selective inhibitors are provided. Prepared compounds correspond to structure XIV.... Agent: Ranbaxy Inc.

20100022574 - Methods to treat pain using an alpha-2 adrenergic agonist and an endothelin antagonist: The present invention relates, in general to treatment of pain comprising administering an alpha-2 adrenergic agonist and an endothelin antagonist, wherein administration of the agents acts as an analgesic and ameliorates pain in a subject.... Agent: Marshall, Gerstein & Borun LLP

20100022575 - Oxymatrine compositions and related methods for treating and preventing chronic infectious diseases: Compositions and methods for treating chronic infectious diseases using substantially pure oxymatrine or pharmaceutically acceptable salts or esters thereof are disclosed. In one embodiment described herein, the chronic infectious disease is chronic fatigue syndrome. Further described are compositions having an anti-infective amount of substantially pure oxymatrine or pharmaceutically acceptable salts... Agent: K&l Gates LLP

20100022577 - Dry syrup containing loratadine: Dry syrup preparations comprising loratadine as a hydrophobic medicinal drug are provided. The loratadine dry syrup preparations can be produced using a cellulose material or an argininic acid salt together with sugar.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20100022576 - Stable and bioavailable formulations and a novel form of desloratadine: An active pharmaceutical ingredient comprising 95% of form I of desloratadine and 5% of form II of desloratadine is disclosed. Also disclosed are a process for its preparation as well as a bioavailable and stable formulation containing this active pharmaceutical ingredient for the treatment of allergic diseases like allergic rhinitis,... Agent: Manelii Denison & Selter PLLC

20100022578 - Macrocyclic inhibitors of hepatitis c virus:

20100022579 - Substituted tetrahydroquinolines: Compounds of the formula (I), in which R1, R2, R3, R4, R5, X, Y, W, Q1, Q2, Z, s and m have the meanings indicated in claim 1, can be employed, inter alia, for the treatment of tumours.... Agent: Millen, White, Zelano & Branigan, P.C.

20100022580 - New 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indole compounds and methods of use thereof: This disclosure relates to new tricyclic compounds that may be used to modulate a histamine receptor in an individual. Compounds are described, including new 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole compounds. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment... Agent: Morrison & Foerster LLP

20100022581 - Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity: i

20100022583 - Pyridinyl modulators of gamma-secretase: The present invention relates to compounds of Formula I as shown below, wherein the definitions of A, X, R1 R2, R3, R4, R5, R6, R7, R8, and R9 are provided in the specification. Compounds of Formula I are useful for the treatment of diseases associated with γ-secretase activity, including Alzheimer's... Agent: Philip S. Johnson Johnson & Johnson

20100022582 - Tetrahydroisoquinoline compound and medicinal use thereof: The present invention provide a tetrahydroisoquinoline compound having a superior ACAT-inhibitory activity and/or anti-oxidation action, particularly, novel compound represented by the formula (I) (wherein each symbol is as described in the specification) and a pharmaceutically acceptable salt thereof.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100022584 - Modulation of glutamine synthetase activity: Methods of screening and designing compounds as inhibitors of glutamine synthetase are provided herein. Compounds, e.g., serine protease inhibitors, and compositions comprising the same, that are useful for the treatment, prevention, and/or amelioration of bacterial infections, including Mycobacterium tuberculosis, are also provided.... Agent: Ladas & Parry LLP

20100022585 - Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds: Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a... Agent: Michael Best & Friedrich LLP

20100022586 - Bicyclic heteroaryl inhibitors of pde4: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PD E4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.... Agent: Global Patent Group - Kal

20100022587 - Derivatives of 2-phenyl-3-hydroxyquinoline-4(1h)-one and methods of their preparation and utilization: Derivatives of 2-phenyl-3-hydroxyquinoline-4(1H)-one of the general formula (II), where X represents a nitro group, amino group, and Y represents an atom of halogen, oxygen or sulphur substituted by C1 to C6 alkyl or phenyl group, whereby both the alkyl and phenyl group may be further substituted and the substituents may... Agent: Ostrolenk Faber Gerb & Soffen

20100022588 - Pharmaceutical carrier composition and pharmaceutical composition: The present invention relates to a pharmaceutical carrier composition and a pharmaceutical composition comprising said pharmaceutical carrier composition. The pharmaceutical composition comprises: (a) at least 20% (w/w) of the composition of a sugar or a sugar alcohol; (b) one or more pharmaceutically acceptable excipients; (c) one or more pharmaceutically active... Agent: The Nath Law Group

20100022589 - Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase: e

20100022594 - Heterocyclic sulfonamide inhibitors of beta amyloid production:

20100022590 - Novel compounds: and pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides thereof, which are modulators of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the preparation of a medicament for the treatment of... Agent: Edwards Angell Palmer & Dodge LLP

20100022591 - Piperidine gpcr agonists: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.... Agent: Osi Pharmaceuticals, Inc.

20100022593 - Process for producing anticancer agent ll-d45042: m

20100022592 - Thiazole derivatives as modulators of g protein-coupled receptors: The invention provides compounds of formula (IA) or (IB) and pharmaceutical compositions thereof, which are useful for modulating G protein-coupled receptor 120 (GPR120), and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated GPR120.... Agent: Genomics Institute Of The Novartis Research Foundation

20100022595 - Benzenesulfonamide compounds and their use as blockers of calcium channels: The invention relates to piperidinyl and hexahydroazepinyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R1-R3, Z and q are defined as set forth in the specification. The invention is also directed to the use compounds of Formula (I) to treat, prevent or ameliorate a... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100022596 - Epothilone analogues: The invention relates to analogues of epothilones, uses and methods of making the same.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100022597 - 2-adamantyl-butyramide derivatives as selective 11beta-hsd1 inhibitors: The present invention relates to 2-adamantyl-butyramide derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension... Agent: Millen, White, Zelano & Branigan, P.C.

20100022599 - Dual-acting antihypertensive agents: wherein: Ar, r, Z, X, R3, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process... Agent: Theravance, Inc.

20100022598 - Substituted inmidazoles as bombesin receptor subtype-3 modulators: Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.... Agent: Merck And Co., Inc

20100022600 - Methods and compositions for treating central nervous system tumors: A method of treating a central nervous system tumor in a subject includes administering a therapeutically effective amount of at least one PPARγ agonist or a derivative thereof to the tumor in the subject.... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20100022601 - Sulfonamide compounds and the use: The sulfoneamide compounds having the following Formula (1), which can be used as an effective component of a CaSR antagonizing agent useful for prophylaxis and/or treatment of bone disorders including osteoporosis and etc., are provided. The compounds have an excellent activity of promoting PTH secretion. In addition, the compounds are... Agent: Greenblum & Bernstein, P.L.C

20100022602 - Pre-mixed, ready-to-use iv bolus nicardipine compositions and methods of use: Provided herein are ready-to-use premixed bolus injection pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.... Agent: Patent Docket Administrator Lowenstein Sandler PC

20100022603 - Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use: wherein the various substituents are defined herein, including their physiologically acceptable salts. Processes for the preparation of compounds are also disclosed. The compounds are suitable for the treatment of fatty acid metabolism and glucose utilization disorders, disorders relating to insulin resistance are involved as well as demyelinating and other neurodegenerative... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100022604 - Prophylactic or therapeutic agent for alopecia: Disclosed is a novel therapeutic agent which is useful for the prevention or treatment of alopecia. Specifically disclosed is a prophylactic or therapeutic agent for alopecia, which comprises 1-[2-((2S)-2-{5-[(3,4-dimethoxyphenoxy)methyl]-1,2,4-oxadiazol-3-yl}pyrrolidin-1-yl)-1,1-difluoro-2-oxoethyl]-3,3,5,5-tetramethylcyclohexanol as an active ingredient.... Agent: Sughrue Mion, PLLC

20100022605 - N-hydroxyamide derivatives possessing antibacterial activity: Described herein are N-hydroxyamlde antibacterial compounds, methods for making the compounds, pharmaceutical compositions containing the compounds and methods of treating bacterial infections utilizing the compounds and pharmaceutical compositions compound of Formula (I): or a salt, solvate ti hydrate thereof, wherein A is (a) eachindicates a point of attachment.... Agent: Pfizer Inc Mary J Hosley

20100022606 - Method for reducing odor in personal care products: A personal care composition which contains 25-200 ppm of 2-methyl-4-isothiazolin-3-one and at least one hydroquinone radical scavenger, and a method for reducing odor arising in personal care compositions containing 2-methyl-4-isothiazolin-3-one.... Agent: Rohm And Haas Company Patent Department

20100022607 - Diazonamide analogs: Novel diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders are provided.... Agent: Morrison & Foerster LLP

20100022608 - Non-steroidal anti-inflammatory drugs for cough: The use of a non-steroidal anti-inflammatory drug for the treatment of nonproductive cough caused by viruses or bacteria and a combination of at least one non-steroidal anti-inflammatory drug with at least one antitussive in a formulation to treat coughs.... Agent: Bayer Healthcare LLC Consumer Care Division

20100022609 - Novel crystalline forms of temozolomide: Disclosed are novel crystalline forms of Temozolomide, methods of preparation thereof, medicaments including the novel crystalline forms of Temozolomide, and uses thereof in the treatment of medical conditions.... Agent: Leydig Voit & Mayer, Ltd

20100022610 - New crystalline forms: A salt of the compound N-{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1H-benzimidazol-5-yl}ethanesulfonamide, which is an ethanesulphonic acid salt, a sulphuric acid salt, an ethane disulphonic acid salt, a hydrochloric acid salt, a hydrobromic acid salt, a phosphoric acid salt, an acetic acid salt, a fumaric acid salt, a maleic acid salt, a tartaric acid salt, a... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100022611 - 1,5-diaryl-pyrazoles as cannabinoid receptor neutral antagonists useful as therapeutic agents: The present invention pertains to cannabinoid (CB) receptor neutral antagonists, and especially CB1 neutral antagonists, and including, for example, certain 1,5-di-aryl-pyrazole compounds. The present invention also pertains to the use of such compounds in the treatment of diseases and disorders that are ameliorated by treatment with a neutral antagonist of... Agent: Swanson & Bratschun, L.L.C.

20100022612 - Fused heterocycles: e

20100022613 - Compounds having crth2 antagonist activity:

20100022614 - Pharmaceutical composition for external application and adhesive skin patch: Disclosed are a pharmaceutical composition for external application, an adhesive skin patch and others which are improved in a drug release property, transdermal absorbability and stability of a pharmacologically active ingredient contained therein and can reduce the aggravation of irritation to the skin. Specifically disclosed is an adhesive skin patch... Agent: Dilworth & Barrese, LLP

20100022615 - Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions: Activated cytotoxic compounds are described for attachment to targeting molecules for the treatment of a mammalian disease condition which comprise, an activator, a spacer linker, a linker (e.g., self-immolative), and a cytotoxic drug selected from the group consisting of AMINO-SUBSTITUTED (E)-2,6-DIALKOXYSTYRYL 4-SUBSTITUTED BENZYLSULFONES, AMINO-AND-HYDROXY SUBSTITUTED STYRYLSULFONANILIDES, and SUBSTITUTED PHENOXY- AND... Agent: Law Offices Of Khalilian Sira, LLC

20100022616 - 3-(phenoxyphenylmethyl)pyrrolidine compounds: where a and R1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing... Agent: Theravance, Inc.

20100022617 - Compositions and methods to control abnormal cell growth: A class of compounds commonly containing a trialkylammonium group have been synthesized and characterized as anticancer compounds. A representative of this class, N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide (CCDTHT) was shown in various tumor models to decrease tumor volume, enhance the effects of other chemotherapeutic agents including cisplatin, reduce chemotherapy-induced loss of body weight,... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20100022629 - Dietary methods and compositions for enhancing metabolism and reducing reactive oxygen species: This invention relates to methods comprising administering to a subject a dietary composition for modifying cellular metabolism, metabolic production of reactive oxygen species and the resulting level of reactive oxygen species. The invention is drawn to a method comprising a combination of carnitine, lipoic acid and polyphenol, which has the... Agent: Davis, Agnor, Rapaport & Skalny, LLC

20100022630 - Method of treatment using fatty acid synthesis inhibitors: The present invention relates to natural products that possess fatty acid synthesis inhibitor activity and can be used to treat and prevent diseases such as obesity, cancer, diabetes, fungal infections, Mycobacterium tuberculosis infections, malarial infections and other apicomplexan protozoal diseases.... Agent: Merck And Co., Inc

20100022631 - Treatment of hepatic encephalopathy and liver cirrhosis: The compounds D9-tetrahydrocannabinol (THC), cannabidiol (CBD) and capsaicin are useful for prevention, treatment, or both, of hepatic encephalopathy. The compounds capsaicin, 2-arachidonoylglycerol (2-AG), HU-308 and cannabidiol are useful for prevention, treatment, or both, of liver cirrhosis.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100022632 - Use certain diterpene compounds in the treatment of androgen receptor-associated diseases: The present invention discloses certain diterpenes that can be used to inhibit androgen receptor activity, induce apoptosis and block cell cycle progression of androgen receptor-dependent cells. Androgen receptor has been associated with various diseases such as prostate cancer, androgeneic alopecia, breast cancer, acne etc. Accordingly, the present invention further discloses... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100022633 - Cognitive abilities improving agent: A composition containing bark extract from the genus Pinus is described to improve, or prevent a decline in, human cognitive abilities or improve, or prevent symptoms of, neurological disorders in a human. The composition is advantageous for treatment where the human does not suffer from any kind of neurodegenerative disease... Agent: Duane Morris LLP - San Diego

20100022634 - Laidlomycin compositions and methods: An animal feed additive composition comprises an effective amount of a laidlomycin, a carrier, magnesium sulfate, and silicon dioxide. Other embodiments include methods of making the animal feed additive compositions, and the use of a laidlomycin in the manufacture of an animal feed additive for increasing the efficiency of feed... Agent: G Kenneth Smith

20100022635 - Heat shock protein 90 inhibitor dosing methods: The disclosure provides novel dosing regimens for Hsp90 inhibitors for use in the treatment or prevention of a neurodegenerative disorder, an autoimmune disorder, or cancer. The methods involve administering one or more doses of a therapeutically effective amount of at least one Hsp90 inhibitor to a subject in need thereof... Agent: Merchant & Gould PC

20100022636 - Compositions and methods for enhancing the antioxidant status of animals: Compositions suitable for enhancing the antioxidant status of animals containing methionine, taurine, vitamin C, and vitamin E and methods for preparing and using such compositions to enhance the antioxidant status of animals.... Agent: Colgate-palmolive Company

20100022637 - Identification of anti-cancer compounds and compounds for treating huntington's disease and methods of treatment thereof: Small molecule screening via high-throughput screening (HTS) methods was employed to identify compounds useful for treating or preventing cancer (such as compounds that enable cells to overcome E6-oncoprotein-mediated drug resistance) or neurodegenerative disorders (such as Huntington's disease, HD). Compounds were identified that potentiate the lethality of anti-tumor agents as well... Agent: Bryan Cave LLP

20100022638 - Isosorbide nitrates: The present invention relates to new 3-substituted 6-nitrooxy-hexahydrofuro[3,2-b]furane derivatives possessing a superior pharmacological activity in thrombosis and in coronary ischemia models.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100022639 - Methods of inducing weight loss: This invention provides a method for inducing weight loss in an animal by administering to the animal a compound which reduces the expression and/or secretion of neuropeptide Y (NPY). The effect may be accomplished directly, indirectly, or humorally. Preferably, administration of this compound has the effect of increasing malonyl CoA... Agent: Hunton & Williams LLP Intellectual Property Department

20100022640 - Esters of 2-phenylalkanenitriles and antifungal compositions containing them: Esters of 2-phenylalkanenitriles, such as 3-acetoxy-2-(2-chloro-5-(difluoromethoxy)phenyl)propanenitrile and 3-acetoxy-2-(4-chlorophenyl)propanenitrile, and compositions containing such esters, are useful as fungicides at very low concentrations.... Agent: Leonard P Miller

20100022641 - Solid forms of selective androgen receptor modulators: The present invention relates to solid forms of (S)—N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide and process for producing the same.... Agent: Pearl Cohen Zedek Latzer, LLP

20100022642 - Dermatological/cosmetic compositions comprising a retinoid and benzoyl peroxide: Dermatological/cosmetic compositions contain, in a physiologically acceptable medium, at least one retinoid, dispersed benzoyl peroxide and a gelling system comprising at least two categories of compounds.... Agent: Buchanan, Ingersoll & Rooney PC

20100022643 - Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers: The present invention provides compositions comprising at least one GHB moiety bonded to at least one physiologically compatible carrier molecule. The compositions can enhance the uptake of the drug, deliver effective therapeutic doses in a time-delayed fashion, or can target specific organs.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100022644 - Peroxycarboxylic acid compositions with reduced odor: The present invention relates to compositions of peroxycarboxylic acid that have reduced odor compared to conventional peroxycarboxylic acid compositions, methods employing these reduced-odor compositions, and methods of making these compositions. Typically, the reduced-odor compositions include an amine oxide surfactant.... Agent: Ecolab Inc.

20100022645 - Pkc-activating compounds for the treatment of neurodegenerative diseases: The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20100022646 - method of neutralising organoboronates with acids: The use of specified compounds for the manufacture of a medicament for therapeutically neutralising an organoboronate drug. The specified compounds are typically hydroxy fatty acids or hydroperoxy fatty acids, for example 9(S)-HODE, 8(S)-HETRE or 8(S)-HEPE, or their salts or prodrugs. The organoboronate drug may be TRI 50c or a salt... Agent: Bozicevic, Field & Francis LLP

20100022647 - High arachidonic acid producing strains of yarrowia lipolytica: Engineered strains of the oleaginous yeast Yarrowia lipolytica capable of producing greater than 10% arachidonic acid (ARA, an ω-6 polyunsaturated fatty acid) in the total oil fraction are described. These strains comprise various chimeric genes expressing heterologous desaturases, elongases and acyltransferases, and optionally comprise various native desaturase and acyltransferase knockouts... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20100022648 - Oral use of at least one monounsaturated fatty acid for hair improvement: The present invention relates to the cosmetic use by the oral route of at least one monounsaturated fatty acid, a salt thereof and/or an ester thereof, preferably petroselinic acid, for improving the quality of the hair and/or the appearance of the hair, in particular for preventing and/or treating the changes... Agent: Oliff & Berridge, PLC

20100022649 - Pharmaceutical composition and procedure to treat and prevent prostatic hyperplasia and prostatitis from the royal palm (roystonea regia) fruits: A method for treating and/or preventing BPH prostatitis, alopecia and hirsutism including administering a medication of the pharmaceutical composition obtained from the green or mature fruits of Roystonea regia including a mixture of primary fatty acids with 8 to 28 carbon atoms, the fatty acid selected from the group consisting... Agent: Lackenbach Siegel, LLP

20100022650 - Benzamide derivatives as ep4 receptor agonists: m

20100022651 - Method for increasing hair growth: The present invention provides a method for stimulating hair growth, which comprises applying a composition containing a combination of a creatine compound and carnitine. The composition may further comprise 5′-AMP and NADH. Such a composition is effective in stimulating cell proliferation in the hair bulb of hair plugs.... Agent: The Estee Lauder Cos, Inc

20100022652 - Antimicrobial and anticoagulant compositions and methods: A composition may include a combination of at least one chelating agent and at least one antioxidant agent, the combination may have a fractional inhibitory concentration coefficient of about 0.5 or less and/or an INR of > about 2.82.... Agent: Tyco Healthcare Group Lp

20100022653 - Process for the preparation of and crystalline forms of optical enantiomers of modafinil: The invention relates to a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 8.54, 4.56, and 3.78 Å, and a process for the preparation thereof.... Agent: Ross J. Oehler Cephalon, Inc.

20100022654 - Antimicrobial compositions: Antimicrobial compositions are provided that include a hydroalcoholic solvent system comprising a lower C2-C5 alcohol and water; a cationic antimicrobial agent such as chlorhexidine gluconate; a fatty component containing at least one free hydroxyl group, such as a C12-C21 fatty alcohol, a C12-C21 fatty ester, a C12-C21 fatty ether, a... Agent: 3m Innovative Properties Company

20100022656 - Optically active phenylethanol amines and preparing method thereof: The invention provides compounds of formula (I) having (−) or (+) configuration, or pharmaceutically acceptable salts thereof, wherein R1 is H or halo; R2 is CF3, CN, or halo; R3 is linear or branched alkyl having 1 to 6 carbon atoms, or cycloalkyl having 3 to 6 carbon atoms. The... Agent: Seed Intellectual Property Law Group PLLC

20100022655 - Therapeutic agents for the treatment of lymphoid malignancies: Methods—for treatment and prevention of lymphoid malignancies, including, but not limited to acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell lymphoma, Acute Myeloid leukemia (AML), and mantle cell lymphoma (MCL). The methods include administration of a therapeutically effective amount of FTY720 (2-Amino-2-[2-(4-octylphenyl)ethyl]propane 1,3-diol hydrochloride) or a derivative, pharmaceutically acceptable... Agent: Calfee Halter & Griswold, LLP

20100022657 - Treatment of faecal incontinence and other conditions with 1r, 2s-methoxamine: 1R,2S-Methoxamine may be used topically for effective treatment of faecal incontinence at low doses without local or systemic side effects, for example, without affecting blood pressure. 1R,2S-Methoxamine may be used to treat other disturbances and disorders of the gastrointestinal, as a pressor agent, as a nasal decongestant and in ophthalmology,... Agent: Leon R. Yankwich

20100022659 - Methods and compositions for the treatment of cns-related conditions: The invention provides methods and compositions for the treatment of dementia-related conditions, such as Parkinson's disease and Alzheimer's disease.... Agent: Adamas Pharmaceuticals, Inc.

20100022658 - Methods for treating cognitive impairment in humans: Cognitive impairments in humans with multiple sclerosis are treated and cognition is improved with an amphetamine compound. In one embodiment, the method includes administering an l-amphetamine compound. In another embodiment, the method includes administering an l-methamphetamine compound.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100022660 - Foaming alcohol compositions with selected dimethicone surfactants: Foaming alcohol compositions with selected dimethicone surfactants are disclosed. The dimethicone surfactants are PEG-8 to PEG-12 linear dimethicone surfactants and in particular PEG-10 linear dimethicone surfactant. The compositions are useful as antimicrobial products and in particular handcare or skincare products.... Agent: Ecolab Inc.

20100022661 - Controlled release compositions for modulating free-radical induced damage and methods of use thereof: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with free-radical modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).... Agent: Wilson, Sonsini, Goodrich & Rosati

20100022662 - Modified comb copolymers: The present invention relates to modified comb copolymers comprising special structural units, which are produced by converting SMA resins and optionally special copolymers with an AB block copolymer structure with a mixture of at least one polyalkylene oxide monoamine and at least one amino alcohol, with a mixture of at... Agent: Gerstenzang, William C. Norris Mclaughlin & Marcus, Pa

20100022663 - Methods for manufacturing amino acid mimetic copolymers and use of same: Biocompatible polymers are manufactured to include an ammo acid mimetic monomer and one or more hydrophobic acrylate monomers. The amino acid mimetic monomers are selected to mimic the side chain of the amino acids asparagine or glutamine. The amino acid mimetic monomer can be a methacryloyl or acryloyl derivative of... Agent: Squire, Sanders & Dempsey LLP

20100022665 - Oil-in-water emulsion cosmetic composition and method for producing the same: To provide an oil-in-water emulsion cosmetic composition obtained by using a polyglycerin fatty acid ester as a surfactant, which has high stability against temperature and is excellent in tactile sensation, and a method for producing the same, the present invention provides an oil-in-water emulsion cosmetic composition, wherein the composition comprises... Agent: Knobbe Martens Olson & Bear LLP

20100022664 - Process for the partial hydrogenation of fatty acid esters: Suggested is a process for the manufacture of unsaturated fatty acid alkyl esters or glycerides having a total content of C 18:1 of about 30 to about 80 Mol-% by partial hydrogenation of unsaturated fatty acid esters having a total content of (C18:2+C18:3) of at least 65 Mol-%—calculated on the... Agent: Fox Rothschild LLP

  
01/21/2010 > patent applications in patent subcategories. recently filed with US Patent Office

20100016207 - Methods and compositions for raising levels and release of gamma aminobutyric acid: The present invention provides methods of increasing the level or release of gamma aminobutyric acid (GABA) in the brain, treating Alzheimer's disease, Huntington's disease, symptoms thereof, anxiety, aggression, insomnia, cognitive or memory disturbances; seizures of any cause (e.g. idiopathic epilepsy), primary or metastatic brain tumors, depression (e.g. bipolar depression), or... Agent: Pearl Cohen Zedek Latzer, LLP

20100016212 - Methods for treating pulmonary hypertension and compositions comprising vasoactive intestinal peptide: A method and device for discharging an electrical defibrillation pulse or an electrical demand pacer pulse or delivering at least one pharmaceutical agent to treat conditions such as cardiac arrest bradycardia, arrhythmia, cardiac standstill, PEA, EMD and other heart conditions are disclosed. The pharmaceutical agent can be delivered into the... Agent: Hoxie & Associates LLC

20100016209 - Methods of reducing side effects in cancer therapy: The present invention provides a method of decreasing side effects in a human or animal cancer patient due to radiation therapy or chemotherapy. With this method, methionine enkephalin is administered to the patient at least one time per week for a first time period, where the first time period is... Agent: Peters Verny , L.L.P.

20100016208 - Photoactivatable antimicrobial agents: Photoactivatable antimicrobial compounds and methods for the use thereof in the treatment of infections are provided.... Agent: Edwards Angell Palmer & Dodge LLP

20100016210 - Sensotherapy: o

20100016211 - Treatment of melanoma with alpha thymosin peptides: A method of treating melanoma or a metastasis thereof in a human patient by administering a melanoma-treating effective amount of an alpha thymosin peptide to a human melanoma patient, wherein the human melanoma patient does not have a substantially elevated LDH blood level.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100016214 - Carbohydrates mixture: m

20100016213 - Use of a diterpenoid compound for treating diabetes: A method for lowering the plasma glucose level in a subject and for treating diabetes with a diterpenoid compound.... Agent: Occhiuti Rohlicek & Tsao, LLP

20100016215 - Compound and method for treating myotonic dystrophy: An antisense compound for use in treating myotonic dystrophy DM1 or DM2, a method of enhancing antisense targeting to heart and quadricep muscles, and a method for treating DM1 or DM2 in a mammalian subject are disclosed. The oligonucleotide has 8-30 bases, with at least 8 contiguous bases being complementary... Agent: King & Spalding LLP

20100016216 - Adiponectin and uses thereof: The invention provides methods and reagents for regulation of metabolic events, such as those mediated by adiponectin and adiponectin agonists. The invention also provides screening assays for identification of biologically active agents, diagnostic and therapeutic agents, and other methods and reagents.... Agent: Duane Morris LLP - San Diego

20100016218 - Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders: Disclosed herein are compositions and methods for the treatment of otic disorders with anti-apoptotic agent or pro-apoptotic agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).... Agent: Wilson, Sonsini, Goodrich & Rosati

20100016217 - Derivatisation of granulocyte colony-stimulating factor: The present invention relates to a compound which is a polysaccharide derivative of GCSF, or of a GCSF like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the... Agent: Morrison & Foerster LLP

20100016219 - Ophthalmic compositions containing solubilized cyclosporin: An ophthalmic composition containing solubilized cyclosporin is able to be obtained in the presence of at least one 1,2-alkanediol having 5 to 7 carbon atoms and at least one polysorbate surface active agent in an ophthalmically acceptable medium. The composition is stable without crystallization and/or precipitation of cyclosporin. The composition... Agent: Jerry Zhang

20100016224 - Compositions and methods for modulating an immune response: The present invention relates to a method of enhancing a pro-inflammatory immune response through the administration of the DEAD-box protein DDX3, as encoded by SEQ ID NO:1. The invention further extends to a method of suppressing an aberrant immune response, such at that associated with autoimmune conditions, through inhibition of... Agent: Marshall, Gerstein & Borun LLP

20100016225 - Conjugates comprised of polymer and hiv gp-41-derived peptides and their use in therapy: Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the... Agent: Jones Day

20100016220 - Genes and polypeptides relating to human colon cancers: The present application provides novel human genes RNF43 whose expression is markedly elevated in colorectal cancers, as well as CXADRL1 and GCUD1 whose expression is markedly elevated in gastric cancers compared to corresponding non-cancerous tissues. The genes and polypeptides encoded by the genes can be used, for example, in the... Agent: Townsend And Townsend And Crew, LLP

20100016233 - Heterocyclic aromatic compounds useful as growth hormone secretagogues: e

20100016227 - Ligand/lytic peptide compositions and methods of use: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack... Agent: Pillsbury Winthrop Shaw Pittman LLP

20100016221 - Method of degrading protein by chaperone-mediated autophagy: p

20100016222 - Novel agent for inducing apoptosis comprising msx1 or a gene encoding the same as an active ingredient: The present invention relates to a novel use of Msx1 protein or a nucleotide encoding the same for inducing apoptosis. The Msx1 of the present invention induces apoptosis through direct interaction with p53 via a homeodomain and such interaction leads to increased stability, and/or nuclear localization of p53 in cells.... Agent: Sheridan Ross PC

20100016229 - Oral glp-1 formulations: The present invention provides pharmaceutical compositions comprising of at least one delivery agent and GLP-1. These pharmaceutical compositions facilitate the oral delivery of GLP-1, providing improved (e.g. increased) bioavailability of GLP-1 compared to administration of GLP-1 without a delivery agent.... Agent: Emisphere Technologies, Inc

20100016234 - Signal peptides, nucleic acid molecules and methods for treatment of caries: Compounds that competitively inhibit binding of CSP to S. mutans histidine kinase are provided. The compounds are preferably a peptide or an antibody, and are preferably a derivative of [SEQ ID NO:2], a fragment of [SEQ ID NO:2] or a derivative of a fragment of [SEQ ID NO:2]. Methods of... Agent: Merchant & Gould PC

20100016223 - Treatment of cartilage disorders with fgf-18: This invention concerns the treatment of cartilage disorder and osteoarthritis in particular. More specifically, it relates to the use of FGF-18 in treatment regimens and for the manufacture of a medicament for the treatment of patients having a cartilage disorder such as osteoarthritis, such as for example knee osteoarthritis or... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100016230 - Treatment of inflammatory bowel diseases with mammal beta defensins: The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins.... Agent: Novozymes North America, Inc.

20100016232 - Treatment of inflammatory diseases with mammal beta defensins: The present invention relates to suppression of TNF-alpha activity with mammal beta defensins, which has utility in the treatment of pathological conditions associated with tumor necrosis factor alpha.... Agent: Novozymes North America, Inc.

20100016231 - Treatment of rheumatoid arthritis with mammal beta defensins: The present invention relates to treatment of rheumatoid arthritis with mammal beta defensins.... Agent: Novozymes North America, Inc.

20100016228 - Truncated bard1 protein, and its diagnostic and therapeutic uses: The invention concerns a novel polypeptide derived from the cleavage of the BARD1 protein, a nucleic acid encoding for said polypeptide, and their diagnostic and therapeutic uses, in particular for treating tumors.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100016226 - Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease: The present invention relates to a method for treating a cardiovascular disease, for increasing the number of circulating angiogenic cells (CAC) and/or improving the function of CAC and a method for improving vascular remodeling and/or neovascularisation. The method comprises administering to the subject a therapeutically effective amount of unacylated ghrelin... Agent: Darby & Darby P.C.

20100016235 - Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof: The present invention relates to the use of a protein phosphatase inhibitor selected from an inhibitor of the catalytic subunit of the protein phosphatase 1 (PP1), an inhibitor of GADD34 and an inhibitor of the PP1/GADD34 complex to prepare a pharmaceutical composition to prevent or treat a cancer in a... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100016239 - Heparin binding motif and use thereof: A method for reducing cytotoxicity of eosinophil derived toxins comprising administering to a subject an effective amount of heparin, heparan sulfate, a potent heparanase inhibitor or a polypeptide which has sequence as follows: BZBXBX, XBBBXXBX, XBBXBX, BBXXBBBXXBB, BXBBXB, XBBBXXBBBXXBBX, or TXXBXXTBXXXTBB, wherein X represents any amino acid, Z represents an... Agent: Wpat, PC Intellectual Property Attorneys

20100016237 - Novel peptides for use in the treatment of obesity: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100016236 - Osteogenic synthetic peptides, pharmaceutical compositions comprising the same, and medium containing the same: Disclosed herein is an osteogenic synthetic peptide, derived from bone morphogenetic protein-7, consisting of a sequence of 15 amino acid residues. Provided are also a pharmaceutical composition and a medium composition comprising the same. Having remarkable activity related to promoting osteoblast differentiation, the osteogenic synthetic peptide is very useful in... Agent: The Nath Law Group

20100016238 - Peptides for use in the treatment of obesity: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100016240 - Facilitating cells and diabetes and methods related thereto: This disclosure describes methods of screening for compounds that increase the number of p-preDCs and/or Tregs.... Agent: Fish & Richardson P.C.

20100016241 - Methods and compositions for inhibiting c-met dimerization and activation: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating c-met dimerization and/or binding of ligand to c-met using a c-met antagonist that disrupts c-met multimerization.... Agent: Genentech, Inc.

20100016242 - Myosin light chain kinase inhibitors and methods of use: Disclosed are inhibitors of myosin light chain kinase, pharmaceutical compositions and kits comprising the inhibitors and methods of use.... Agent: Michael Best & Friedrich LLP

20100016243 - Crystalline d-isoglutamyl-d-tryptophan and the mono ammonium salt of d-isoglutamyl-d-tryptophan: A process for making pure crystalline D-isoglutamyl-D-tryptophan is provided which includes the step of deprotecting essentially pure N-tert-butoxycarbonyl-D-isoglutamyl-D-tryptophan or its diester to yield essentially pure D-isoglutamyl-D-tryptophan. A process is also provided for the preparation of pure mono ammonium salt of D-isoglutamyl-D-tryptophan from essentially pure N-tert-butoxycarbonyl-D-isoglutamyl-D-tryptophan. D-isoglutamyl-D-tryptophan, ammonium salt (1:1) is... Agent: Apotex, Inc.

20100016244 - D-glucopyranose 1-[3,5-bis (1,1-dimethylethy)-4-hydroxybenzoate] and its derivatives, preparation and use thereof: The invention relates to a D-glucopyranose 1-[3,5-bis(1,1-dimethyl-ethyl)-4-hydroxybenzoate compound defined by formula (I). It applies in particular to the preparation and the use of this compound and of its derivatives for the preparation of medicaments for the treatment and/or prevention of infections with enveloped viruses, and in particular, in humans, the... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100016246 - Food composition for functional foods and nutritional supplements: A food composition for functional foods and nutritional supplements is for preventing, reducing or treating cardiovascular diseases or mild manifestations thereof, obtained from the combination of extracts derived from citrus species, which contain between 25 and 80% by weight of hesperidin; between and 10% by weight of isonaringin; between 0.5... Agent: Merchant & Gould PC

20100016245 - Rhamnose substituents of sl0101 and therapeutic uses thereof: The present invention provides compositions and methods useful for preparing and using analogs, derivatives, and modifications of kaempferols that have anti-neoplastic activity. More specifically, the compounds are analogs, derivatives, and modifications of SLO1O1. The invention further provides compounds that are inhibitors of rsk activity. The invention further provides compounds that... Agent: Barnes & Thornburg LLP

20100016247 - Using budding yeast to screen for inhibitors of aurora kinases: Methods of screening for novel Aurora kinase inhibitors in higher organisms are provided using hypomorphic ipl1 mutant yeast cells. Putative Aurora kinase inhibitors identified by present screening methods may be useful in treating individuals having a proliferative disease, such as cancer. Chemical compounds identified by present methods as selectively inhibiting... Agent: Vedder Price, PC

20100016248 - Tablet formulation: The invention relates to a tablet formulated for administration to an animal to treat parasite infestation. The tablet includes at least one macrocyclic lactone compound with anthelmintic activity dissolved in at least one organic solvent and subsequently formulated into a tablet. The tablets produced have a high degree of stability... Agent: Sheridan Ross PC

20100016249 - Cancer sensitizer comprising glucosamine, glucosamine derivatives or salts thereof: Disclosed herein is a cancer sensitizer comprising glucosamine, a glucosamine derivative, or a salt thereof. When administered to patients with cancer, the cancer sensitizer functions to sensitize cancer cells to anticancer agents without producing side effects, thereby increasing the therapeutic efficiency of chemotherapy.... Agent: Birch Stewart Kolasch & Birch

20100016406 - Antisense rna for treating cancer and inhibition of metastasis and vectors for antisense sequestration: Provided is the use of antisense RNA and methods for the treatment, diagnosis and prophylaxis of cancer comprising administering said antisense RNA, particularly miRs 15 and 16 to a patient in need thereof.... Agent: Greenlee Winner And Sullivan P C

20100016407 - Combined telomerase inhibitor and gemcitabine for the treatment of cancer: A method and kit for inhibiting the proliferation of cancer cells are disclosed, based on a combination of a gemcitabine and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with gemcitabine alone or the telomerase inhibitor alone. Preferably, efficacy... Agent: Geron Corporation Attn. David J. Earp

20100016405 - Compositions and methods for inhibiting expression of the myc gene: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the MYC gene (MYC gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part... Agent: Alnylam/fenwick

20100016408 - Modulating the cdc14b-cdh1-plk1 axis and methods for sensitizing target cells to apoptosis: The invention relates to modulating Cdc14B levels (cell division cycle 14 homolog B) and/or Cdh1 (Fzr1 protein, CDC20-like 1b, or fizzy-related protein) levels to sensitize cells to DNA damage by increasing the abundance of Plk1 (polo-like kinase 1) in a target cell. In certain embodiments, the invention relates to modulating... Agent: Darby & Darby P.C.

20100016404 - Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use: Provided herein are methods of treating a pathophysiological state or symptoms thereof resulting from aldose reductase-mediated signaling in a cytotoxic pathway in a subject using an inhibitor of aldose reductase. Particularly, specific inhibitors may be a small-interfering RNA (siRNA) or may be inhibitors of glutathione-aldehyde binding to aldose reductase which... Agent: Benjamin Aaron Adler Adler & Associates

20100016412 - Inhibition of ornithine aminotransferase for the treatment of proliferative disorders: The invention relates to inhibition of ornithine aminotransferase (OAT) for suppression of tumor cells proliferation. More particularly, the invention relates to methods of treatment of proliferative disorders by the selective inhibition of OAT, and further provides the use of OAT inhibitors, specifically, 5-amino-1,3-hexadienyl-carboxylic acid (Gabaculine), and Gabaculine analogue 8, for... Agent: Edell, Shapiro & Finnan, LLC

20100016411 - Method of modulation of expression of epidermal growth factor receptor(egfr) involving mirna: The present invention relates to a method for modulating the expression of epidermal growth factor receptor (EGFR) and its downstream signalling effectors. In particular, the present invention relates to a method for modulating the expression of epidermal growth factor receptor (EGFR) or like molecule in a cell comprising contacting said... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100016410 - Methods and compositions related to eosinophil regulation: Disclosed are compositions and methods for regulating eosinophils.... Agent: Ballard Spahr LLP

20100016416 - Oligonucleotide conjugates: Oligonucleotide conjugates, where an oligonucleotide is covalently attached to an aromatic system, are provided. In particular embodiments the oligonucleotide is complementary to the RNA component of human telomerase and is covalently attached to a nucleobase via an optional linker. The conjugates inhibit telomerase enzyme activity.... Agent: Geron Corporation Attn. David J. Earp

20100016413 - Pathotropic targeted gene delivery system for cancer and other disorders: Systems for pathotropic (disease-seeking) targeted gene delivery are provided, including viral particles with extremely high titers. In particular, the viral particles are engineered to specifically deliver therapeutic or diagnostic agents to a disease site, such as cancer metastic sites. Personalized dosing regimens are also provided to treat diseases such as... Agent: Wilson, Sonsini, Goodrich & Rosati

20100016415 - Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines: The present invention is directed to reagents useful for generating immune responses to Mycobacterium tuberculosis and for diagnosing infection and disease in a subject that has been exposed to M. tuberculosis.... Agent: Patent Docket Administrator Lowenstein Sandler PC

20100016409 - Rna nanoparticles and nanotubes: The instant invention provides polyvalent RNA nanoparticles comprising RNA motifs as building blocks that can form RNA nanotubes. The polyvalent RNA nanoparticles are suitable for therapeutic or diagnostic use in a number of diseases or disorders.... Agent: Edwards Angell Palmer & Dodge LLP

20100016414 - Targets for human micro rnas in avian influenza virus (h5n1) genome: The present invention relates to targets for Human microRNAs in Avian Influenza Virus (H5N1) Genome and provides specific miRNA targets against H5N1 virus. Existing therapies for Avian flu are of limited use primarily due to genetic re-assortment of the viral genome, generating novel proteins, and thus escaping immune response. In... Agent: Seed Intellectual Property Law Group PLLC

20100016250 - Toll-like receptor 9 agonists: (wherein a represents 0 or 1; n represents an integer of 0 to 2; m represents an integer of 0 to 5; X1 and X2 each independently represent a hydrogen atom or hydroxy; Y represents an oxygen atom or a sulfur atom; -Q1-represents —O— or the like; -Q2- represents —O—... Agent: Edwards Angell Palmer & Dodge LLP

20100016252 - Mannich base n-oxide drugs: Disclosed are Mannich base N-oxides of drugs containing acidic N—H groups. Pharmaceutical compositions comprising a therapeutically effective amount of Mannich base N-oxides, or a N-oxide rearrangement product, pharmaceutically acceptable salt or prodrug thereof, are also disclosed. Further, disclosed are methods of using the compounds, alone or in combination with one... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100016251 - Nucleoside phosphoramidate prodrugs: s

20100016254 - Gemcitabine prodrugs, pharmaceutical compositions and uses thereof: The present invention provides gemcitabine prodrugs, methods of making gemcitabine prodrugs, pharmaceutical compositions of gemcitabine prodrugs and methods of using gemcitabine prodrugs and pharmaceutical compositions of using gemcitabine prodrugs to treat or prevent diseases or disorders such as cancer or viral infections.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20100016253 - Methods and compositions related to heightened apobec-1 related protein (arp) expression: Disclosed are methods and compositions related to determining the status and mechanisms underlying long-term nonprogression of viral infections.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100016255 - Method of treating vitamin b12 deficiency: A novel method and composition for treating vitamin B12 deficiency mammals that fail to respond to oral vitamin B12 therapy.... Agent: Emisphere Technologies, Inc. C/o Darby & Darby P.C.

20100016256 - Taxane compounds for treating eye disease: The present invention is directed to methods of treating eye disease. In one embodiment, the method can comprise administering a taxane-cobalamin bioconjugate or another taxane compound to a subject to treat the eye disease. In one embodiment, the bioconjugate can be dissolved in an aqueous solution prior to administration.... Agent: Thorpe North & Western, LLP.

20100016257 - Method of treatment for osteoarthritis by local intra-articular injection of microparticles: A method of treatment of osteoarthritis is described, where a therapeutically effective amount of a composition having biodegradable microparticles in an aqueous vehicle is delivered into the intra-articular space of a joint. In one aspect, the microparticle-containing composition is injected into the synovial fluid-containing portion of an affected joint.... Agent: Philip S. Johnson Johnson & Johnson

20100016258 - Phosphonate derivatives as autotaxin inhibitors: The present invention provides β-hydroxy phosphonate compounds that are autotaxin inhibitors.... Agent: Iplm Group, P.A.

20100016259 - Malonyl-coa decarboxylase inhibitors useful as metabolic modulators: The present invention relates to novel compounds (I), their prodrugs, and the pharmaceutically acceptable salts as well as pharmaceutical compositions containing such compounds useful in treating certain metabolic diseases and diseases modulated by the inhibition of the enzyme malonyl-coenzyme A decarboxylase (malonyl-CoA decarboxylase, MCD). In particular, the invention relates to... Agent: Fish & Richardson P.C.

20100016260 - Agonists of sphingosine-1 phosphate receptor (slp): The invention provides compounds of formula I and formula II, their preparation, and their use as pharmaceutically active immunosuppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or SIP receptors.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100016261 - Chemical compounds: A compound of formula (I) is described; wherein the substituents are as defined in the text and wherein the compound is intended for use in the production of a vascular damaging effect in a warm-blooded animal.... Agent: Michael Best & Friedrich LLP

20100016262 - Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis: The present invention relates to the discovery that acetylsalicylic acid (ASA or aspirin), salicylic acid (SA) and related salicylate esters and their pharmaceutically acceptable salts, when coadministered in effective amounts with a drug or other bioactive agent which typically (in the absence of the salicylate compound) produces significant hepatotoxicity as... Agent: Coleman Sudol Sapone, P.C.

20100016263 - 9, 10-secopregnane derivative and pharmaceutical: Y is a single bond, an alkylene, an alkenylene or phenylene; R1 and R2 are the same or different, each represents hydrogen, an alkyl or a cycloalkyl; or R1 and R2, taken together with the adjacent carbon atom, form a cycloalkyl; R3 is hydrogen or methyl; Z is hydrogen, hydroxy... Agent: Darby & Darby P.C.

20100016264 - Treatment for dry eye using testosterone and progestagen: The present invention comprises a composition and methods for treating eye conditions using a composition having a therapeutically effective amount of a progestagen, or a therapeutically effective amount of a progestagen with a testosterone; and pharmaceutically acceptable carrier, wherein the composition is applied to the palpebral part of the eye... Agent: Patton Boggs LLP

20100016265 - Anti-inflammatory composition and method for preparation: A pharmaceutical anti-inflammatory preparation and method for preparation and treatment of arthritis and related inflammatory conditions used for mild to severe pain for relatively long acting results. This anti-inflammatory preparation comprises anti-inflammatory corticord steroid in aqueous-like suspension, a muscle relaxant in oil-like composition, and amide anesthetic compound in aqueous-like composition... Agent: Michael L. Parks Parks & Associates, PLLC

20100016266 - Pyridine imidazoles and aza-indoles as progesterone receptor modulators: The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders mediated by one or more estrogen receptors. The compounds of the invention are useful in the treatment of disorders associated with the depletion of estrogen such as... Agent: Philip S. Johnson Johnson & Johnson

20100016267 - Pharmaceutical compositions for administraton to a sinus: Pharmaceutical compositions for delivering a drug to a sinus in a subject are provided. The compositions are formed by the combination of a carrier material and a drug and are specially adapted for delivery to a sinus. The compositions have no fixed shape, and the carrier material serves to increase... Agent: Durect Corporation Thomas P. Mccracken

20100016268 - Method and system for dermal tissue treatment: A method and article of manufacture of treating abnormal biological tissue. The article includes use of electrochemically treated water in combination with a biologically active tissue treatment component, particularly for dermal tissue treatment. The electrochemical treatment method includes exposure of untreated water to halogen containing species, such as hypochlorous and... Agent: Foley & Lardner LLP

20100016269 - Composition of plant sterol and phosphatidylcholine and method for producing the same: The present invention is intended to discover a composition that contains a large amount of a plant sterol completely insoluble in water and exhibiting poor solubility in oil because of its extremely high crystallinity. Such composition can be easily dispersed in water, and to produce the composition. It has been... Agent: Lucas & Mercanti, LLP

20100016270 - Bridged polycyclic compound based compositions for controlling cholesterol levels: A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups,... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20100016271 - Anti-dandruff hair conditioning compositions: A hair conditioning composition comprising a cationic surfactant, triglyceride oil, and an anti dandruff agent.... Agent: Unilever Patent Group

20100016272 - Heteroarylacrylamides and their use as pharmaceuticals: in which Het, X, Ra, Rb, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100016274 - Beta-lactam cannabinoid receptor modulators: Described herein are substituted 2-(azetidin-2-on-1-yl)alkanoic acids, alkanedioic acids and 2-hydroxyalkyl alkanoic acids, and 2-acyl alkanoic acids, and derivatives thereof, that are capable of modulating activity at the cannabinoid-1 (CB1) and/or cannabinoid-2 (CB2) receptor. Also described herein are methods for treating mammals in need of relief from disease states associated with... Agent: Barnes & Thornburg LLP

20100016273 - Use of ezetimibe in the prevention and treatment of cholesterol gallstones: This invention discloses the use of compounds of the azetidinone family in the prevention or treatment of cholesterol gallstone disease of the biliary tree in mammals. This invention is in the general area of cholesterol stones disease in the biliary tree and gallbladder. In particular, the invention evidences that the... Agent: Merchant & Gould PC

20100016276 - Compositions and methods for the identification of a carbapenemase gene: Compositions and methods for the rapid and sensitive detection of a carbapenemase in a sample is provided. The compositions include novel primer and probe compositions for use in detecting the presence of this enzyme in a sample, particularly using PCR methods. These primers and probe sets can be used in... Agent: David W. Highet, Vp & ChiefIPCounsel Becton, Dickinson And Company

20100016277 - Diazabicyclic central nervous system active agents: m

20100016278 - Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals: in which Het, X, Ra, Rb, Rc, Rd, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100016275 - Novel compound 395:

20100016279 - Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155: wherein the integers X1, X2, X3, Ring A, R4, R5 and m are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or... Agent: Astrazeneca R&d Boston

20100016280 - Low dosage serotonin 5-ht2a receptor agonist to suppress inflammation: Activation of 5-HT2A receptors using agonists at surprisingly low concentrations was shown to potently inhibit TNF-α-induced inflammation in multiple cell types. Significantly, proinflammatory markers were also inhibited by the agonist, (R)-DOI, even many hours after treatment with TNF-α. With the exception of a few natural toxins, no current drugs or... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20100016282 - Novel heterocyclyl compounds: wherein A, X, Y1, Y2, Y3, R3, R4, R5, R6, R7, R8, R9, R10, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100016281 - Pyrimidine compounds as serotonin receptor modulators: Certain pyrimidine-containing compounds are serotonin receptor modulators useful in the treatment of serotonin-mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20100016283 - Compounds and uses thereof - 150: Formula (I) below: and their pharmaceutically acceptable salts or tautomers, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of at least one symptom or condition associated with schizophrenia and other psychotic disorders, dementia and other cognitive disorders, anxiety disorders, mood disorders, sleep disorders, disorders... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100016284 - Compounds and uses thereof - 151: This invention relates to novel compounds having the structural Formula I below: and their pharmaceutically acceptable salts or tautomers, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of at least one symptom or condition associated with schizophrenia and other psychotic disorders, dementia and other... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100016285 - Heterocyclidene-n-(aryl) acetamide derivative: (wherein k, m, n, and p each represent 0 to 2; j and q represents 0 or 1; R1 represents a halogen atom, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, NH2, OH, a carboxyl group, an alkanoyl group, CN, NO2, or the like; R2 represents... Agent: Oliff & Berridge, PLC

20100016286 - Anti-inflammatory agents: The invention provides compounds, pharmaceutical compositions and uses of compounds and salts thereof of general formula (I), for the preparation of a medicament for treatment of an inflammatory disorder, but excluding (S)-3-(r-methylcyclohexyl-carbonylamino)-caprolactam: wherein z is 1, 2, 3 or 4; A is —CO— or —SO2-; Q is linear or branched... Agent: Schwegman, Lundberg & Woessner, P.A.

20100016287 - Compounds having affinity for dopamine d3 receptor and uses thereof\": e

20100016288 - Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof: Compounds with α7 nicotinic acetylcholine receptor (α7 nAChR) agonistic activity, processes for their preparation, pharmaceutical compositions containing the same and the use thereof for the treatment of neurological and psychiatric diseases.... Agent: Arent Fox LLP

20100016289 - Compounds useful as antagonists of ccr2: The present invention provides compounds of general formula I: (I) or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R1 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR2 and accordingly are useful for the treatment of a variety of inflammatory, allergic,... Agent: Millennium Pharmaceuticals, Inc.

20100016290 - Amorphous polymorph of bazedoxifene acetate: The invention provides a novel polymorphic form C of bazedoxifene acetate, methods of preparing the polymorphic form, and compositions and methods of treatment using the polymorphic form.... Agent: Wilmerhale/wyeth LLC

20100016291 - Mtp inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives: The present invention is concerned with novel tetrahydro-naphthalene-1-carboxylic acid derivatives having apoB secretion/MTP inhibiting activity and concomitant lipid lowering activity. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of... Agent: Philip S. Johnson Johnson & Johnson

20100016292 - Inhibitors of lethal factor protease: The invention provides compounds that can efficiently and specifically inhibit bacterial toxins, such as inhibit the lethal factor (LF) protease activity of anthrax toxin and/or botulinum neurotoxin type A. The invention also provides methods for inhibiting proteases, such as lethal factor protease, as well as methods for treating bacterial infections,... Agent: Schwegman, Lundberg & Woessner, P.A.

20100016293 - Quinazolines and related heterocyclic compounds, and their therapeutic use: Compounds that interact with the histamine H4 receptor, and which may be useful for treating or preventing disorders and conditions mediated by the histamine H4 receptor, e.g. inflammation, are of formula (I) wherein Q is CR1 or N; X is CR2 or N, provided that Q and X are not... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100016294 - Methods for reducing the risk of an adverse drug interaction in a patient suffering from insomnia: Disclosed herein is a method for treating a patient with Quazepam that reduces the risk of an adverse interaction between the Quazepam and drug that is a substrate of the cytochrome P450 enzyme isoform 2B6 (CYP2B6 substrate drug), e.g., Bupropion. The method includes determining if the patient to be treated... Agent: Wilson, Sonsini, Goodrich & Rosati

20100016295 - Preparation and use of biphenyl amino acid derivatives for the treatment of obesity: This invention relates to certain biphenyl amino acid compounds, compositions, and methods for treating or preventing obesity and related diseases.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100016297 - Alkyl-substituted 3' compounds having 5-ht6 receptor affinity: i

20100016296 - Heteroaryl compounds and uses thereof: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.... Agent: Patent Department Choate, Hall & Stewart LLP

20100016298 - Theramutein modulators: This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified... Agent: Kenyon & Kenyon LLP

20100016299 - Substituted benzoxepino-isoxazoles and use thereof: The present application relates to novel substituted benzoxepinoisoxazole derivatives, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular disorders, especially of dyslipidemias, arteriosclerosis, restenosis and... Agent: Edwards Angell Palmer & Dodge LLP

20100016300 - Imidazoacridine compounds for treating flt3-mediated disorders: A method of treating a FLT3-mediated condition in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof: (I), The conditions that can be treated by the compounds of the present invention and the... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100016301 - Inhibitors of bruton's tyrosine kinase: wherein, variables Q, R, X, Y1, Y2, Y3, Y4, n, and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20100016302 - Inhibitors of bruton's tyrosine kinase: wherein, variables Q, R, Y1, Y2, Y3, Y4, n, and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune... Agent: Roche Palo Alto LLC

20100016303 - Novel phenylimidazole derivatives as pde10a enzyme inhibitors: This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20100016304 - Glucokinase activator: (wherein the carbon atom denoted by * is in the R-configuration; R1 and R2 are each independently a hydrogen atom, a halogen atom, an amino group, a hydroxyl group, a hydroxyamino group, a nitro group, a cyano group, a sulfamoyl group, a C1-C6 alkyl group, a C1-C6 alkoxy group, a... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100016305 - Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders: The present invention relates generally to a method for the treatment of renal failure or renal hypertension and, more particularly, for improving the recovery from acute renal failure or renal hypertension by treatment with activators of soluble guanylate cyclase or stimulators of guanylate cyclase.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100016306 - Pyrimidine derivatives as pi3k inhibitors: wherein R1-R3 have any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with PI3 kinase, in particular the p110 delta subtype, such... Agent: Viksnins Harris & Padys Pllp

20100016307 - Novel compounds: e

20100016309 - 1,2,3,4-tetrahydroisoquinoline derivatives, preparation process therefor and pharmaceutical composition containing the same: wherein R1 represents propargyl or cyclopropylmethyl; wherein R2 represents N-ethyl-N-methylamino, 1-Pyrrolidyl, 1-Piperidinyl, or 1-Morpholinyl. The invention provides further a process for preparing said derivatives and a pharmaceutical composition containing the same. Said derivatives can be used to modulate the proteolytic process of amyloid precursor proteins (APP), and provides further novel... Agent: Schmeiser Olsen & Watts

20100016314 - Derivatives of azabicyclo octane, the method of making them and the uses thereof as inhibitors of dipeptidyl peptidase iv: Derivatives of azabicyclo octane presented by formula (I), the method of making them, and the compositions containing the same and the uses thereof as inhibitors of dipeptidyl peptidase IV (DPP-IV), wherein the substitutes in formula (I) have the same meanings as what is mentioned in the descriptions.... Agent: Birch Stewart Kolasch & Birch

20100016313 - Intestinal alkaline phosphatase modulators and uses thereof: Disclosed are modulators, i.e., activators and inhibitors, of Intestinal Alkaline Phosphatase (IAP). Also disclosed are methods for treating bacterial infections of the intestinal tract and methods for maintaining the health of the intestinal tract using IAP activators. Further disclosed are methods to assist in weight gain of emaciated patients and... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100016310 - Methods of using aryl sulfonyl compounds effective as soluble epoxide hydrolase inhibitors: Disclosed are methods of using soluble epoxide hydrolase (sEH) inhibitors for treating diseases related to cardiovascular disease.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100016311 - Novel minor groove binders: There is provided compounds of formula (I), wherein R1, R11, R12, Qa, X, Qb, Qc, A and D have meanings given in the description, or a pharmaceutically acceptable salt or solvate thereof, which compound, salt or solvate binds to the minor groove of DNA.... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20100016312 - Substituted indolyl and indazolyl derivatives and uses thereof: e

20100016308 - Tetrahydroindole derivatives for treatment of alzheimer's disease: Tetrahydroindole derivatives of formula (I): are disclosed. These compounds modulate the activity of gamma-secretase and hence find use in treatment or prevention of Alzheimer's disease.... Agent: Merck And Co., Inc

20100016315 - Iminopyridine derivative and use thereof: wherein each symbol is as defined in the specification, or a salt thereof, and a method of screening for an agent having an α1D adrenergic receptor antagonistic action for the prophylaxis or treatment of a lower urinary tract disease, which includes measuring the bladder smooth muscle tension of rats with... Agent: Sughrue Mion, PLLC

20100016318 - Anthranilamide inhibitors of aurora kinase: e

20100016316 - Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors: or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L1, R3, R4, R8a, R11 and M are as defined herein. The compounds of Formula (I) or (II) are selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example... Agent: Louis J. Wille Bristol-myers Squibb Company

20100016317 - Hiv inhibiting 6-substituted pyrimidines:

20100016320 - Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors: and pharmaceutically-acceptable salts, prodrugs, solvates, isomers, and/or hydrates thereof, wherein Q is an optionally-substituted phenyl, pyridyl, pyridazinyl, pyrimidinyl, or pyrazinyl ring; R2 is alkyl or an amino group as defined herein; and Z is optionally-substituted oxadiazolyl or —C(═O)NR6, wherein R6 is lower alkyl or cyclopropyl. The compounds are surprisingly advantageous... Agent: Louis J. Wille Bristol-myers Squibb Company

20100016319 - Arylmethylene urea derivative and use thereof: d

20100016321 - Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulator: The present invention relates to certain novel compounds of the formula (I) to processes for preparing such compounds, to their utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory... Agent: Pepper Hamilton LLP

20100016322 - Water dispersible pharmaceutical formulation and process for preparing the same: Water dispersible compressed tablets and a process for preparing the same. The tablet comprising about 0.1 to 50% w/w of lamotrigine or its pharmaceutically acceptable salts, solvates, hydrates or polymorphs, about 5 to about 50% w/w of a water-soluble diluent(s), about 15 to about 70% w/w of a water swellable... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20100016323 - 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors: t

20100016324 - Pharmaceutical compositions for the treatment of cellulite: There are disclosed pharmaceutical compositions for topical administration or for use in mesotherapy, containing a PDE3 inhibitor as active ingredient, and their use in the treatment of cellulite.... Agent: Young & Thompson

20100016325 - Tetrahydrocinnoline derivatives: e

20100016326 - Concentrated methotrexate solutions: Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 25 mg/ml. The invention also... Agent: Scully Scott Murphy & Presser, PC

20100016328 - Pterin analogs: Disclosed herein are analogs of tetrahydrobiopterin, compositions containing the same, and methods of treating an individual suffering from a condition responsive to tetrahydrobiopterin by administration of the analog. These analogs are contemplated for use wherever tetrahydrobiopterin is currently used to treat conditions responsive to tetrahydrobiopterin therapies.... Agent: Jones Day

20100016327 - Quinoline compounds: s

20100016330 - Novel derivatives: The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100016329 - Xanthine-based cyclic gmp-enhancing rho-kinase inhibitor inhibits physiological activities of lung epithelial cell line: The present invention provides a pharmaceutical composition including a compound of 7-[2-[4-(2-chlorophenyl)piperazinyl]-ethyl]-1,3-dimethylxanthine (KMUP-1), wherein the compound is a Rho-kinase inhibitor, and the pharmaceutical composition inhibits a physiological activity of a lung epithelial cell.... Agent: Volpe And Koenig, P.C.

20100016331 - Novel compounds: e

20100016332 - Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride: The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbomyl-benzofuran-5-yl)-piperazine, crystaline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbomyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia,... Agent: Millen, White, Zelano & Branigan, P.C.

20100016333 - Once-a-day (rna-polymerase inhibiting or phenazine) - dihydropteroate synthase inhibiting - dihydrofolate reductase inhibiting antibiotic pharmaceutical product, formulation thereof, and use thereof in treating infection caused by methicillin-resistant st: Disclosed are once-a-day antibiotic products for treating Methicillin-Resistant Staphylococcus aureus, or “MRSA,” the products comprising: a combination of at least three different antibiotics, wherein one of the at least three different antibiotics is selected from the group consisting of RNA-Polymerase Inhibiting antibiotics or Phenazine antibiotics, wherein one of the at... Agent: Raymond E. Stauffer, Esq. C/o Carella, Byrne, Bain, Gilfillan, Cecchi,

20100016334 - Pharmaceutical formulations containing dopamine receptor ligands: The present invention relates to stable and bioavailable immediate release formulations comprising dopamine receptor ligands. Methods of treating various disorders by administering the formulations are also described.... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20100016336 - Human protein tyrosine phosphatase inhibitors and methods of use: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis.... Agent: Ballard Spahr LLP

20100016335 - Novel aminopyridine derivatives having aurora a selective inhibitory action: e

20100016338 - 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1-arylquinolin-2-ones, a process for their production and their use as anti-inflammatory agents:

20100016337 - Heteroaryl-substituted carboxamides and their use as pharmaceuticals: in which Het, A, X, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100016339 - Fungicidal compounds and compositions: The present invention relates, inter alia, to a compound having the formula (I):—wherein (R)n is selected from the group consisting of 4-Br, 4-OCH2CH3, 4-OCH2CF3, 2-CH3-4-Cl, 2-CH3-4-OCH3, 2-CH3-4-OCF3, 2-F-4-Br, 2-F-4-CF3, 3-CH3-4-Br, 3-F-4-Cl, 3-F-4-CH3, 3-F-4-Br, 3-F-4-OCH3 and 3-F-4-F. The present invention further relates to a fungicidal composition comprising a compound having the... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100016340 - Pharmaceutical compounds: e

20100016341 - Aspartyl protease inhibitors containing a tricyclic ring system: Disclosed are compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof or wherein R1, R2, R3, R4, R6, R7, R14, W, V, X, Y, A and b are as described above in the specification. Also disclosed is a method of inhibiting aspartyl protease, methods... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20100016342 - Solid forms comprising 3-(2,5-dimethyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same: Provided herein are solid forms comprising 3-(2,5-dimethyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione. Pharmaceutical compositions comprising the solid forms and methods for treating, preventing and managing various disorders are also disclosed.... Agent: Jones Day

20100016343 - Alpha7 nicotinic acetylcholine receptor inhibitors: The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.... Agent: Choate, Hall & Stewart LLP

20100016344 - Amino heterocyclic linked pyrimidine derivatives: Macrocyclic benzofused pyrimidine compounds, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions and disorders using such compounds and compositions are described herein.... Agent: Paul D. Yasger Abbott Laboratories

20100016345 - Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4: Disclosed are compounds, which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a human or animal subject such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease,... Agent: Swiss Tanner, P.C. P.o. Box 1749

20100016346 - Elasmobranch-repelling dompounds and methods of use: Compounds for repelling elasmobranch having an aldehyde or derivative, a carboxylic acid a derivative, a ketone or a derivative thereof, a di-ketone or a derivative thereof, a pyridine or derivative thereof, or an antipyrine or a derivative thereof and methods of use thereof.... Agent: Kenyon & Kenyon LLP

20100016347 - Series of skin whitening (lightening) compounds: The present invention is directed to inhibitors of tyrosinase, pharmaceutical compositions comprising such tyrosinase inhibitors, and methods of making and using the same. Specifically, included in the present invention are compositions of matter comprised of at least one 2,4-dihydroxybenzene analog, which inhibit the activity of tyrosinase and which inhibit the... Agent: Swanson & Bratschun, L.L.C.

20100016348 - Orally disintegrative dosage form: The present invention features an orally disintegrating dosage form including from about 5% to about 40%, by weight, of at least one hydrated salt and a pharmaceutically active agent, wherein the at least hydrated salt has a dehydration temperature of from about 20 to about 120° C.... Agent: Philip S. Johnson Johnson & Johnson

20100016349 - Pseudoazulenyl nitrones: Disclosed herein are pseudoazulenyl nitrone compounds and methods of using these compounds to trap free radicals and to treat, prevent, or ameliorate various diseases associated with free radicals.... Agent: Marshall, Gerstein & Borun LLP

20100016350 - Novel mch receptor antagonists: The present invention relates to a melanin concentrating hormone antagonist compound of formula (I): wherein R1, Ra, Rb, R2, L1, R3, R4 and R5 are as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases.... Agent: Eli Lilly & Company

20100016351 - Nicotinic alpha-7 receptor ligands and preparation and uses thereof: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds which act as ligands for the α7... Agent: Millen, White, Zelano & Branigan, P.C.

20100016352 - Compounds and methods for treating estrogen receptor-related diseases: Provided herein in certain embodiments are compounds, pharmaceutical compositions and methods for modulating the functions of estrogen receptor alpha 36, for preventing and/or treating diseases mediated by estrogen receptor alpha 36, for preventing and/or treating osteoporosis, for inducing cell death and/or inhibiting cell proliferation and for preventing and/or treating diseases... Agent: Perkins Coie LLP

20100016355 - Alpha-2b adrenergic receptor agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain: Disclosed herein is a pharmaceutical composition comprising a serotonin-norepinephrine reuptake inhibitor and an alpha-2B receptor agonist. The composition is effective for treating chronic pain, and methods of treating pain using the composition and compounds comprising it are also disclosed.... Agent: Allergan, Inc.

20100016353 - Benzoimidazole derivatives useful as antiproliferative agents: The invention relates to substantially pure compounds of the formula (1) and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R, R1, R2, R3, R4, and R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising the compounds of formula (1) and methods of treating abnormal... Agent: Pharmacia Corporation Global Patent Department

20100016356 - Method for treating thrombosis and inhibiting platelet aggregation with 21-(s)-argatroban: A method for inhibiting coagulation including administering to a patient in need thereof a pharmaceutical composition having 21-(S)-Argatroban and/or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for inhibiting coagulation having 21-(S)-Argatroban and/or a pharmaceutically acceptable salt thereof. Compared with 21 (R) Argatroban, 21-(S)-Argatroban significantly prolongs coagulation time of... Agent: Matthias Scholl

20100016354 - Novel oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity: The present invention relates to Compounds represented by the formula (I) or salts thereof. In the formula (I), the ring A represents a benzene ring, a thiophene ring, or a pyridine ring; Ra represents a hydrogen atom, a halogen atom, an alkyl group, or an alkoxy group; the ring B... Agent: Frishauf, Holtz, Goodman & Chick, PC

20100016357 - Use of beta-aminoalcohols for the treatment of inflammatory disorders and pain: Compounds that may be used for the treatment or prevention of a condition associated with T-cell proliferation or that is mediated by pro-inflammatory cytokines are of formula (I): wherein at least one of R1, R2 or R3 is not H and each is independently H, alkyl, CF3, CONH2, CN, halogen,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100016360 - Alpha7 nicotinic acetylcholine receptor inhibitors: The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.... Agent: Choate, Hall & Stewart LLP

20100016361 - Aryl carboxylic acid cyclohexyl amide derivatives: A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: (I) wherein the variants R and X are defined in the specification.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100016358 - Gamma-globin inducer: The present invention is directed to a γ-globin inducer, to a prophylactic and/or therapeutic agent for sickle cell disease, and to a prophylactic and/or therapeutic agent for β-thalassemia, each containing, as an active ingredient, 4-[N-(4-methoxyphenyl)-N-[[5-(3,4,5-trimethoxyphenyl)pyridin-3-yl]methyl]amino]-1-[[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl]piperidine, a salt thereof, or a solvate of either of these.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100016359 - Methods for controlling sr protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control sr protein activity: The present invention provides: (1) antiviral agents that act by reducing or inhibiting the activity of SR proteins, more specifically, (i) antiviral agents that act by enhancing dephosphorylation of SR proteins, and (ii) antiviral agents that act by inhibiting proteins that phosphorylate SR proteins; (2) antiviral agents that act by... Agent: Klarquist Sparkman, LLP

20100016362 - Stabilized pharmaceutical composition containing donepezil, process of producing same and method for stabilization: An object of the present invention is to provide a novel pharmaceutical composition containing donepezil, which is already used as a remedy for the treatment of dementia (cognitive impairment), in order to increase options for administration methods and improve patient compliance. The present invention provides a pharmaceutical composition containing donepezil... Agent: Birch Stewart Kolasch & Birch

20100016363 - Fixed combination dosage forms for the treatment of migraine: Therapeutic regimens and dosage forms are disclosed for the treatment of migraine headache. The regimens preferably combine a serotonin receptor agonist, such as sumatriptan, eletriptan or almotriptan, with a fast acting formulation of diclofenac potassium.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100016364 - Method of predictive determination of responsiveness to pharmacological intervention: A diagnostic test for determining the efficacy of 5HT1 agonists in a human patient exhibiting symptoms of a cranial facial pain syndrome includes the steps of collecting a sample of saliva from said human patient; and identifying whether calcitonin-gene-related peptide is present in said sample of saliva.... Agent: Husch Blackwell Sanders LLP

20100016365 - Substituted 4-amino-piperidines: The present invention relates to new substituted 4-amino-piperidine opioid receptor modulators, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100016366 - Novel compounds active as muscarinic receptor antagonists: e

20100016367 - Bis-pyrinidium compounds: A method of treating, inhibiting, or preventing an infection in a subject is described. The method comprises administering to the subject an effective amount of at least one bis-pyridinium compound. The bis-pyridinium compound comprises two aromatic ring structures. Each of the ring structures comprises a pyridine ring, and the ring... Agent: Townsend And Townsend And Crew, LLP

20100016368 - Aminotetrahydroindazoloacetic acids: and pharmaceutically acceptable salts and esters thereof, wherein Q, R1-R3 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100016369 - Aminotetrahydroindazoloacetic acids: and pharmaceutically acceptable salts and esters thereof, wherein Q, W, X, R1-R5 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100016370 - Process for the preparation of esomeprazole magnesium in a stable form: There is provided a process for preparing purified esomeprazole magnesium, comprising the steps of: providing esomeprazole magnesium; contacting said esomeprazole magnesium with a non-solvent comprising an aqueous component up to a maximum content defined by water saturation in the non-solvent; and recovering purified esomeprazole magnesium formed from the contacting step.... Agent: Arent Fox LLP

20100016372 - Benzimidazole derivatives: Novel compounds of the formula I (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R, Q, W, X and Z have the meanings indicated in Patent Claim 1, are suitable as antidiabetics.... Agent: Millen, White, Zelano & Branigan, P.C.

20100016371 - Indole compounds: The present application relates to compounds of formula (I) or a pharmaceutically acceptable derivative thereof; wherein X, R1, R2, and R3 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100016373 - Imidazole carboxamides: The present invention provides certain imidazole carboxamide derivatives, pharmaceutical compositions thereof, methods of using the same and processes for preparing the same.... Agent: Eli Lilly & Company

20100016375 - 1,5-diphenyl-3-pyridinylamino-1,5-dihydropyrrolidin-2-one as cb1 receptor modulator: Compound and pharmaceutical compositions of Formula by blockade of the CB1 receptors via an inverse agonism mechanism, and are useful for reducing body weight in mammals, cognitive impairment associated with schizophrenia, mitigating treatment emergent weight gain observed during treatment with antipsychotics and have increased bioavailability.... Agent: Eli Lilly & Company

20100016374 - Compounds which inhibit the glycine transporter and uses thereof: wherein R2 is selected from phenyl substituted with n R1 groups, and pyridyl substituted with n R1 groups; n=0, 1 or 2; each R1 is independently selected from the group consisting of halo, C1-4alkyl, C1-4alkoxy, haloC1-4alkyl, haloC1-4alkoxy and cyano; R3 is selected from hydrogen and C1-2 alkyl; R4 is selected... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100016376 - Caspase inhibitors based on pyridone scaffold: The present invention relates to a pyridone derivative which can be used as a caspase inhibitor, process for the preparation thereof, and pharmaceutical composition for inhibiting caspase comprising the same.... Agent: Birch Stewart Kolasch & Birch

20100016377 - Use of a p38 kinase inhibitor for treating psychiatric disorders: The use of 6-(S-Cyclopropylcarbamoyl-S-fluoro-2-methyl-phenyl)-N-(2,2-dimethylproyl)-nicotinamide, which is known in the art as a p38 kinase inhibitor in the treatment or prophlaxis of one or more psychiatric disorders.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100016378 - Method of preventing dihydropyridine compound from degradation: As the addition of water to dihydropyridine compounds such as amlodipine accelerates their degradation into the pyridine form, either immediately or following the formation of unstable hydrates, methods for producing pharmaceutical compositions that contain dihydropyridine compounds are limited to methods in which no water is added, such as methods in... Agent: Birch Stewart Kolasch & Birch

20100016379 - Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors: Described herein are compounds having a terephthalamate structural feature. Also described herein, are methods of making such compounds, methods of using such compounds to modulate the activity of HIV integase, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and... Agent: Genomics Institute Of The Novartis Research Foundation

20100016380 - Tnf-alpha production inhibitors: wherein A is —O—; B is alkylene or alkenylene optionally containing —O—, —S—, —(NR7)—, —CO— or —N═; R1 and R2 are alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl is unsubstituted or substituted by halogen, cycloalkyl, aryl, adamantyl or amino; R3 is a substituted... Agent: Frishauf, Holtz, Goodman & Chick, PC

20100016381 - Stable emulsion composition: The present invention provides an emulsion composition comprising (A) a compound stable in an acidic range, and (B) a buffer, wherein the pH is adjusted from about 3.7 to about 5.5.... Agent: Edwards Angell Palmer & Dodge LLP

20100016383 - 4-(3,3-dihalo-allyloxy)phenol derivatives having pesticidal properties: and, where applicable, their possible E/Z isomers, E/Z isomeric mixtures and/or tautomers, in each case in free form or in salt form, a process for the preparation of those compounds and their use, pesticidal compositions in which the active ingredient has been selected from those compounds or an agrochemically acceptable... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100016382 - Pharmaceutical composition: The present invention provides a solid pharmaceutical composition containing an active ingredient, a fat and oil-like substance having a low melting point and a low viscosity binder, and a method of improving dissolution of an active ingredient from a solid pharmaceutical composition containing the active ingredient and a fat and... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100016384 - Pesticidal composition and method for controlling a pest: A pesticidal composition containing 4-methoxymethyl-2,3,5,6-tetrafluorobenzyl 3-(2-cyano-1-propenyl)-2,2-dimethylcyclopropanecarboxylate and 1-(2-chloro-1,3-thiazolyl)methyl-3-methyl-2-nitroguanidine has a high pesticidal activity.... Agent: Birch Stewart Kolasch & Birch

20100016385 - Process and formulation containing epothilones and analogs thereof: A process for formulating certain epothilones and analogs thereof for parenteral administration is provided wherein the pH of the formulation for administration can be controlled to enhance the stability and thus, potency of the epothilone, or analog thereof.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100016387 - Method of treatment: Method of preventing or treating myocardial ischemia by inhibiting DGAT1 enzyme with a DGAT1 inhibitor compound.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100016388 - Salts of a selective beta-2 andrenoceptor agonist: A pharmaceutically acceptable salt of 7-[(1R)-2-({2-[3-{[2-(2-Chlorophenyl)ethyl]amino}propyl)thio]ethyl}amino)-1-hydroxyethyl]-4-hydroxy-1,3-benzothia-zol-2(3H)-one provided it is not the ditrifluoroacetate, dihydrobromide or di-acetate salt; and the use of such a compound as a medicament (for example in the treatment of respiratory diseases (such as asthma or COPD).... Agent: Fish & Richardson P.C.

20100016386 - Selective glycosidase inhibitors and uses thereof: The invention provides compounds of formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc... Agent: Clark & Elbing LLP

20100016389 - Indole acetic acids exhibiting crth2 receptor antagonism and uses thereof: The invention relates to indole acetic acid compounds which function as antagonists of the CRTH2 receptor. The invention also relates to the use of these compounds to inhibit the binding of prostaglandin D2 and its metabolites or certain thromboxane metabolites to the CRTH2 receptor and to treat disorders responsive to... Agent: Wyeth LLC/finnegan Henderson, LLP

20100016390 - Stable, low voc, low viscous biocidal formulations and method of making such formulations: A stable, low VOC, low viscosity biocide formulation comprising an effective amount of at least one biocide, 1,2-benzisothiazolin-3-one (BIT), and a polyglycol liquid carrier of formula (I): R—O-(AO)n—O—R1, wherein n is 4-25, R and R′ are hydrogen, C1-C3 alkyl groups, O═C—CH3 group, or O═C—C2H5 group, and AO is a) CH2CH2O,... Agent: The Dow Chemical Company

20100016391 - Isoxazoline compounds having mif antagonist activity: Methods of use and pharmaceutical compositions for a genus of low molecular weight compounds comprising optionally substituted isoxazoline ring systems that act as inhibitors of MIF (macrophage migration inhibitory factor) are disclosed. Specifically, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses,... Agent: Law Office Of John K. Pike, PLLC

20100016392 - Pesticidal aggregates: In one aspect, this invention relates to a substantially water-insoluble pesticidal aggregate produced from a mixture comprising: (a) a polymer having at least three similarly charged electrostatic moieties; (b) an amphiphilic surfactant having at least one electrostatically charged moiety of opposite charge to the polymer; and (c) a pesticide. In... Agent: Patent Administrator Fmc Corporation

20100016394 - Biocidal compositions: Provided are synergistic biocidal compositions. The compositions comprise diiodomethyltolylsulfone and methyl 2-benzimidazolecarbamate and optionally 1,3-dicyano-tetrachlorobenzene. The compositions are useful for controlling growth of microorganisms in a variety of applications, including in building materials such as wallboard panels.... Agent: The Dow Chemical Company

20100016393 - Novel hydrogen sulfate salt: The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation. Compound I... Agent: Hogan & Hartson LLP

20100016395 - Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia: Ophthalmic compositions for the treatment of presbyopia, including combinations of parasympathomimetics and non-steroidal anti-inflammatories.... Agent: Young & Thompson

20100016396 - Pyrazole compound: h

20100016397 - Pyrrole and pyrazole daao inhibitors:

20100016398 - Combination product for controlling parasites on animals: The invention relates to novel compositions for controlling parasites on animals, comprising an N-arylpyrazole and also a pyrethroid in a formulation comprising aliphatic cyclic carbonates and aliphatic cyclic or acyclic polyethers.... Agent: Bayer Healthcare LLC

20100016399 - Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders: wherein R1, R2, R3, R4, R5, R6, R7, R8, R21 and m are as defined in the description. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed. The invention further... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100016401 - 3-aza-bicyclo[3.1.0]hexane derivatives: The invention relates to 3-aza-bicyclo[3.1.0]hexane derivatives of formula (I) wherein A, B, n, X, and R1 are as described in the description, and salts thereof, and their use as orexin receptor antagonists.... Agent: Hoxie & Associates LLC

20100016400 - Azabicyclic muscarinic receptor antagonists: The present invention generally relates to muscarinic receptor antagonists, which are useful for treating various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to processes for preparing compounds described herein, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases... Agent: Ranbaxy Inc.

20100016402 - Unit dose formulations of ketorolac for intranasal administration: This invention relates to therapeutic compositions, particularly sprayable aqueous compositions, and unit dose formulations comprise ketorolac or a pharmaceutically acceptable salt, alone or in combination with lidocaine or a pharmaceutically acceptable salt thereof. The compositions are nasally administered to a subject in need thereof to treat pain or inflammation.... Agent: Foley & Lardner LLP

20100016403 - Use of d-serine derivatives for the treatment of anxiety disorders: Compounds of Formula I are useful for the treatment of anxiety disorders such as generalized anxiety disorder (GAD), panic attack, post traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD) and social phobias. wherein: A is chosen from: aryl or heteroaryl, A being optionally substituted with up to 5 independently-selected groups... Agent: Stoel Rives LLP - Slc

20100016417 - Elastin protective polyphenolics and methods of using the same: Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for... Agent: Pepper Hamilton LLP

20100016418 - Cannabinoids for use in the treatment of neuropathic pain: The present invention relates to the use of cannabidiol (CBD) type compounds or derivative thereof and tetrahydro-cannabinol (THC) type compounds or derivative thereof in the manufacture of a medicament for the treatment of neuropathic pain. Preferably the ratio of the CBD type compounds or derivative thereof and THC type compounds... Agent: Wolf Greenfield & Sacks, P.C.

20100016419 - Antibacterial composition: e

20100016420 - Composition for the treatment of resistant cancers comprising oridonin: The present invention relates to the treatment of therapy-resistant neoplasias. The compounds and methods of the invention are particularly useful for the treatment of taxol-resistant human cancers, particularly cervical and breast cancer. Components of the compositions of the present invention show strong synergy with one another allowing them to be... Agent: Antoinette G. Giugliano, P.C. Dba Agg Intellectual Property Law

20100016421 - Methods for determining sensitivity to aminoflavones: Methods and compositions for treating cancer are discussed herein. Specifically, methods for determining the sensitivity of a patient to treatment with therapeutic agents, compositions for treating patients, and the treatment methods thereof are provided.... Agent: Dickstein Shapiro LLP

20100016422 - Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use: Solid forms of anhydrous (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol are disclosed, in addition to methods of their use in the treatment of various diseases and disorders.... Agent: Lexicon Pharmaceuticals, Inc.

20100016423 - Use of dronedarone for the treatment of patients with arrhythmia and having an increase of creatinine level due to dronedarone administration: Methods of using dronedarone or a pharmaceutically acceptable salt thereof for the treatment of patients with arrhythmia, said patients having an increase of creatinine level due to dronedarone administration, said creatinine level increasing following dronedarone treatment initiation, said creatinine level increase reaching a plateau and being used as a new... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100016424 - Production and use of derivatized homoserine lactones: The present invention provides analogues of autoinducer molecules that are derivatized to allow their attachment to other molecules and surfaces. Libraries of the autoinducer analogues are also contemplated. Also provided are methods for using the compounds of the invention to produce compositions, such as immunoconjugates, antibodies and vaccines, which are... Agent: Wilson, Sonsini, Goodrich & Rosati

20100016425 - Methods of treating an overweight or obese subject: The invention herein generally relates to pharmaceutical formulations and methods of treating an overweight or obese subject, and overweight- or obesity-related conditions.... Agent: Goodwin Procter LLP Patent Administrator

20100016426 - Post-impregnation treatments to improve distribution of metal biocides in an impregnated substrate: The present invention relates to post-treatment compositions and methods useful for modifying the distribution of metal biocide(s) in biodegradable substrates such as wood, other cellulosic products, starch-based products, and the like that are vulnerable to decay due to insects, fungi, microbes, and the like. The compositions include complexing agents of... Agent: The Dow Chemical Company Kagan Binder, PLLC

20100016427 - External preparation comprising prostaglandin derivative: e

20100016428 - Use of polyunsaturated fatty acids for the primary prevention of major cardiovascular events: The use of polyunsaturated fatty acids of the ω-3 series such as eicosapentaenoic acid (EPA, C20:5 ω-3), docosahexaenoic acid (DHA, C22:6 ω-3), or their pharmaceutically acceptable derivatives is described for the primary prevention of major cardiovascular events in subjects who have not undergone previous infarct episodes.... Agent: Arent Fox LLP

20100016429 - Enzymatic production of peracids using perhydrolytic enzymes: A process is provided to produce a concentrated aqueous peracid solution in situ using at least one enzyme having perhydrolase activity in the presence of hydrogen peroxide (at a concentration of at least 500 mM) under neutral to acidic reaction conditions from suitable carboxylic acid esters (including glycerides) and/or amides... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20100016431 - Genes encoding a novel type of lysophophatidylcholine acyltransferases and their use to increase triacylglycerol production and/or modify fatty acid composition: Described nucleic acid molecules (and corresponding peptides) encode lyso-phosphatidylcholine (LPC) acyltransferases. Over-expression of the LPC acyltransferases in a cell may lead to enhanced production of PUFA, or other unusual fatty acids, and/or to increased oil content in the cell.... Agent: Traskbritt, P.C.

20100016430 - Modified coconut oils with broad antimicrobial spectrum: The present invention discloses antimicrobial compositions of modified coconut oil and palm kernel oil derived from catalytic activity of 1,3 positional specific lipases. Said modified oil compositions comprises of free fatty acids (>9.4%), monoglycerides (>1.3%), diglycerides (>22.8%) and triglycerides (>25%) which inhibits the growth of gram positive bacteria i.e. Staphylococcus... Agent: Merchant & Gould PC

20100016433 - Nerve-regenerating agent: A nerve-regenerating agent comprising, as an active ingredient, arachidonic acid and/or a compound containing arachidonic acid as a constituent fatty acid.... Agent: Drinker Biddle & Reath (dc)

20100016432 - Resolvins: biotemplates for novel therapeutic interventions: The present invention is generally drawn to novel isolated therapeutic agents, termed resolving, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20100016434 - Inhibitors of egln3 activity for the treatment of neurodegenerative disorders: The present invention provides methods for preventing or reducing neuronal apoptosis, particularly wherein the apoptosis is associated with a neurodegenerative disorder in a subject.... Agent: Fibrogen, Inc.

20100016435 - Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties: Novel chemical agents are described. More specifically, hybrid molecules comprising a vitamin D receptor agonist moiety and an HDAC inhibitor moiety are described herein.... Agent: Fulbright & Jaworski L.L.P.

20100016437 - Alpha-aminoamide derivatives useful in the treatment of cognitive disorders: The present invention is in the field of pharmacotherapy of cognitive deficits in learning and memory by administering an α-aminoamide, particularly safinamide. Examples of disturbances in cognition that can be treated with compounds of the invention are the ones associated with disorders such as autism, dyslexia, attention deficit hyperactivity disorder,... Agent: Dechert LLP

20100016436 - Transdermal administration of active agents, in particular diclofenac: The present invention relates to compositions for transdermal administration of therapeutic agents for providing a local and sustained therapeutic effect, wherein the extent of systemic administration can be controlled. In particular, the invention relates to spreadable compositions, or compositions which may be solid at a temperature of about 25° C.... Agent: Davidson, Davidson & Kappel, LLC

20100016438 - Granulated crystal compilation composed of pure organic minerals used in all food applications resulting in energy supplementation, diet and weight regulation, and medicinal effects: A composition made of pure natural minerals that can be used in all food applications resulting in energy supplementation, diet and weight regulation, and medicinal benefits.... Agent: Daniel W. Hassani

20100016439 - Ophthalmic device having therapeutic agent delivery capability and method of forming same: The present invention is directed to ophthalmic devices that are loaded with therapeutic agent. The devices provide prolonged release of the therapeutic agent to the eye. The ophthalmic devices are typically formed of an ophthalmic material that is particularly desirable for the loading of therapeutic agent and/or the therapeutic agent... Agent: Alcon

20100016440 - Alpha-aminoamide derivatives useful as anti-inflammatory agents: Methods of using certain a-aminoamide derivatives as anti-inflammatory agents. The anti-inflammatory agents of the invention are able to reduce or even stop inflammatory s conditions substantially without side effects.... Agent: Dechert LLP

20100016441 - Biocidal composition and method: Composition and method for the inhibition of microbial growth in alkaline aqueous media requiring both rapid decontamination and long term preservation. The composition is a blend of 2,2-dibromo-3-nitrilopropionamide and 2-bromo-2-nitro-1,3-propanediol.... Agent: The Dow Chemical Company

20100016442 - Small molecule solubilization system: The invention relates to a drug delivery system for the topical administration of therapeutic agents.... Agent: Ropes & Gray LLP

20100016443 - Method for preparing particles comprising metal oxide coating and particles with metal oxide coating: The invention relates to a process for coating a solid, water-insoluble particulate matter, with a metal oxide comprising: (a) contacting the solid, water-insoluble particulate matter with an ionic additive and an aqueous medium to obtain a dispersion of said particulate matter having positive charges on its surface; (b) subjecting the... Agent: Oliff & Berridge, PLC

20100016444 - Methods and compositions for treating mammalian nerve tissue injuries: To achieve, an in vivo repair of injured mammalian nerve tissue, an effective amount of a biomembrane fusion agent is administered to the injured nerve tissue. The application of the biomembrane fusion agent may be performed by directly contacting the agent with the nerve tissue at the site of the... Agent: Mueting, Raasch & Gebhardt, P.A.

20100016445 - Transdermal diethylstilbestrol for treating prostate cancer: Methods for treating prostate cancer comprising transdermally administering a therapeutically effective amount of diethylstilbesterol (DES), or a pharmaceutically acceptable salt or complex thereof, to a subject. In one embodiment, transdermally administered DES may be used to treat hot flashes in castrate prostate cancer patients. In another embodiment, transdermal DES may... Agent: Klarquist Sparkman, LLP

20100016446 - Stable water-based topical pharmaceutical creams and methods of making and using same: Disclosed are stable, water-based topical creams comprising nitroglycerin and suitable for pharmaceutical and/or cosmetic use. Also disclosed are methods for preparing the creams. Also disclosed are methods for treating circulatory disorders, methods for preventing or alleviating insufficient circulation, methods for enhancing localized activity of systemically administered drugs, methods for enhancing... Agent: Ballard Spahr LLP

20100016447 - Spray oil and method of use thereof for controlling turfgrass pests: A paraffinic spray oil and a method of using the spray oil for controlling turfgrass pests is disclosed. The spray oil comprises paraffinic oil and a quick break emulsifier, which is formulated as an oil-in-water (O/W) emulsion for use. The paraffinic oil and emulsifier are present in a weight ratio... Agent: Sean W. Goodwin

20100016448 - Flashmelt oral dosage formulation: There is provided granules for the production of flash-melt pharmaceutical oral dosage forms. In addition to one or more medicaments, the granules are composed of an excipient combination consisting of a superdisintegrant, a dispersing agent, a distributing agent, and a binder and may also include other conventional ingredients such as... Agent: Louis J. Wille Bristol-myers Squibb Company

20100016449 - Formulations with improved bioavailability: Disclosed are solid oral formulations with improved dissolution and bioavailability for poorly water soluble pharmaceutical compounds.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100016450 - Controlled release delivery devices for the treatment of otic disorders: Disclosed herein are delivery devices for use in the treatment of otic disorders wherein the delivery device is administered locally to an individual afflicted with an otic disorder, through direct application or via perfusion into the targeted auris structure(s).... Agent: Wilson, Sonsini, Goodrich & Rosati

20100016451 - Orally disintegrative dosage form: The present invention features an orally disintegrating dosage form including from about 5% to about 40%, by weight, of at least one hydrated salt and a pharmaceutically active agent, wherein the at least hydrated salt has a dehydration temperature of from about 20 to about 120° C.... Agent: Philip S. Johnson Johnson & Johnson

  
01/14/2010 > patent applications in patent subcategories. recently filed with US Patent Office

20100009896 - Capture agents and related compositions, methods and systems: Multi-ligand capture agents comprising two or more ligands are described, and related compositions, methods and systems.... Agent: Steinfl & Bruno

20100009895 - Method for selective localization of active agents at and in mitochondria and corresponding active agents: The present invention relates to novel methods for selective localization of active agents both at and in mitochondria within living cells, as well as corresponding active agents that penetrate through the cell membrane into the cells without further adjuvants and there can be localized both at and in mitochondria. These... Agent: Frommer Lawrence & Haug

20100009897 - Polypeptide having larvae growth inhibiting or insecticidal effect on scarabaeidae insects and polynucleotide encoding the same: Through screening using an antibody to a polypeptide that constitutes a parasporal body in sporangia of Bacillus popilliae and has a larvae growth inhibiting or insecticidal effect on a Scarabaeidae insect and through polymerase chain reaction, polynucleotides encoding the polypeptide and polypeptides similar thereto are isolated.... Agent: Edwards Angell Palmer & Dodge LLP

20100009899 - Novel insulin derivatives: r

20100009898 - Protease resistant insulin analogues: The present invention relates to novel insulin analogues exhibiting resistance towards protease, wherein at least two amino acids are substituted and/or deleted relative to the parent insulin molecule. A method for the preparation of such insulin analogues, insulin preparations containing the insulin analogues of the invention and a method of... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100009900 - Substituted indole-o-glucosides: Substituted indole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20100009901 - Mineral amino acid polysaccharide complex: This document provides complexes comprising a mineral-amino acid compound and a polysaccharide. For example, the document provides compositions containing such complexes and methods of making and using such complexes.... Agent: Fish & Richardson P.C.

20100009902 - Glycoconjugation using saccharyl fragments: The present invention provides conjugates between a substrate, e.g., peptide, glycopeptide, lipid, etc., and a modified saccharyl fragment bearing a modifying group such as a water-soluble polymer, therapeutic moiety or a biomolecule. The conjugates are linked via the enzymatic conversion of the activated modified saccharyl fragment into a glycosyl linking... Agent: Morgan, Lewis & Bockius LLP (sf)

20100009906 - Anticancer treatments: A method of treating the human body for cancer comprises administering an effective therapeutic amount of docetaxel in combination with an effective therapeutic amount of ET-743.... Agent: King & Spalding

20100009905 - Compositions and methods for detection, prognosis and treatment of colon cancer: The present invention relates to methods of detection, prognosis and treatment of colon cancer using a plurality genes or gene products present in normal and neoplastic cells, tissues and bodily fluids. Additional uses include identifying, monitoring, staging, imaging and treating colon cancer and non-cancerous diseases of the colon as well... Agent: Licata & Tyrrell P.C.

20100009915 - Compositions comprising fungal immunomodulatory protein and use thereof: This invention relates to a method for stimulation or an activation of immunological function directed to activate natural killer cells and macrophages or increase production of serum antibody in a patient in need of such stimulation or activation, comprising administering an isolated and/or purified polypeptide of a fungal immunomodulatory protein.... Agent: Wpat, PC Intellectual Property Attorneys

20100009908 - Galectin 9-polymer conjugates: Galectin 9, which is an immune function-controlling factor belonging to a new class that is different from known cytokines and is expected to be used as a therapeutic drug for various immune-related diseases such as an autoimmune disease, has disadvantages (such as high sensitivity to protease and poor solubility) to... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100009907 - Glucagon-like peptides and uses thereof: The present invention relates to non-mammalian Glucagon-like peptides (nmGLP-1), analogs thereof, related nucleic acids, and processes production of such peptides. The nmGLP-1 peptides and analogs thereof of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent obesity, reducing... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20100009912 - Insecticidal extract from legume plants and method of preparing the same: The invention may be summarized as follows. The present invention provides insecticides comprised of naturally-occurring compounds, such as, for example, PA1b-related peptides and terpenoid saponins. The present invention also provides for identification and characterization of a synergistic insecticidal effect between peptides and saponins extracted from plants. Furthermore, simplified extraction procedures... Agent: Ronald I. Eisenstein Nixon Peabody LLP

20100009918 - Method for the administration of ligands, agonists of ligands of the tnf family with reduced toxicity: The present invention concerns the use of a multimerized form of ligands of the TNF family for the preparation of a medicament for injection into an appropriate cavity of the body, for the treatment of diseases wherein cell proliferation has to be controlled wherein the ligand of the TNF family... Agent: Connolly Bove Lodge & Hutz, LLP

20100009914 - Method of protecting sensitive molecules from a photo-polymerizing environment: In one embodiment, the present invention is a substrate system of photo-polymerizable monomers and bioactive molecules admixed with the monomers and shielded from the monomers by an insoluble material that undergoes a solid-gel transition at body temperature. Upon polymerization, the monomers produce a cross-linked structure and the shielded bioactive molecules... Agent: Choate, Hall & Stewart LLP

20100009910 - Methods for administering long-lasting hypoglycemic agents: The present invention relates to methods and pharmaceutical compositions relating to administering hypoglycemic agents and/or GLP-1 agonists wherein the mean maximum plasma concentration (Cmax) and/or Area Under the Curve (AUC) values of the hypoglycemic agent are increased and/or sustained.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100009903 - Methods for promoting wound healing and/or reducing scar formation: The present invention provides methods for promoting wound healing and/or reducing scar formation, by administering to an individual in need thereof one or more of the heat shock protein 20-derived polypeptides disclosed herein.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100009904 - Modified exedins and uses thereof: Novel exendins with modifications at one or more of following positions: 2, 14, 27 or 28 and polyethylene glycol derivatives thereof are provided. These compounds are useful in treating type 2 diabetes as GLP-1 receptor agonists.... Agent: Londa, Bruce S.

20100009917 - Modulating enzymatic processes by addition of diolcontaining substances: The present invention relates to a method for increasing the selectivity of an enzyme, which method comprises performing the reaction in the presence of an enhancing compound selected from one of ethylene glycol, propylene glycol or glycerol.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100009911 - Osteogenic synergic composition: The invention relates to an osteogenic synergic composition comprising at least one osteogenic growth factor, and at least one growth factor having a chemoattractant and angiogenic capacity. It also relates to the method for the preparation thereof and to the use thereof for the preparation and production of pharmaceutical products... Agent: Oliff & Berridge, PLC

20100009909 - Peptides binding the phosphatase 2a protein: The invention relates to novel synthetic or natural E4orf4 or Bcl-2 peptides particularly useful in antitumoral, antiviral and antiparasitic treatments, said peptides being less than 30 amino acids long and binding in vitro to a phosphatase 2A protein holoenzyme or one of its subunits. The invention also relates to polynucleotides... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100009916 - Selective vpac2 receptor peptide agonists: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.... Agent: Eli Lilly & Company

20100009913 - Uses for yerba santa: Methods of in vitro propagation of plants of the genus Eriodictyon are described, including, in particular embodiments, plants of the species E. californicum, E. trichocalyx and E. sessilifolium. Methods of producing transgenic plants of the genus Eriodictyon are also described, along with methods of producing recombinant proteins in such plants.... Agent: Ballard Spahr LLP

20100009919 - Apolipoprotein a1 mimetics and uses thereof: The present invention provides peptidomimetics derived from Apolipoprotein A-I, which is useful for beneficially influencing lipid parameters and/or plasma cholesterol levels. The invention also provides pharmaceutical compositions and methods of treatment for elevated levels of plasma cholesterol.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100009921 - Pharmaceutical compositions and methods for peptide treatment: wherein X and Y are defined above, m and n are integers having a value from 1 to 20 and the sum of m+n is not greater than 25, p is an integer having a value of 0 or 1, q is an integer having a value of 0 or... Agent: Axinn, Veltrop & Harkrider LLP Attn. Michael A. Davitz

20100009920 - Ttk as tumor marker and therapeutic target for lung cancer: Disclosed herein is a method for determining kinase activity of TTK for EGFR and methods of screening for modulators of this kinase activity. Also disclosed are methods and pharmaceutical compositions for preventing and/or treating lung cancer that use or include such modulators. Methods for diagnosing lung cancer using the kinase... Agent: Townsend And Townsend And Crew, LLP

20100009922 - Hypotensive peptides from soy proteins and method of preparation: A method for preparing an anti-hypertension peptide composition, using a microbe which is intrinsic to common soybean food and capable of producing protease. The composition mainly contain peptides with a molecular weight of less than 10 kD which are produced by decomposition of soy proteins by the microbe in a... Agent: Wilkinson & Grist

20100009923 - Antigens targeted by pathogenic al4 t cells in type 1 diabetes and uses thereof: Provided are oligopeptide antigens to A14-like T cells, and mouse proteins comprising those antigens. The oligopeptide antigens comprise the amino acid sequence XX(I/D/F/L)ENY(I/L)(E/W/Y)(L/M) or VMLENYTHL. Additionally provided are methods for treating a mammal having or at risk for type 1 diabetes using these antigens, or compounds which reduce or eliminate... Agent: Amster, Rothstein & Ebenstein LLP

20100009924 - Compositions and methods for improving cardiovascular function: The present invention relates to methods for supplementing the diet of subjects suffering from cardiovascular disease. D-Ribose is given long term alone or in combination with vasodilators in order to improve or maintain the diastolic or systolic function of the subjects.... Agent: Mueting, Raasch & Gebhardt, P.A.

20100009925 - 18-membered macrocycles and analogs thereof: The present invention relates generally to the 18-membered macrocyclic antimicrobial agents called Tiacumicins, specifically, OPT-80 (which is composed almost entirely of the R-Tiacumicin B), pharmaceutical compositions comprising OPT-80, and methods using OPT-80. In particular, this compound is a potent drug for the treatment of bacterial infections, specifically C. difficile infections.... Agent: Morgan Lewis & Bockius LLP

20100009926 - Ph-sensitive polymeric micelles for drug delivery: Mixed micelles containing poly(L-histidine-co-phenylalanine)-poly(ethylene glycol) block copolymer and poly(L-lactic acid)-poly(ethylene glycol) block copolymer are a pH-sensitive drug carrier that release the drug in an acidic microenvironment, but not in the blood. Since the microenvironment of solid tumors is acidic, these mixed micelles are useful for treating cancer, including those cancers... Agent: Alan J. Howarth

20100009927 - Anti-inflammatory and anti-allergy extracts from nettle: The present invention relates in part to nettle extracts that are useful for treating or preventing seasonal allergies, allergic rhinitis, and other inflammatory conditions.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100010067 - Arginine-conjugated bioreducible poly(disulfide amine) polymers for gene delivery system: An arginine-grafted bioreducible poly(disulfide amine) (“ABP”) as a reagent for efficient and nontoxic gene delivery is described. ABP forms positively charged nano-particles of less than 200 nm with siRNA. ABP is biodegraded under reducing conditions, such as in the cytoplasm. ABP exhibits much higher transfection efficiency than polyethyleneimine in mammalian... Agent: Alan J. Howarth

20100010064 - Cancer treatment by combined inhibition of proteasome and telomerase activities: A method and kit for inhibiting the proliferation of cancer cells are disclosed, based on a combination of a proteasome inhibitor and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with the proteasome inhibitor alone or the telomerase inhibitor... Agent: King & Spalding LLP

20100010065 - Methods and compositions for cellular reprogramming: Compositions and methods useful for the treatment of aberrant programming diseases, particularly those associated with aberrant apoptosis are disclosed... Agent: Dann, Dorfman, Herrell & Skillman

20100010066 - Optimized methods for delivery of dsrna targeting the pcsk9 gene: This invention relates to optimized methods for treating diseases caused by PCSK9 gene expression.... Agent: Alnylam/fenwick

20100010071 - Compositions and use of epas1 inhibitors: The present invention relates to inhibitors of endothelial PAS domain protein 1 (EPAS1), and methods and compositions related to the EPAS1 inhibitors. In certain embodiments, the EPAS1 inhibitors include nucleic acids, such as for example siRNAs.... Agent: Ropes & Gray LLP

20100010075 - Compounds for eliciting or enhancing immune reactivity to her-2/neu protein for prevention or treatment of malignancies in which the her-2/neu oncogene is associated: Compounds and compositions for eliciting or enhancing immune reactivity to HER-2/neu protein are disclosed. The compounds include polypeptides and nucleic acid molecules encoding such peptides. The compounds may be used for the prevention or treatment of malignancies in which the HER-2/neu oncogene is associated.... Agent: Seed Intellectual Property Law Group PLLC

20100010069 - Extended length borane phosphonate nucleic acid compounds: The present invention provides a novel method for solid-phase phosphoramidite based synthesis of borane phosphonate DNA. Also provided are novel phosphoramidite molecules, novel extended length borane phosphonate nucleic acid compounds, and methods of use thereof.... Agent: Townsend And Townsend And Crew, LLP

20100010074 - Inhibiting serum response factor (srf) to improve glycemic control: Described are methods of improving glycemic control/improving insulin sensitivity by administering an inhibitor of serum response factor (SRF) activity, and methods of identifying new compounds for use in the described methods of treatment.... Agent: Fish & Richardson PC

20100010068 - Liver-directed gene therapy: The present invention methods, including surgical methods, and compositions for use in liver-directed nucleic acid sequence transfer, such as in liver-directed gene therapy including for the treatment of diabetes. The invention also relates to pharmaceutical compositions comprising therapeutic viral vectors, including therapeutic lentiviral vectors and to surgical means of using... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100010073 - Microrna (mirna) for the diagnosis and treatment of heart diseases: The invention relates to microRNAs (miRNAs) for the diagnosis, prophylaxis and/or treatment of heart diseases. It relates in particular to SEQ ID No: 1 to SEQ ID No: 29 for the diagnosis, prophylaxis and/or treatment of heart diseases. In addition, the invention relates to the use of these sequences to... Agent: Viksnins Harris & Padys Pllp

20100010072 - Microrna biomarkers for human breast and lung cancer: The present invention relates to novel molecular markers for diagnosis and classification of human breast cancer and lung cancer.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100010070 - Use of nucleic acid sequences for the treatment of neuralogical and psychiatric diseases and compositions: The present invention relates to the use of one or more expression vectors comprising certain nucleic acid sequences encoding a combination of NPY and/or one or more of its receptors (Y1, Y2, Y4, Y5, y6), and/or galanin and/or one or more of its receptors (GALR1, GALR2, GALR3), and/or somatostatin and/or... Agent: Schwegman, Lundberg & Woessner, P.A.

20100009929 - Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof: This application relates to combination therapies including triciribine and related compounds and bortezomib and derivatives thereof analogs and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.... Agent: Morgan Lewis & Bockius LLP

20100009928 - Compositions including triciribine and taxanes and methods of use thereof: This application relates to combination therapies including triciribine and related compounds and taxanes and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.... Agent: Morgan Lewis & Bockius LLP

20100009930 - Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in conbination with anti-tumor agents: In one aspect, the present invention provides a method of treating uterine cancer, endometrial cancer, or ovarian cancer, comprising administering to a subject at least one PARP inhibitor. In another aspect, the present invention provides a method of treating uterine cancer, endometrial cancer, or ovarian cancer, comprising administering to a... Agent: Bipar Sciences Inc. C/o Morrison Foerster

20100009931 - Association of a tensor agent or device and a saccharide compound: The invention concerns a composition for topical application on the skin comprising, in a physiological acceptable medium, at least one saccharide compound which augments the expression of mechanoreceptors in skin cells and at least one tensor agent. The invention also concerns a skin care health kit comprising (a) a composition... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100009932 - Liquid satiety enhancing composition: The present invention relates to shelf-stable satiety enhancing and/or satiating liquid compositions that can be used as satiety enhancing and/or satiating composition in a method of treating or preventing any of a variety of diseases and/or disorders associated with overeating and/or excessive caloric intake of a subject. It was found... Agent: Unilever Patent Group

20100009933 - Hydroxylated amide skin moisturizer: The invention relates to the cosmetic use, as a skin moisturizer, of a compound of formula (I): with (i) R1 and R2 represent a hydrogen atom or a C1-C6-alkyl group, or (ii) R1 and R2 can form, together with the nitrogen atom which bears them, a saturated heterocycle with 5... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100009934 - Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders: The invention features a method of treating a B-cell proliferative disorder by administering to a patient a BAR agonist, e.g., formulated for administration by a route other than inhalation (such as for oral or intravenous administration), in an amount effective to treat the B-cell proliferative disorder. The BAR agonist may... Agent: Clark & Elbing LLP

20100009935 - Resistance-repellent retroviral protease inhibitors: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.... Agent: Proskauer Rose LLP

20100009936 - Chemical compounds: The invention provides compounds formula I, their preparation, and their use as pharmaceutically active immuno-suppressive agents for the treatment of autoimmune disorders, organ transplant rejection, disorders associated with an activated immune system, as well as other disorders modulated by lymphopenia or SIP receptors.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100009937 - Pesticide formulation with streaming birefringence: A pesticide composition exhibiting streaming birefringence and methods for making the pesticide composition are disclosed. In one embodiment, the pesticide composition comprises an active ingredient and a surfactant adjuvant.... Agent: Huntsman Petrochemical LLC

20100009939 - Concurrent drugs: p

20100009938 - Method to identify and treat subjects resistant to acetyl salicylic acid: The invention relates to the use of acetyl salicylic acid (ASA) in combination with MRP4 channel inhibitors for the treatment of all diseases related to so-called ASA resistance. Particularly preferred among the MRP4 channel inhibitors is dipyridamole. The invention also relates to an in-vitro diagnostic method for identifying ASA-resistant patients... Agent: Knobbe Martens Olson & Bear LLP

20100009944 - 19-nor-vitamin d analogs with 1,2-dihydrofuran ring: 19-nor-vitamin D analogs having an additional dihydrofuran ring connecting the 1α-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro and in vivo activities, making them therapeutic agents for the treatment or prophylaxis of autoimmune diseases, some types of... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall, LLP

20100009945 - 19-nor-vitamin d analogs with 3,2-dihydrofuran ring: 19-nor-vitamin D analogs having an additional dihydrofuran ring connecting the 3β-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro and in vivo activities, making them therapeutic agents for the treatment or prophylaxis of autoimmune diseases, some types of... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall, LLP

20100009942 - 2-methylene-(17z)-17(20)-dehydro-19,21-dinor-vitamin d analogs: This invention discloses 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs, and specifically 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-1α, 25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall, LLP

20100009940 - 2-methylene-(20e)-20(22)-dehydro-19-nor-vitamin d analogs: This invention discloses 2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(20E)-20(22)-dehydro-19-nor-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall, LLP

20100009943 - 2-methylene-(22e)-25-(1-methylene-hexyl)-26,27-cyclo-22-dehydro-19-nor-vitamin d analogs: This invention discloses 2-methylene-(22E)-25-(1-methylene-hexyl)-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(22E)-25-(1-methylene-hexyl)-26,27-cyclo-22-dehydro-19-nor-1α,24(R)-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall, LLP

20100009946 - 2-methylene-19,26-dinor-(20r,22e,25r)-vitamin d analogs: This invention discloses 2-methylene-19,26-dinor-(20R,22E,25R)-vitamin D analogs, and specifically 2-methylene-19,26-dinor-(20R,22E,25R)-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall, LLP

20100009947 - 2-methylene-19,26-dinor-(20s,22e,25r)-vitamin d analogs: This invention discloses 2-methylene-19,26-dinor-(20S,22E,25R)-vitamin D analogs, and specifically 2-methylene-19,26-dinor-(20S,22E,25R)-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall, LLP

20100009941 - 2-methylene-20(21)-dehydro-19-nor-vitamin d analogs: This invention discloses 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-20(21)-dehydro-19-nor-1α,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall, LLP

20100009948 - Combined calcium, magnesium and vitamin d supplements: The present invention relates to oral nutritional and therapeutic products which are useful for providing vitamins and minerals required for bone health. The present invention is an oral nutritional and therapeutic composition of calcium succinate, magnesium R-(+)-alpha-lipoate, and Vitamin D for use in the maintenance of bone health, the optimization... Agent: Casimir Jones, S.c.

20100009949 - Novel method: The invention provides for the use of Vitamin D compounds such as 1-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-chole-calciferol, in the prevention or treatment of prostate cancer.... Agent: Edwards Angell Palmer & Dodge LLP

20100009950 - Substituted ethanolamines: The present invention relates to new substituted ethanolamine adrenergic receptor modulators, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20100009951 - Ciclesonide containing sterile aqueous suspension: The present invention relates to a sterile aqueous suspension containing ciclesonide, a microgel and a water soluble ionic polymer. The present invention provides a sterile aqueous suspension in which ciclesonide is dispersed homogeneously over a long period of time.... Agent: Nath & Associates PLLC

20100009952 - Controlled release corticosteroid compositions and methods for the treatment of otic disorders: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and... Agent: Wilson, Sonsini, Goodrich & Rosati

20100009953 - Cyclosporin derivatives for treating ocular and dermal diseases and conditions: —N═C(R8)(NR9R10), i.e. amidines wherein R3-R7 10 is H, Alk, Ar or (CH2)nAr wherein Ar is an aryl group and n is an integer of from 1 to 13 or R3 and R4 or R4 and R5 or R5 and R7 or R3 and R7, or R9 and R10, together may... Agent: Allergan, Inc.

20100009954 - Beta-lactamase inhibitory compounds: Inhibitors of the enzyme beta-lactamase are provided. The compounds are adapted to inhibit beta-lactamase as produced by beta-lactam resistant bacterial strains. Methods of treatment of beta-lactam resistant bacterial infections in patients are provided.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100009955 - Pharmaceutical compositions of cefixime: A pharmaceutical suspension formulation comprising a dose greater than 100 mg/5 ml Cefixime and pharmaceutically acceptable excipients.... Agent: Merchant & Gould PC

20100009957 - Novel inhibitors of beta-lactamase: A class of 7-oxo-2,6-diazabicyclo-[3.2.0]-heptane-6-sulfonic acid compounds substituted at the two position of the bicyclic ring with a heterocyclylaminocarbonyl group or a carbocyclylaminocarbonyl group are β-lactamase inhibitors. The compounds and their prodrugs and pharmaceutically acceptable salts are useful in the treatment of bacterial infections in combination with β-lactam antibiotics. In particular,... Agent: Merck And Co., Inc

20100009959 - Pentacyclic indole derivatives as antiviral agents: The present invention relates to pentacyclic indole derivatives of formula (I): wherein A, Ar, R1, R2, W, X, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.... Agent: Merck And Co., Inc

20100009958 - Quinazoline derivatives: e

20100009961 - Dipeptidyl peptidase-iv inhibitors: The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.... Agent: Hoffmann & Baron, LLP

20100009960 - Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure formula (I) enantiomers, diastereomers, solvates, salts, tautomers or prodrugs thereof... Agent: Louis J. Wille Bristol-myers Squibb Company

20100009956 - Novel substituted pyrimidines as cysteine protease inhibitors: v

20100009962 - Benzyl-substituted quinolone m1 receptor positive allosteric modulators: which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions... Agent: Merck And Co., Inc

20100009963 - Kinase antagonists: The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tyrosine kinase, PI3 kinase and mTOR, or PI33 kinase, mTOR and tyrosine kinase.... Agent: Townsend And Townsend And Crew, LLP

20100009964 - Compounds which modulate the cb2 receptor: Compounds of formula (I) are disclosed. Compounds according to the and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100009965 - Cyclic malonamides as inhibitors of abeta protein production: to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of... Agent: Kelley Drye & Warren LLP

20100009966 - Substituted lactams as inhibitors of abeta protein production: having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the... Agent: Kelley Drye & Warren LLP

20100009967 - Solid dosage formulations of telcagepant potassium: A solid dosage pharmaceutical formulation comprising as an active ingredient the potassium salt of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide (telcagepant), arginine, and a pharmaceutically acceptable surfactant. The invention is also directed to an amorphous form of the potassium salt of telcagepant.... Agent: Merck And Co., Inc

20100009968 - 11beta-hydroxysteroid dehydrogenase type 1 active compounds: The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, of the general formula I. Their use in therapy, pharmaceutical compositions comprising the compounds, as well as... Agent: High Point Pharmaceuticals, Inc.

20100009969 - Fused oxazoles & thiazoles as histamine h3- receptor ligands: The present invention relates to compounds comprising fused oxazole or thiazole derivatives of formula (I), processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H3-receptor ligands, wherein A is a cyclic amine which is linked to the propylene group via an amino nitrogen; B is selected... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100009970 - Compositions and methods for treatment of viral diseases: The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B,... Agent: Gearhart Law LLC

20100009971 - Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound: A novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound or its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound of the present disclosure is also useful in the treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100009972 - Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound: A novel pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound and its pharmaceutically acceptable salt has a potent FAAH-inhibitory activity. Further, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound of the present disclosure is also useful in the treatment of urinary frequency and urinary incontinence, overactive bladder and/or pain.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100009973 - Integrase inhibitors 3: The present invention provides a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. Compounds of formula (I) are also provided.... Agent: Darby & Darby P.C.

20100009974 - Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compostions containing them: e

20100009976 - Benzothiazin-3-one compound and intermediate therefor: (wherein n is 3 or 4; R represents ethyl or hydrogen; and R1 represents hologeno, alkoxy, haloalkyl, or haloalkoxy) or a pharmaceutically acceptable salt thereof. It is useful as a therapeutic or preventive agent for arthrosis deformans, chondrodegenerative discases such as chronic articular rheumatism, cancers, gingivitis, etc. Also provided are... Agent: Sughrue Mion, PLLC

20100009975 - Benzoxazines, benzothiazines, and related compounds having nos inhibitory activity: The present invention features benzoxazines, benzothiazines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for... Agent: Clark & Elbing LLP

20100009977 - Process for the preparation of (r)-(+)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2h-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide.: Disclosed herein is an improved process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide (Brinzolamide) and novel intermediates thereof.... Agent: Pharmaceutical Patent Attorneys, LLC

20100009978 - Benzoxazoles and oxazolopyridines being useful as janus kinases inhibitors: s

20100009980 - Novel 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials:

20100009979 - Pharmaceuticals containing fluoroquinolones: The invention relates to the use of quaternary ammonium compounds for preventing precipitations of fluoroquinolones from their solutions and to stable, tolerated pharmaceuticals which are particularly suitable for parenteral use and which contain, in dissolved form, a fluoroquinolone and a quaternary ammonium compound.... Agent: Bayer Healthcare LLC

20100009981 - Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits: The present disclosure is directed to compositions and methods which utilize the tetracycline scaffold, preferably the scaffold of tetracycline or minocycline, and which significantly lack antibiotic activity. The compounds have neuroprotective attributes without interfering with the drugs capacity to pass through the blood brain barrier. These compounds have neuroprotective activity... Agent: Peters Verny , L.L.P.

20100009982 - Modulators of acetyl-coenzyme a carboxylase and methods of use thereof: along with methods of use of these compounds as pharmaceuticals, particularly in the treatment of obesity, metabolic syndrome, atherosclerosis, cardiovascular disease, insulin resistance, diseases associated with reduced neuronal metabolism, and cancer as well as the use of these compounds for treatment of pathogens of humans and animals, and for the... Agent: Myers Bigel Sibley & Sajovec

20100009983 - 5 ht receptor mediated neurogenesis: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a 5HTR agent, in combination with one or more other neurogenic agents, or anti-astrogenic agent, to stimulate or... Agent: Dla Piper LLP (us)

20100009984 - Aerosol formulations for the inhalation of beta-agonists: e

20100009985 - Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds:

20100009986 - Substituted heteroaryl derivatives: The invention relates to substituted heteroaryl derivatives, to methods for the production thereof, to medicaments containing said compounds and to the use of substituted heteroaryl derivatives for producing medicaments.... Agent: Briscoe, Kurt G.

20100009987 - Aminothiazole derivatives as inhibitors of mark: Compounds of formula (I): inhibit microtubule affinity regulating kinase (MARK) and therefore find use in treatment of neurodegenerative diseases associated with hyperphosphorylation of tau.... Agent: Merck And Co., Inc

20100009988 - Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase: m

20100009989 - Urea glucokinase activators: This application relates to novel urea glucokinase activators and use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes. Further encompassed is a pharmaceutical composition comprising a compound according to the invention and a... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100009990 - Imidazolyl pyrimidine inhibitor compounds: A compound of general Formula (I) having histone deacetylase (HDAC) and/or Cyclin-dependent kinase (CDK) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.... Agent: Harness, Dickey, & Pierce, P.l.c

20100009991 - Polycyclic acid compounds useful as crth2 antagonists and antiallergic agents: The present invention relates to a novel compound or a salt thereof, which is useful as a CRTH2 antagonist, especially as a medicament for disorder that participates eosinophil, for example, allergic disorder such as asthma, allergic rhinitis, allergic dermatitis, conjunctival inflammation, hives, eosinophilic bronchitis, food allergy, inflammation of the nasal... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100009992 - Ampk modulators: e

20100009998 - Compositions and methods employing aminopterin: The present invention relates to pharmaceutical compositions containing the antifolate aminopterin, processes for making the compositions, and methods of using them to treat disorders in adult and pediatric patients. Pharmaceutical compositions substantially free of impurities are provided comprising a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof.... Agent: Syntrix Biosystems, Inc.

20100009993 - Diketo fused azolopiperidines and azolopiperazines as anti-hiv agents: Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, diketo fused azolopiperidine and azolopiperazine derivatives that possess unique antiviral activity are provided. These compounds are useful for the treatment of HIV and AIDS.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100009994 - L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine: A novel L-malate salt of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) is provided.... Agent: Heslin Rothenberg Farley & Mesiti P.C.

20100009995 - Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine: A novel maleate salt of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) is provided.... Agent: Heslin Rothenberg Farley & Mesiti P.C.

20100009997 - Method of treating a metabolic or neuropsychiarty disorder with a bh4 derivative prodrug: Low dose therapeutic methods for use of BH4 derivatives to treat BH4-responsive disorders, such as hyperphenylalanemia and neuropsychiatric diseases, and combination therapies of BH4 derivatives and other therapeutic regimens, are described.... Agent: Marshall, Gerstein & Borun LLP

20100009996 - Methods and compositions for the treatment of metabolic disorders: The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated.... Agent: Marshall, Gerstein & Borun (biomarin)

20100009999 - Alkyl substituted indoloquinoxalines: e

20100010001 - Novel modulators of sphingosine phosphate receptors: Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-4-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated... Agent: Schwegman, Lundberg & Woessner, P.A.

20100010000 - Amino alcohol derivative and immunosuppresive agent having same as an active ingredient: m

20100010002 - Anticancer use of caffeic acid and its derivatives: in all its stereoisomeric and tautomeric forms, and mixtures thereof in all ratios, and a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, pharmaceutically acceptable polymorph or a prodrug, in the treatment of chronic myeloid leukemia (CML) which is resistant to treatment with GLEEVEC. The invention also relates to a method for... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20100010004 - Inhibitors of histone deacetylase:

20100010003 - Pyrimidine derivatives and their use as pesticides: The invention relates to new pyrimidine compounds of formula (1) wherein the variables have the meaning as indicated in the claims; in free form and in salt form; and optionally the enantiomers and geometrical isomers thereof. The compounds of formula (1) are useful in the control of parasites, in particular... Agent: Womble Carlyle Sandridge & Rice, PLLC

20100010005 - renal function with quercetin-containing compositions: This invention relates to a method of improving renal function by administering to a subject in need thereof an effective amount of a composition containing quercetin, vitamin C, vitamin B3, and folic acid.... Agent: Occhiuti Rohlicek & Tsao, LLP

20100010006 - Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals: Non-domesticated mammalian animals are anesthetized and immobilized by injecting an effective amount of an anesthetizing and immobilizing drug comprising pharmaceutically active ingredients of butorphanol tartrate, azaperone tartrate and medetomidine hydrochloride (BAM) into the animal from a dart. The BAM combination is preferably initially formed as lyophilized powder of the pharmaceutically... Agent: John R Ley, LLC

20100010007 - Piperidine derivatives as modulators of chemokine receptor ccr5: n

20100010008 - Substituted pyrrolo-pyrazole derivatives as kinase inhibitors: Substituted pyrrolo-pyrazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with dysregulated protein kinase activity, like cancer.... Agent: Scully Scott Murphy & Presser, PC

20100010009 - Furo[3,2-b] pyrrol -3-one derivatives and their use as cysteinyl porteinase inhibitors: The present invention relates to compounds of formula (1), and pharmaceutically acceptable salts thereof, A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof (I), wherein: one of R1 and R2 is H, and the other is selected from F and Cl, or R1 and... Agent: Edwards Angell Palmer & Dodge LLP

20100010010 - Hdac inhibitors: Compounds of formula (I) inhibit HDAC activity, wherein A, B and D independently represent ═C— or ═N—; W is a divalent radical —CH═CH— or CH2CH2—; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid... Agent: Banner & Witcoff, Ltd.

20100010011 - Compounds that act as a vehicle for delivery through the blood-brain barrier and charge delivery vehicle constructions: Compounds of formula (I), where R1 and R3 are H or (C1-C4)-alkyl; R2 is H or a C-radical derived from one of the known ring systems with 1-4 rings; X1 is a (C1-C6)-alkyl biradical derived from a linear or branched carbon chain; and X2 is —NH—, —NH—(CH2)1-3—COO—, —NH—(CH2)1-3—S—, or —NH—CO—(CH2)1-3—S—,... Agent: Berenbaum Weinshienk PC

20100010012 - Glutamate aggrecanase inhibitors: The present invention relates to modulators of metalloproteinase activity.... Agent: Wyeth Patent Law Group

20100010014 - Aminopyrimidine compounds and methods of use: The invention relates to aminopyrimidine compounds useful for treating diseases mediated by polo-like kinase 1 (Plk1). The invention also relates to the therapeutic use of such aminopyrimidine compounds and compositions thereof in treating disease states associated with abnormal cell growth and unwanted cell proliferation.... Agent: Amgen Inc.

20100010013 - Dihydropyrimidine compounds and their uses in manufacture of a medicament for treatment and prevention of viral diseases: The present invention relates to compounds of the formula (I) or pharmaceutically acceptable salts or hydrates thereof. The present invention further relates to processes for the preparation of the compounds of formula (I) and optical isomers and to use of the compounds of formula (I), isomers, pharmaceutically acceptable salts or... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20100010015 - Heterocyclic spiro-compounds as aldosterone synthase inhibitors: The patent application relates to new heterocyclic compounds of the general formula (I) in which A, R, R1, R2, U, V, W, X, Y, Z, n and p have the definitions elucidated in more detail in the description, to a process for preparing them and to the use of these... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100010016 - Bicyclic compounds having antimitotic and/or antitumor activity and methods of use thereof: The present invention provides bicyclic compounds, pharmaceutically acceptable salts, prodrugs, solvates, and hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, such as for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells... Agent: Buchanan Ingersoll & Rooney PC

20100010017 - Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors: Certain thienopyrimidine derivatives are useful for the inhibition of PDE10 enzymes, and thus are useful for treating psychiatric or neurological syndromes, e.g., psychoses, obsessive-compulsive disorder and/or Parkinson's disease, as well as, for example, treating a disease state modulated by PDE10 activity.... Agent: Darby & Darby P.C.

20100010018 - 4-amino-3-arylamino-6-arylpyrazolo[3,4-d) pyrimidine derivatives, methods for their preparation and their use as antiviral agents: 4-amino-3-arylamino-6-arylpyrazolo[3,4-d]pyrimidine derivatives of general formula (I), pharmaceutically acceptable salts thereof, method for preparation of the aforesaid compounds and their use as antiviral agents.... Agent: Jordan And Hamburg LLP

20100010019 - Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof: A reactive oxygen generating enzyme inhibitor with NO donor bioactivity, e.g., nitrated allopurinol, is useful to treat heart failure, stable angina, ischemic disorder, ischemic reperfusion injury, atherosclerosis, sickle cell disease, diabetes, Alzheimer's disease, Parkinson's disease, ALS and asthma and to obtain proper contraction of heart, skeletal and smooth muscle.... Agent: Bacon & Thomas, PLLC

20100010021 - Novel compounds: r

20100010020 - Phosphodiesterase 4 inhibitors:

20100010022 - Cancer treatment method: A method of treating cancer is described including administration of a pyrimidine derivative and a quinazoline derivative as well as a pharmaceutical composition including the same.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100010023 - Quinazoline derivatives and pharmaceutical compositions containing them: particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction mediated by tyrosine kinases, their use in the treatment of diseases, especially tumoral diseases and diseases of the lungs and airways, and the preparation... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100010024 - Use of1,4-diaryl-dihydropyrimidine-2-on derivatives for treating pulmonary arterial hypertension: The present application relates to the use of 1,4-diaryldihydropyrimidin-2-one derivatives of the formula (I) for the treatment and/or prophylaxis of pulmonary arterial hypertension and other types of pulmonary hypertension, and to the use thereof for the manufacture of medicaments for the treatment and/or prophylaxis of pulmonary arterial hypertension and other... Agent: Barbara A. Shimei Director, Patents & Licensing

20100010025 - Pyrimidine derivatives: Disclosed are pyrimidine derivatives having interesting pharmacological properties.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100010026 - Statin and omega-3 fatty acids for reduction of apo-b levels: Methods of utilizing a combined administration or a unit dosage of a combination of an HMG-CoA inhibitor and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of patients with hypertriglyceridemia or hypercholesterolemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease,... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20100010027 - Abnormal cannabidiols as agents for lowering intraocular pressure: t

20100010028 - Use of polyols to obtain stable polymorphous forms of rifaximin: Polyols stabilize polymorphous form of rifaximin, in particular the β form. When polyols having at least two hydroxy groups are added to rifaximin powder, polymorph β is stable and remains stable in time independently from the environment humidity. In this invention a method to prepare formulations constituted by pure and... Agent: Techlaw LLP

20100010029 - Acute pain medications based on fast acting diclofenac-opioid combinations: Provided are combined oral dosage forms for the treatment of pain, particularly combined dosage forms that are specially formulated for rapid bioavailability, and that contain diclofenac potassium and an opioid selected from hydrocodone, oxycodone, fentanyl and tramadol.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100010030 - Extended release hydrocodone acetaminophen and related methods and uses thereof: The present invention generally provides a method of treatment and improvement of quality of life for patients adversely affected by various pain conditions. One preferred embodiment provides a method of treatment of acute pain, moderate to moderately severe pain, chronic pain, non-cancer pain, osteoarthritic pain, bunionectomy pain or lower back... Agent: Paul D. Yasger Abbott Laboratories

20100010031 - Transoral dosage forms comprising sufentanil and naloxone: The invention pertains to methods that include administering to a subject a transoral dosage form comprising a pharmaceutical carrier and sufentanil, and maintaining a mean pH ranging from about 3.5 to about 5.5 during a dosing period after administration of the transoral dosage form as determined using an in vitro... Agent: Durect Corporation Thomas P. Mccracken

20100010032 - Camptothecin derivatives with antitumor activity: Novel camptothecin derivatives having antitumor activity, the processes for the preparation thereof, the use thereof as antitumor drugs and pharmaceutical compositions containing them.... Agent: Arent Fox LLP

20100010033 - Bis-carbazole dna intercalating agents for antitumor therapy: The present invention is a DNA intercalating agent represented by the structure Y-Z-Y, wherein Y is an anti-tumor bis-carbazole and Z is a linear arrangement of multiple aromatic rings, containing at least two aromatic rings, or at least two alicyclic rings, said rings being linked in a 1,4 or 1,3... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20100010034 - Crth2 antagonists: The following compounds are CRTH2 antagonists, useful in treatment of respiratory disease: [3-(2,4-dichlorophenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid, [6-fluoro-3-(2-fluoro-4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [6-fluoro-3-(4-methanesulfonyl-2-trifluoromethylphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, (R)-2-[6-fluoro-3-(4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]propionic acid, [3-(4-ethanesulfonylphenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid, (S)-2-[6-fluoro-3-(4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]propionic acid, ethanesulfonylaminobenzenesulfonyl)-6-fluoro-2-methyiindolizin-1-yl]acetic acid, [7-chloro-6-fluoro-3-(4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [3-(2-chloro-4-methanesulfonylphenylsulfanyl)-7-cyano-2-methylindolizin-1-yl]acetic acid, [6-cyano-3-(4-methanesulfonylbenzyl)-2-methylindolizin-1-yl]acetic acid, [3-(4-chlorobenzyl)-7-cyano-2-methylindolizin-1-yl]acetic acid, [6-cyano-3-(6-fluoroquinolin-2-yl-methyl)-2-methylindolizin-1-yl]acetic acid, [6-fluoro-3-(4-methoxyphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [7-chloro-6-fluoro-3-(4-methoxyphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [3-(4-bromophenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid, and [3-(4-cyclopropylsulfamoylphenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100010037 - 1h-pyrrolo[2,3-b]pyridine derivatives useful as hsp90 inhibitors: ring A is an aryl or heteroaryl ring or ring system; R1 is hydrogen, fluoro, chloro, bromo, or a radical of formula (1A): —X-Alk1-(Z)m-(Alk2)n-Q (IA) wherein X is a bond, —O—, —S—, —S(O)—, —SO2—, or —NH—, Z is —O—, —S—, —(C═O)—, —(C═S)—, —S(O)—, —SO2—, —NRA—, or, in either orientation —C(═O)O—,... Agent: Banner & Witcoff, Ltd.

20100010036 - Drugs for the treatment of sarcoglycanopathies: Inhibitors of the endoplasmic reticulum associated degradation (ERAD) pathway, particularly inhibitors of mannosidase I, are used for the preparation of a medicinal product intended to treat sarcoglycanopathies.... Agent: Heslin Rothenberg Farley & Mesiti PC

20100010035 - Novel dual action receptors antagonists (dara) at the ati and eta receptors: The present invention relates to new compounds of the formula [Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, R3, and R31 are as specified herein. The invention also relates to a method for preparation thereof, as well as combinations of the new compounds with previously... Agent: Jacobson Holman PLLC

20100010038 - Tricyclic compound and pharmaceutical use thereof: wherein R1 is a hydrocarbon group optionally having substituent(s), amino optionally having substituent(s), hydroxy optionally having a substituent or a heterocyclic group optionally having substituent(s), R2 is a hydrogen atom or a hydrocarbon group optionally having substituent(s), R3 is a hydrogen atom, a halogen atom, a hydrocarbon group optionally having... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100010039 - Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist: New polymorphic crystal form of (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one maleate designated crystal form Qalpha that is useful in the treatment of inflammatory or obstructive airways diseases. A method for preparing crystal form Qalpha is also described.... Agent: Novartis Corporate Intellectual Property

20100010040 - Triazol derivatives useful for the treatment of diseases: w

20100010041 - Difluorinated piperidines for treatment of alzheimer's disease and related conditions: Compounds of formula (I). Selectively inhibit production of Aβ(1-42) and hence find use in treatment of diseases associated with deposition of β-amyloid in the brain.... Agent: Merck And Co., Inc

20100010042 - Arylvinylazacycloalkane compounds and methods of preparation and use thereof: Novel vinylazacycloalkane compounds of Formula (I) are disclosed. The compounds are ligands of various nAChRs. The compounds and their pharmaceutically acceptable salts can be used to prepare pharmaceutical compositions and/or medicaments intended to prevent or treat disorders associated with dysfunction of nAChRs, especially within the central nervous system or the... Agent: Womble Carlyle Sandridge & Rice, PLLC

20100010043 - Percutaneously absorbable preparation: The present invention provides a percutaneously absorbable preparation comprising 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one and/or a hydrochloride thereof wherein the percuneously absorbable preoaration is able to administer to a patient such that Cmax per unit surface area of the percutaneously absorbable preparation is 0.025 to 0.5 ng/ml·cm2 in a plasma concentration profile.... Agent: Birch Stewart Kolasch & Birch

20100010044 - Novel crystalline form of 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-n-(2-oxo-2,3-dihydro-benzoxazol-6-yl)-acetamide: The present invention relates to a novel crystalline form of 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-N-(2-oxo-2,3-dihydro-benzoxazol-6-yl)-acetamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described.... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20100010045 - Pyrazole-derivatives as factor xa inhibitors: in which R0; R1; R2; R3; R4; Q; V, G and M have the meanings indicated below. The compound of formula I is a pharmacologically active compound. It exhibits a strong anti-thrombotic effect and is suitable, for example, for the therapy and prophylaxis of a cardio-vascular disorder like a thromboembolic... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100010047 - Isotopically substituted proton pump inhibitors:

20100010046 - Pharmaceutical formulation for parenteral administration: Parenteral formulations comprising ketorolac, and a compound of formula II wherein R is hydrogen or lower alkyl. Such formulations are used for the treatment and prevention of pain.... Agent: Heslin Rothenberg Farley & Mesiti PC

20100010050 - Formulations for the controlled release of agrochemical active agents: There have been found novel compositions for the controlled release of agrochemical active substances, containing at least one agrochemical active substance, cellulose ester and calcium carbonate.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100010048 - Fungicide 2-pyridyl-methylene-carboxamide derivatives: The present invention relates to 2-pyridyl-methylene-carboxamide derivatives of formula (I) in which the substituents are as in the description, their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds... Agent: Ostrolenk Faber Gerb & Soffen

20100010049 - Novel tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof: e

20100010051 - Suspension concentrates: The present invention relates to novel suspension concentrates of certain agrochemically active compounds, to a process for preparing these formulations and to their use for applying the active comprised therein.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100010052 - Topical composition comprising a dihydropyridine calcium antagonist: A topical composition comprising a dihydropyridine calcium antagonist, a stiffening agent and a release modifier. The stiffening agent comprises a fatty alcohol, a fatty acid sorbitane ester, or a fatty acid glycerol ester, having a hydrocarbon chain containing 12 to 22 carbon atoms and having a melting point of about... Agent: Birch Stewart Kolasch & Birch

20100010053 - Compounds: The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100010054 - Therapeutic agent for amyotrophic lateral sclerosis: A novel therapeutic agent for amyotrophic lateral sclerosis. A therapeutic agent for amyotrophic lateral sclerosis, including a compound having xanthine dehydrogenase inhibitory action and not acting as a substrate for the purine salvage pathway.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100010055 - Antagonists of the vanilloid receptor subtype 1 (vr1) and use thereof: n

20100010056 - Treatment for nicotine-induced lung disease using peroxisome proliferator-activated receptor gamma agonists: This invention provides pertains to the discovery that that nicotine interrupts molecular signaling between endodermal and mesodermal cells of the lung alveolus. Treatment of the lung with specific molecular agents (e.g., PPAR gamma agonists) can prevent and/or reverse the injury caused by nicotine.... Agent: Weaver Austin Villeneuve & Sampson LLP

20100010058 - Azoline compounds for combating arthropod pests: The present invention relates to azoline compounds and their salts which are useful for combating arthropod pests. The present invention also relates to a method for combating arthropod pests and to agricultural compositions for combating said pests. It has been found that these objectives can be achieved by azoline compounds... Agent: Brinks, Hofer, Gilson & Lione

20100010057 - Thiazole derivatives as inhibitors of p13 kinase: Compounds of formula (I) are inhibitors of P13 kinase activity, and useful in treatment of, inter alia, autoimmune, inflammatory and proliferative diseases: wherein: s is 0 or 1; U is hydrogen or halogen; X is —(C═O), an optionally substituted divalent phenylene, pyridinylene, pyrimidinylene, or pyrazinylene radical, or a bond; P... Agent: Banner & Witcoff, Ltd.

20100010059 - Anticancer oral formulation: m

20100010060 - Isoindolin-1-one-, isoindolin-3-one- and isoindolin-1,3-dione-derivatives and use thereof: The invention relates to novel isoindolin-1-one, isoindolin-3-one and isoindoline-1,3-dione derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100010061 - Cb1 receptor modulators: A1 is hydrogen, —COOH, or tetrazolyl, and A2 is hydrogen, —COOH, or tetrazolyl, provided that one of A1 and A2 is either —COOH or tetrazolyl; p is 0 or 1 and A3 is phenyl or cycloalkyl, either of which is optionally substituted with R4 and/or R5; q is 0 or... Agent: Banner & Witcoff, Ltd.

20100010062 - Method of treatment using eprosartan: The disclosed invention relates to a method of treatment of a disorder modulated by blocking angiotensin II (AII) receptors, and particularly selected from the group consisting of hypertension, congestive heart failure, renal failure, and combinations thereof, by administering to a subject in need thereof an effective dose of an eprosartan... Agent: Mayer Brown LLP

20100010063 - Heterocyclocarboxamide derivatives: where Het is a 5- or 6-membered heterocyclic ring containing one to three heteroatoms, each independently selected from oxygen, nitrogen and sulphur, provided that the ring is not 1,2,3-triazole, the ring being substituted by groups R8, R9 and R10; X is a single or double bond; Y is O, S,... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100010076 - Macrocyclic polymorphs, compositions comprising such polymorphs and methods of use and manufacture thereof: The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful... Agent: Morgan Lewis & Bockius LLP

20100010078 - Methods of treating androgen dependent prostate cancer by administering an active pharmaceutical ingredient being fisetin, 3,3',4',7-tetrahydroxyflavone or a derivative thereof, in an oral, transdermal or topical dosage form: Administration of fisetin (3,3′,4′,7-tetrahydroxyflavone) to a human male to treat androgen dependent prostate cancer. Fisetin is found in fruits and vegetables, such as strawberry, apple, persimmon, grape, onion and cucumber. Fisetin treatment, through modulations in cki-cyclin-cdk network, inhibits PI3K and Akt resulting in inhibition of cell growth followed by apoptosis... Agent: Quarles & Brady LLP

20100010079 - Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases: A method of treating an amyloid disease, or a disease characterized by α-synuclein or NAC fibrillogenesis, in a mammalian subject. The method includes administering to the mammal a therapeutically effective amount of a various disclosed proanthocyanidins or a proanthocyanidin characterized by disclosed general formulae. A pharmaceutical composition comprising a therapeutically... Agent: Jones Day

20100010077 - Process for the additivation of wine: The present invention relates to a process for the additivation of wine, more specifically for the formation of compounds that are beneficial to health. The process is based on the contact of natural materials, namely cork, with wine, under conditions where certain compounds of the said materials react with other... Agent: Scully Scott Murphy & Presser, PC

20100010080 - Use of tylvalosin as antiviral agent: The invention relates to the use of a macrolide antibiotic, tylvalosin, as an anti-viral agent. Tylvalosin is particularly useful for the treatment of PRRSV.... Agent: Venable LLP

20100010081 - Anti-tumor effect of dimeric phthalide compound: The present invention provides for the use of a dimeric phthalide compound, the dimeric phthalide compound has broad anti-tumor activity, can directly inhibit the proliferation of tumor cells and induce cell death, but also indirectly inhibit the development of tumors by suppressing neovascularization. And further, the dimeric phthalide compound can... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100010082 - Formulations for treating eye disorders: The present disclosure relates to ophthalmic solutions and methods of using the solutions to treat ocular disorders... Agent: Dechert LLP

20100010083 - Pharmaceutical composition for oral administration: An oral pharmaceutical composition characterized in that it consists of a suspension of a platinum complex of general formula I, wherein A and A′ independently of one another are an NH3 group or an amino or diamino group containing 1 to 18 carbon atoms, B and B′ independently of one... Agent: Notaro & Michalos P.C.

20100010084 - High penetration prodrug compositions of retinoids and retinoid-related compounds: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of retinoids and retinoid-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier... Agent: Perkins Coie LLP

20100010085 - Compositions and methods for treating jellyfish stings: Methods and compositions for treating skin conditions, in particular jellyfish stings, are provided.... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20100010086 - Antimicrobial therapy for indwelling catheters and for sanitizing surfaces: The invention relates to compositions that provide antimicrobial therapy for indwelling catheters and as topical disinfectants, and methods, devices and kits relating thereto. In one aspect, the invention relates to the infusion of a catheter lock solution into an indwelling catheter. Use of inventive compositions as catheter lock solutions advantageously... Agent: Krieg Devault LLP

20100010087 - Methods for inducing stem cell migration and specialization with ec-18: The present invention relates to promoting stem cell migration and specialization by administering one or more MADG compounds. The present invention further pertains to repairing or promoting the healing of injured tissue or a wound of an individual by administering a MADG compound (e.g., EC-18) to the individual, or subjecting... Agent: Antoinette G. Giugliano, P.C. Dba Agg Intellectual Property Law

20100010088 - Compositions and methods for prevention and treatment of mammalian diseases: The present invention discloses processes of making a polyunsaturated fatty acid compositions, and compositions thereof. Thus, one method of making a polyunsaturated fatty acid compositions comprises at least 8% polyunsaturated fatty acids, the process comprising extracting the fatty acids from a microalgae, wherein the fatty acids can be (a) GLA... Agent: Womble Carlyle Sandridge & Rice, PLLC

20100010090 - Ampa receptor potentiators: The present invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.... Agent: Eli Lilly & Company

20100010089 - System and method for production and use of fulvic acid: A method and system for producing fulvic acid and humic acid comprises extracting a liquid from an organic compost mixture. The liquid may be extracted by collecting liquid that percolates from the organic compost mixture or by separating liquid from solid components in the organic compost mixture. The extracted product... Agent: Bryan C. Bryner

20100010091 - Anhydrous, dermatological or cosmetic preparation containing urea: A dermatological or cosmetic preparation, which is anhydrous and contains urea, and is administered to improve the water retention capability of the stratum corneum, contains phytantriol and comprises a gel-like basis, which is essentially free of straight-chained hydrocarbons with 6 to 50 C-atoms. Compared with known such preparations, the preparation... Agent: Larson & Anderson, LLC

20100010093 - Antiparasitic agents: d

20100010092 - Use of modafinil to treat restless leg syndrome: A method for relieving, treating, improving or attenuating one or more symptoms of RLS and related movement disorders such as PLMS, and snoring ICSD 780.53-1 is disclosed. The method includes the administration to a host afflicted with RLS or related disorder a pharmaceutically effective amount of a modafinil compound or... Agent: Diamond Law Office LLC

20100010094 - Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents: The present invention relates to novel nitrophenyl mustard and nitrophenylaziridine alcohols, to their corresponding phosphates, to their use as targeted cytotoxic agents; as bioreductive drugs in hypoxic tumours, and to their use in cell ablation, including gene-directed enzyme-prodrug therapy (GDEPT) and antibody-directed enzyme-prodrug therapy (ADEPT), in conjunction with nitroreductase enzymes.... Agent: Nixon & Vanderhye, PC

20100010095 - Process for purifying rasagiline base: Disclosed is crystalline R(+)-N-propargyl-1-aminoindan and racemic N-propargyl-1-aminoindan characterized by colorless crystals a pharmaceutical composition comprising the same, and the process for the manufacture and the validation thereof. Also disclosed is pure liquid R(+)-N-propargyl-1-aminoindan and a pharmaceutical composition comprising the same, and the process for the manufacture thereof.... Agent: Cooper & Dunham, LLP

20100010096 - Methadone chiral isolate as an improved pharmaceutical: Methadone is a frequently employed agent for the treatment of drug addiction and the treatment of pain. Methadone prolongs the cardiac action potential, which on the surface electrocardiogram is represented by QT prolongation. This QT prolongation is known to increase the risk for the development of cardiac arrhythmias, especially the... Agent: John C. Somberg, Md

20100010097 - Methods for treating mild cognitive impairment and alzheimer's disease: Mild cognitive impairment and Alzheimer's disease are treated with an amphetamine compound. In one embodiment, the method includes administering an l-amphetamine compound. In another embodiment, the method includes administering an l-methamphetamine compound.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100010098 - Polymorphs of rasagiline hydrochloride: A polymorph of rasagiline hydrochloride displays improved stability and is useful in forming pharmaceutical compositions for treating Parkinson's disease. Another polymorph is useful as an intermediate in forming the stable crystalline form.... Agent: SynthonIPInc

20100010099 - Medium and device for proliferation of stem cells and treatment of cancer-related stem cell with resveratrol: The invention relates to a device for selecting stem cells with a serum free medium for amplification of stem cells. The invention also relates to a method of treating or preventing diseases caused by cancer-related stem cells. The invention further provides a method of enhancing radiosensitivity of cancer-related stem cells... Agent: Wpat, PC Intellectual Property Attorneys

20100010100 - Dermatological compositions with anti-aging and skin even-toning properties: The present invention relates to methods and compositions comprising benzoquinones such as Duroquinone, for the use of treating, regulating or preventing a skin condition characterized by oxidative stress or a degenerative process. Methods of preventing, lightening or reducing the appearance of visible and/or tactile discontinuities of the skin resulting from... Agent: Morrison & Foerster LLP

20100010101 - Rapid-melt compositions and methods of making same: The present invention provides a novel rapid-melt pharmaceutical composition comprising a binder, a super emulsifier, a diluent/bulking material; and an active ingredient. The present invention also provides a rapid-melt bead composition comprising a binder having a melting point from about 20 to about 90° C., an emulsifier; a diluent/bulking material;... Agent: Blank Rome LLP

20100010103 - Polymer encapsulation and/or binding: Encapsulation of and binding to pegylated bioactive molecules via functionalized comb, block, branched type polymers formed by nitroxide mediated controlled radical polymerization is disclosed.... Agent: Arkema Inc. Patent Department - 26th Floor

20100010102 - Triggered release of drugs from polymer particles: The present invention includes compositions and methods for the controlled delivery of active agents, e.g., drugs, based on one or more release triggers found in the environment in which the active agent-loaded particle is located. The composition and methods include a polymer network having a polymer cross-linked by peptides that... Agent: Chalker Flores, LLP

20100010104 - Semi-solid delivery vehicle and pharmaceutical compositions: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.... Agent: Hdc LLP

  
01/07/2010 > patent applications in patent subcategories. recently filed with US Patent Office

20100004157 - Pharmaceutical compositions for the oral or rectal administration of protein substances: Pharmaceutical compositions with differentiated, controlled and/or site-specific release are claimed for the oral or rectal administration of peptide or protein substances, including antibodies and soluble receptors capable of antagonising the pathogenetic role of several cell mediators such as interleukines, chemokines, growth factors, tissue necrosis factors, and interferons. Through the incorporation... Agent: Darby & Darby P.C.

20100004156 - Small compounds that correct protein misfolding and uses thereof: The invention features compositions and methods that are useful for treating or preventing a protein conformation disease in a subject by correcting misfolded proteins in vivo. In addition, the invention provides compositions and methods that are useful for expressing a recombinant protein in a biochemically functional conformation.... Agent: Edwards Angell Palmer & Dodge LLP

20100004158 - Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included. (I)... Agent: Merck And Co., Inc

20100004160 - Substituted fused heterocyclic c-glycosides: This invention relates to substituted fused heterocyclic C-glycosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X.... Agent: Philip S. Johnson Johnson & Johnson

20100004159 - Substituted imidazolone derivatives, preparations and uses: The present invention relates to polysubstituted imidazolone derivatives, to the pharmaceutical compositions comprising them and to the therapeutic uses thereof in the human and animal health fields. The present invention also relates to a process for preparing these derivatives.... Agent: Nixon & Vanderhye, PC

20100004161 - Toll like receptor 4 dysfunction and the biological applications thereof: The present invention relates to an in vitro method of assessing the sensitivity of a subject to a treatment of cancer, which method comprises detecting the presence of a mutated Toll Like Receptor 4 (TLR4) nucleic acid or an abnormal TLR4 protein expression or activity in a sample from the... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100004178 - Albumin-based colloid composition and method of use in treating hypovolemia and multiorgan dysfunction: A composition comprising an albumin-based colloid and its use in treating hypovolemic conditions such as capillary leak syndrome and shock are disclosed.... Agent: Emch, Schaffer, Schaub & Porcello Co

20100004176 - Axmi-115, axmi-113, axmi-005, axmi-163 and axmi-184: insecticidal proteins and methods for their use: Compositions and methods for conferring insecticidal activity to host cells are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in host cells. Compositions also comprise transformed host cells. In particular,... Agent: Alston & Bird LLP

20100004169 - Ccn3 peptide: The present application relates to nucleic acid and peptide sequences of CCN3 and derivatives and fragments thereof useful in the treatment of disease, in particular tumours and/or for use as a clinical marker.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100004163 - Composition and uses of a galectin for treatment of dry eye syndrome: Methods for the therapeutic treatment of dry eye in mammals comprising administering to a mammal afflicted with an epithelial wound a therapeutically effective amount of a galectin-1 protein, a galectin-3, a galectin-7 protein and/or a galectin-8 protein are provided. Pharmaceutical and ophthalmic compositions and kits, comprising a pharmaceutically an active... Agent: Lawson & Weitzen, LLP

20100004172 - Compositions for mucosal and oral administration comprising hcg fragments: The invention relates to the field of immunology, more specifically to the field of immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease and other inflammatory diseases. The invention in particular relates to the systemic treatment of inflammatory disease by oral or mucosal administration of a pharmaceutical composition with a... Agent: Traskbritt, P.C.

20100004167 - Csf3r polypeptides and uses thereof: The present invention relates to CSF3R polypeptide variants and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids encoding said polypeptides, vectors comprising such nucleic acids and recombinant cells containing the same. The invention further discloses methods of producing such polypeptides,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100004166 - Endothelin and endothelin receptor agonists in the treatment of metabolic diseases: Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an endothelin or an endothelin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20100004162 - Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses thereof: The present invention provides a novel family of polypeptides which are ligand-gated channel receptor accessory molecules or ligands, denoted Lynx. This invention provides an isolated polypeptide comprising an amino acid sequence of a Lynx polypeptide in which the amino acid sequence is set forth in SEQ ID NO:2, SEQ ID... Agent: Patent Docket Administrator Lowenstein Sandler PC

20100004175 - Novel bmp-12-related proteins and methods of their manufacture: The invention provides novel BMP-12-related proteins, including methods of their manufacture. The proteins include substituted, truncated and substituted-truncated BMP-12-related proteins. The substituted BMP-12-related proteins contain a substitution at one or more oxidation-sensitive methionine residues with non-methionine residues, such as norleucine. The substituted BMP-12-related proteins exhibit normal bioactivity and enhanced resistance... Agent: Wyeth/finnegan Henderson, LLP

20100004165 - Novel protein transduction domains and uses therefor: The present invention provides novel transduction domains, compositions comprising such transduction domains, and their use for in vivo molecular delivery.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100004164 - Platelet aggregation inhibitor composition: e

20100004170 - Protein-containing substance with increased thermal stability: The invention relates to an agent with increased thermal stability comprising a core and a coating layer characterized in that the core comprises at least one biologically active protein and that the coating layer comprises a micronized product from leguminous plants, a method for the production of this agent as... Agent: Edwards Angell Palmer & Dodge LLP

20100004173 - Reconstituted surfactants having improved properties: Reconstituted surfactants comprising a lipid carrier, a polypeptide analog of the native surfactant protein SP-C, and a polypeptide analog of the native surfactant protein SP-B are useful for the treatment and/or prophylaxis of RDS and other respiratory disorders.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100004171 - Therapeutic methods for neuropathic pain: The agrin protein was shown to be important in preventing the development of neuropathic pain, as well as in treating neuropathic pain. Both agrin protein and gene expression were shown to be down-regulated in mammals with neuropathic pain. Increasing either agrin gene expression or protein resulted in a decrease in... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20100004177 - Toxin complex proteins and genes from xenorhabdus bovienii: The subject invention relates to novel Xenorhabdus toxin complex (TC) proteins and genes that encode these proteins. More specifically, the subject invention relates to TC genes and proteins obtainable from Xenorhabdus bovienii strain ILM104.... Agent: Baker & Daniels LLP- Dow Agrosciences

20100004168 - Use of crystallin for the modulation of angiogenesis: The present invention features therapeutic and prophylactic compositions and methods for modulating a blood vessel by altering angiogenesis, vasculogenesis, blood vessel stabilization, regression, persistence, or remodeling.... Agent: Edwards Angell Palmer & Dodge LLP

20100004174 - Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases: The invention concerns the use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases such as multiple sclerosis, and inflammatory bowel diseases such as Crohn's disease or ulcerative colitis.... Agent: Arent Fox LLP

20100004179 - Targeting of ews-fli1 as anti-tumor therapy: Peptides and compounds are provided that function as EWS-FLI1 protein inhibitors. The peptides and compounds have utility in the treatment of Ewing's sarcoma family of tumors. Also provided are methods of preparing the compounds and assays for identifying inhibitors of EWS-FLI1 protein.... Agent: Knobbe Martens Olson & Bear LLP

20100004180 - Agents for the detection and modulation of b-cells and antibodies: The present invention relates to the identification and use of peptide and peptide analogs that represent epitopes for naturally-occurring antibodies (Nabs). These epitopes may be used to monitor the degree of autoimmunity in an organism, as well as to modulate the activity of B-cells producing Nabs.... Agent: Fulbright & Jaworski L.L.P.

20100004181 - Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-(1,3,4-oxadiazol-2-yl)phenyl) pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate: A combination, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, and an LHRH analogue and/or a bisphosphonate is described.... Agent: Astrazeneca R&d Boston

20100004182 - Composition effective to prevent or treat adult disease: Disclosed is a composition comprising, as an active ingredient, an enzyme digest that is produced by digesting a basic fraction of an animal-derived cartilage extract with an enzyme. Also disclosed is a polypeptide composition comprising, as an active ingredient, at least one polypeptide selected from specific polypeptides including a polypeptide... Agent: Young & Thompson

20100004183 - Mineral collagen chelates and methods of making and using same: Collagen peptide chelated mineral products, pharmaceutical formulations thereof and methods for preparing same are provided. Also provided is a method for generating the optimal size of collagen peptide for optimum mineral chelation as well as optimum biological function for supporting bone health and joint health. Also disclosed are methods of... Agent: Gibson & Dernier L.L.P.

20100004184 - Anti-hypercholesterolemic compounds: This invention provides cholesterol absorption inhibitors of Formula (I), and the pharmaceutically acceptable salts and esters thereof. The compounds arc useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.... Agent: Merck And Co., Inc

20100004185 - Extracts derived from sugar cane and a process for their manufacture: An extract derived from sugar cane having GI or burn rate reducing characteristics wherein the extract comprises a mixture of one or more polyphenols, one or more carbohydrates, one or more minerals and one or more organic acids.... Agent: Reed Smith LLP

20100004186 - Antithrombotic dual inhibitors comprising a biotin residue: The present invention relates compounds of the formula (I) oligosaccharide-spacer-A (1), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising two to twenty five monosaccharide units, the charge being compensated by positively charged counterions, and wherein the oligosaccharide residue is derived from an oligosaccharide which has (AT-III mediated) anti-Xa... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20100004187 - Cobalt-amine based metal complex as an antibacterial compound: Disclosed herein is a method of: administering to a subject suspected of being infected with a bacterium, a composition of a cobalt (III) compound having the formula CoR1R2R3R4R5R6 or a salt thereof and an antibiotic compound. Each of R1, R2, R3, R4, and R5 is the same or different and... Agent: Naval Research Laboratory Associate Counsel (patents)

20100004188 - Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides: This invention relates to to substituted benzimidazole-O-glucosides, benztriazole-O-glucosides, and benzimidazolone-O-glucosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X.... Agent: Philip S. Johnson Johnson & Johnson

20100004189 - Compositions and methods for treating cystic fibrosis: Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same... Agent: Davis Wright Tremaine, LLP/seattle

20100004190 - Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof: This invention provides methods, processes, compounds and compositions for modulating the gene expression and modulating the secretion, expression, or synthesis of adhesion proteins or their receptors to cure disease, wherein the modulating comprises positive and negative regulating; wherein comprises inhibiting cancer growth, wherein the adhesion proteins or receptors comprise fibronectin,... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20100004315 - Biodegradable cross-linked branched poly(alkylene imines): Disclosed is a cross-linked branched poly(alkylenimine) and compositions thereof and nucleotide molecules. Also disclosed are methods for preparing the cross-linked branched poly(alkylenimine).... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100004317 - Methods and compositions for the specific inhibition of gene expression by double-stranded rna: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100004318 - Methods and compositions for the specific inhibition of gene expression by double-stranded rna: The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100004313 - Modified poloxamers for gene expression and associated methods: Nucleotide delivery polymers, compositions, and associated methods for the enhancement of gene delivery and expression in solid tissues are provided. In one aspect, for example, a nucleotide delivery polymer may include a poloxamer backbone having a metal chelator covalently coupled to at least one terminal end of the poloxamer backbone.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100004316 - Multifunctional carriers for the delivery of nucleic acids and methods of use thereof: Described herein are multifunctional compounds useful as devices for the delivery of nucleic acids to cells. Also described herein are methods for using the multifunctional compounds.... Agent: Gardner Groff Greenwald & Villanueva. PC

20100004314 - Use of sirna to achieve down regulation of an endogenous gene in combination with the use of a sense construct to achieve expression of a polynucleotide: The present invention relates to the combinatorial use of an siRNA targeted against an endogenous gene to knock out or knock down expression of the endogenous gene in a host and a delivery of a polynucleotide encoding the gene in a delivery vehicle/expression vector to the host to provide expression... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100004319 - Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease: A method for enhancing the clinical responsiveness to an anti-inflammatory therapy in a patient afflicted with an inflammatory condition, comprising administering an oligonucleotide having the sequence 5′-Xm-CG-Yn-3′ in an effective amount to said patient, and wherein X is A, T, C or G; Y is A, T, C or G;... Agent: Dla Piper LLP (us)

20100004320 - Pharmaceutical composition: The invention provides pharmaceutical compositions comprising short single stranded oligonucleotides, of length of between 8 and 17 nucleobases which are complementary to human microRNAs. The short oligonucleotides are particularly effective at alleviating miRNA repression in vivo. It is found that the incorporation of high affinity nucleotide analogues into the oligonucleotides... Agent: Baker Botts L.L.P.

20100004323 - Promoter construct: A polynucleotide comprising a β subunit cGMP-phosphodiesterase promoter operably linked to one or more enhancer elements.... Agent: Frommer Lawrence & Haug

20100004321 - Recombinant staphylococcal phage lysin as an antibacterial agent: The present invention provides a plasmid pSOFLysK contained in the bacterial strain Lactococcus lactis NZ9800 referred herein as Lactococcus lactis NZ9800-pSOFLysK (subsequently designated Lactococcus lactis DPC6132) encoding anti-staphylococcal activity as deposited with DSMZ under accession No. ncimb 41409 and plasmids substantially similar thereto also providing anti-staphylococcal activity. In another aspect,... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100004322 - Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181: The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of chronic lymphocytic leukemia (CLL). The invention also provides methods of identifying anti-CLL agents.... Agent: Macmillan Sobanski & Todd, LLC

20100004191 - Compositions of s-adenosyl-l-methionine.: Compositions of S-adenosyl-L-methionine with indole-3-propionic acid and methods to treat conditions associated with DNA hypomethylation are disclosed.... Agent: Rolland Hebert

20100004192 - 4'-substituted nucleoside derivatives as inhibitors of hcv rna replication: m

20100004193 - Combination therapy: A method of treating a subject affected by neoplastic diseases includes the administration to the subject of an aminoglycoside antibiotic in combination with a nucleoside analogue.... Agent: Young & Thompson

20100004194 - Use of isomaltulose in food products having a regenerative effect: The invention relates to the use of isomaltulose or mixtures of isomaltulose for the production of functional food products for improving the regeneration of individuals exposed to physical exertion.... Agent: Ostrolenk Faber Gerb & Soffen

20100004195 - Decoy influenza therapies: The present invention provides umbrella-topology glycan decoys. The present invention provides systems and methods treating influenza infection utilizing inventive umbrella-topology glycan decoys. The present invention provides methods for identifying novel umbrella-topology glycan decoys.... Agent: Choate, Hall & Stewart LLP

20100004196 - Heparan sulfate proteoglycan composition and use thereof: The present invention relates to method for the preparation of glycosaminoglycan compositions, isolated glycosaminoglycan compositions obtainable therefrom, glycosaminoglycan compositions, kits and use thereof. More specifically, the present invention provides a method for isolating glycosaminoglycan compositions of the invention from human follicular fluid. The compositions, related methods and uses according to... Agent: Baker & Daniels LLP

20100004197 - Procedure for the preparation of glyoxalated cationic guar: Procedure for the preparation of cationic guar having DS comprised between 0.01 and 3, soluble at basic pH and suitable for the use in the cosmetic field and in household cleaning products comprising the following steps: a) 100 parts by weight of guar flour are reacted with 3-chloro-2-hydroxypropyl trimethylammonium chloride... Agent: Mossman, Kumar & Tyler

20100004198 - Polysaccharide gel formulation having increased longevity: Described herein are polysaccharide gel formulations including at least one inhibitor of polysaccharide degradation and methods of making the same. The methods described herein involve the steps of providing at least one polysaccharide and incorporating at least one inhibitor of degradation into the polysaccharide. In some embodiments, the incorporating step... Agent: Allergan, Inc.

20100004199 - Glycine betaine and its use: The present invention provides pharmaceutical uses of betaines, and especially glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation and thrombi formation.... Agent: Hovey Williams LLP

20100004200 - Meloxicam and glucosamine formulation and uses thereof: Provided herein is a process for making compositions and methods of using such compositions to treat pain, inflammation and/or inflammatory disease or disorder including degenerative osteoarticular disease.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100004201 - Cosmetic: o

20100004203 - Medicament for preventive and/or therapeutic treatment of bowel disease: A medicament for preventive and/or therapeutic treatment of a bowel diseases such as inflammatory bowel diseases including Crohn's disease, which comprises as an active ingredient a retinoid such as, for example, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid.... Agent: Greenblum & Bernstein, P.L.C

20100004202 - Quaternary ammonium-functionalized-poss compounds: A silsesquioxane cage structure has a general formula [R1SiO1.5]n, wherein, n is an integer greater than or equal to 4; each R1 is an amine-functional siloxy group, a quaternary ammonium-functional siloxy group, or a texturizing moiety. At least one R1 group may optionally be a quaternary ammonium-functional siloxy group. Compositions... Agent: Foley & Lardner LLP

20100004205 - Pharmaceutical compositions: Synergistic combinations of a squalene epoxidase inhibitor and a leucyl-tRNA synthetase inhibitor are provided, which are useful in particular in the treatment of diseases involving fungal or suspected fungal infection, for immunomodulation or immunosuppression in conditions in which fungal or suspected fungal colonisation of e.g. the skin or nail plays... Agent: Novartis Corporate Intellectual Property

20100004204 - Ros-sensitive iron chelators and methods of using the same: The present invention provides compounds of Formula (I): along with compositions containing the same and methods of use thereof in treating oxidative stress.... Agent: Myers Bigel Sibley & Sajovec

20100004206 - Water-soluble benzoazepine compound and its pharmaceutical composition: wherein R represents a hydrogen atom, a hydroxy group optionally protected with a protecting group, etc., R1 represents a hydrogen atom or hydroxy-protecting group, and X represents an oxygen atom or a sulfur atom. The benzoazepine compound of the present invention and salts thereof have high solubility in water, and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100004207 - Inhibitors of cyclin-dependent kinases, compositions and uses related thereto: The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation.... Agent: Leon R. Yankwich, Esq. Yankwich & Associates, P. C.

20100004208 - Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors: The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerisation inhibitors.... Agent: Woodcock Washburn LLP

20100004209 - [(4-oxo-4h-chromen-3-yl)hydroxymethyl]- or [(4-oxo-4h-chromen-3-yl)methyl]phosphonic acid derivatives: The present invention relates to compounds of the formula (I), where R1 to each, independently of one another, denote H, hydroxyl or alkoxy having 1 to 8 C atoms, R4 denotes alkyl having 1 to 4 C atoms, H, hydroxyl or alkoxy having 1 to 8 C atoms, R5 denotes... Agent: Millen, White, Zelano & Branigan, P.C.

20100004210 - Method and substances for treating t-cell mediated autoimmune diseases: The invention relates to methods for treating T cell mediated autoimmune diseases, such as psoriasis and multiple sclerosis, in a human in need thereof, wherein a therapeutically effective amount of a substance which lowers the cellular glutathione content is administered to the human.... Agent: Morrison & Foerster LLP

20100004211 - 7-n-substituted phenyl tetracycline compounds: 7-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted tetracycline compounds are described.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100004212 - Dual protection of medicinal- pharmaceutical products and new techniques for their application: The present invention solves under the best possible method three problems which preoccupy the production, delivery and use of pharmaceutical, medicinal or other products: A) Their protection from oxidating alterations with the use of reducing or antioxidant substances-mixtures. B) The protection from alterations which are caused by light exposure primarily... Agent: Diane Dunn Mckay, Esq. Mathews, Shepherd, Mckay & Bruneau, P.A.

20100004213 - Gene expression markers for inflammatory bowel disease: The present invention relates to methods of gene expression profiling for inflammatory bowel disease pathogenesis, in which the differential expression in a test sample from a mammalian subject of one or more IBD markers relative to a control is determined, wherein the differential expression in the lest sample is indicative... Agent: Goodwin Procter LLP

20100004214 - Sequential sprm/ progestin treatment: The methods provided herein comprise administering a selective progesterone receptor modulator (SPRM) during a first dosing period and at least one progestogen during a second dosing period. The dosing periods can run concomitantly or sequentially with or without a period where neither the SPRM nor the progestogen is administered.... Agent: Robert Deberardine Abbott Laboratories

20100004215 - Compositions of phosphodiesterase type iv inhibitors: Provided herein are pharmaceutical compositions comprising one or more phosphodiesterase inhibitors of type IV (“PDE-IV”), and at least one other active ingredient such as muscarinic receptor antagonists (MRA), β2-agonists, p38 MAP Kinase inhibitors, or corticosteroids and optionally one or more pharmaceutically acceptable excipients. In addition, methods of treating autoimmune, inflammatory... Agent: Ranbaxy Inc.

20100004216 - Medicinal lipolysis of accumulation of fat: Aqueous preparations comprising at least one phospholipid or at least one bile acid and a component assisting degradation of fat such as riboflavin and water are suitable for producing medicaments for removing subcutaneous accumulations of fat and lead to regression of diet-resistant fat pads.... Agent: The Firm Of Hueschen And Sage

20100004217 - Topical steroidal formulations: The present invention relates to formulations of poorly water soluble pharmaceutical agents of Formula I and II. The present invention also relates to compositions containing compounds of Formula I or II, and glucocorticoids, and methods for reducing side effects from glucocorticoid treatment by co-administration of compounds of Formula I and... Agent: Elmore Patent Law Group, PC

20100004218 - Bridged polycyclic compound based compositions for renal therapy: A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups,... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20100004219 - Modulators of glucocorticoid receptor, ap-1, and/or nf-kappabeta activity and use thereof: Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including metabolic and inflammatory or immune associated diseases or disorders having the structure of formula I or an enantiomer, diastereomer, tautomer, or a pharmaceutically-acceptable salt, thereof, wherein: A... Agent: Louis J. Wille Bristol-myers Squibb Company

20100004220 - Indenoisoquinolinone analogs and methods of use thereof: The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease,... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100004222 - Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same: Compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and... Agent: Jones Day

20100004221 - Thiazepine derivative: R1 represents a hydrogen atom, a C1-C6 alkyl group; R2 represents a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a C1-C6 hydroxyalkyl group; R1 represents a hydrogen atom or a C1-C6 alkyl group; R4 represents a C6-C10 aryl group that may be substituted with 1 to 5 group(s) independently... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20100004223 - Crystalline forms of (r)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride: The present invention is directed to crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, compositions containing the same, preparations, and uses thereof.... Agent: Fish & Richardson P.C.

20100004224 - 1,2,4-triazole derivatives as sigma receptor inhibitors: The invention relates to the use of compounds having pharmacological activity towards the sigma receptor, and more particularly to 1,2,4-triazole derivatives of formula (I) to processes of preparation of such compounds and to pharmaceutical compositions comprising them.... Agent: Hoffmann & Baron, LLP

20100004225 - Controlled release aural pressure modulator compositions and methods for the treatment of otic disorders: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with aural pressure modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris... Agent: Wilson, Sonsini, Goodrich & Rosati

20100004226 - Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects: The present invention provides compositions and methods of using stereospecific benzodiazepine derivatives, their salts and prodrugs for the treatment of anxiolytic or convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnotic, muscle relaxant and ataxic side-effects. The invention further provides... Agent: Boyle Fredrickson S.c.

20100004227 - Compositions and methods relating to novel compounds and targets thereof: The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and related compounds and methods of using benzodiazepine derivatives and related compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation... Agent: Casimir Jones, S.c.

20100004228 - Selected cgrp antagonists, processes for preparing them and their use as pharmaceutical compositions: wherein R1, R2, R3 and R4 are as defined in claim 1, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases,... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100004230 - Azatricyclic compounds and their use: Tricyclic nitrogen containing compounds and their use as antibacterials.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100004229 - Potassium channel inhibitors: The present invention relates to pyridin-3-yl pyridin-3-amine compounds and derivatives thereof having the structure formula (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.... Agent: Merck And Co., Inc

20100004231 - Inhibitors of burton's tyrosine kinase: wherein, variables Q, R, Y1, Y2, Y2′, Y3, Y4, n and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto... Agent: Roche Palo Alto LLC

20100004232 - Pharmaceutical compounds: The use of a compound for the manufacture of a medicament for the prophylaxis or treatment of: A. a disease state or condition mediated by a kinase which is BCR-abl, VEGFR, PDGFR, EGFR, Flt3, JAK (e.g. JAK2 or JAK3), C-abl, PDK1, Chk (e.g. Cbk1 or Chk2), FGFR (e.g. FGFR3), Ret,... Agent: Heslin Rothenberg Farley & Mesiti PC

20100004233 - Novel coumarin derivative having antitumor activity: wherein: X is selected from heteroaryl etc., Y1 and Y2 are selected from —N═ etc., Y3 and Y4 are selected from —CH═ etc., A is selected from sulfamide etc., R1 is selected from hydrogen etc., and R2 is selected from C1-6 alkyl etc. The compound or salt has sufficiently high... Agent: Morgan Lewis & Bockius LLP

20100004234 - Specific kinase inhibitors: Resorcylic acid lactones having a C5-C6 cis double bond and a ketone at C7 and other compounds capable of Michael adduct formation are potent and stable inhibitors of a subset of protein kinases having a specific cysteine residue in the ATP binding site.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100004237 - 2-amino-7,8-dihydro-6h-pyrido[4,3-d]pyrimidin-5-ones: Disclosed are 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Disclosed also are methods of using the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either... Agent: Novartis Institutes For Biomedical Research, Inc.

20100004238 - Fused heterocyclic compound: s

20100004235 - Heterocyclic substituted, anellated pyrazole derivative and its uses: The present application relates to novel heterocyclyl-substituted fused pyrazole derivatives, to processes for their preparation, to their use, alone or in combination, for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention... Agent: Barbara A. Shimei Director, Patents & Licensing

20100004236 - Phosphodiesterase 4 inhibitors: e

20100004239 - Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors: The present invention relates to pyrrolo[3,2-c]pyridine-4-one 2-indolinone compounds of Formula (I) and their pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8X, Y and have the meaning cited in the specification. Also disclosed are the pharmaceutical compositions containing the foregoing compounds, methods for the preparation... Agent: Bingham Mccutchen LLP

20100004240 - Indole compounds: Compounds of Formula (I) or a pharmaceutically acceptable derivative thereof: wherein R1, R2, and R3 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100004241 - Non-imidazole aryloxyalkylamines: Substituted aryloxyalkylamines of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.... Agent: Philip S. Johnson Johnson & Johnson

20100004242 - Process for the preparation of aprepitant: The present invention relates to a highly pure (2R,3S)-4-benzyl-3-(4-fluorophenyl)morpholin-2-yl 3,5-bis(trifluoromethyl)benzoate of Formula II, and a process for its preparation. The present invention further provides a process for preparation of Aprepitant of Formula I or pharmaceutically acceptable salt thereof, using the highly pure compound of Formula II. The present invention also... Agent: Ranbaxy Inc.

20100004243 - Pharmaceutical compounds: The invention provides a cyclin dependent kinase (e.g. cdk-4 kinase) inhibitor of the formula (I) or a salt, tautomer, solvate or N-oxide thereof; wherein R1 is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group containing 0-2 heteroatoms selected from O, N and S wherein the optional substituents are... Agent: Heslin Rothenberg Farley & Mesiti PC

20100004244 - Use of cb2 receptor agonists for promoting neurogenesis: The present invention relates to ligands of the peripheral cannabinoid receptor CB2, especially (+)-α-pinene derivatives, and to pharmaceutical compositions thereof, which are useful for promoting, inducing and enhancing neurogenesis including neural cell regeneration. In particular, pharmaceutical compositions of the invention will be useful for preventing, alleviating or treating neurological injuries... Agent: Winston & Strawn LLP Patent Department

20100004245 - Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase: Azacycloalkane derivatives of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis;... Agent: Merck And Co., Inc

20100004246 - Novel triazinedione derivatives as gabab receptor modulators: The present invention provides novel compounds of formula I wherein W1, W2, W3, W4, W5, B, X1, X2, X3, X4, X5, E and L are as defined herein; invention compounds are gamma amino butyrique acid receptor-subtype B (“GABAB”) positive allosteric modulators (enhancers), which are useful to provide methods of treating... Agent: Edwards Angell Palmer & Dodge LLP

20100004247 - Combination comprising a mek inhibitor and an aurora kinase inhibitor 188: The present invention relates to a therapeutic combination comprising a MEK inhibitor and an Aurora kinase inhibitor, and to methods for the production of an anti-cancer effect in a patient, which is accordingly useful in the treatment of cancer in a patient. More specifically the present invention relates to: a... Agent: Astrazeneca R&d Boston

20100004249 - Bicyclic heterocyclic compound and use thereof: e

20100004251 - Dopamine-agonist combination therapy for improving sleep quality: The present invention generally relates to pharmaceutical compositions comprising a dopamine agonist and sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. In a preferred embodiment, the dopamine agonist is optically... Agent: Heslin Rothenberg Farley & Mesiti P.C.

20100004250 - Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer: Wherein R4 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R5 is the side chain of a natural or non-natural alpha amino acid; and the linker radical —Y-L1-X1 is as defined in the... Agent: Banner & Witcoff, Ltd.

20100004252 - Substituted tetrahydropyrrolopyrazine compounds and the use thereof in the treatment and/or inhibition of pain: e

20100004248 - Use of a nitric oxide synthase modulator for the treatment of cardiac indications: The invention features compositions and methods for modulating NOS that are useful for the prevention and treatment of cardiac diseases and disorders, including cardiac hypertrophy and cardiac dilation. In particular, the invention provides compositions comprising tetrahydrobiopterin (BH4), alone or in combination with one or more additional compounds.... Agent: Edwards Angell Palmer & Dodge LLP

20100004254 - Therapeutic agents useful for treating pain: wherein Ar1, A, R3, x, and m are as disclosed herein and Ar2 is a benzothiazolyl, benzooxazolyl, or benzoimidazolyl group or a pharmaceutically acceptable salt thereof (a “Benzoazolylpiperazine Compound”), compositions comprising a Benzoazolylpiperazine Compound, and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's... Agent: Dechert LLP

20100004253 - Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors: Methods of utilizing biomarkers to identify patients for treatment or to monitor response to treatment are taught herein. Alterations in levels of gene expression of the biomarkers, particularly in response to Raf kinase inhibition, are measured and identifications or adjustments may be made accordingly.... Agent: Novartis Vaccines And Diagnostics Inc.

20100004255 - Method of treating arrhythmias: Methods are provided for treating arrhythmias including tachycardias, such as idiopathic ventricular tachycardia, ventricular fibrillation, and Torsade de Pointes (TdP) in a manner that minimizes undesirable side effects.... Agent: Cv Therapeutics, Inc. Gilead Palo Alto, Inc.

20100004256 - Heteroaryl-fused macrocyclic pyrimidine derivatives: t

20100004257 - Identification of biomarkers predictive of dasatinib effects in cancer cells: A method of predicting response to treatment with inhibitors of EGFR and SRC by screening for status of key biomarkers such as EGFR. Dasatinib is a drug that can inhibit a group of proteins called SRC proteins. In addition, other experiments have suggested that other important signaling proteins are affected... Agent: Smith Hopen, Pa

20100004260 - 2-piperazin-1-yl-3h-imidazo[4,5-b]pyridine derivatives: The present invention is concerned with novel compounds of formula (I) having fundic relaxating activity. The invention further relates to methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use as a medicine of said compounds.... Agent: Philip S. Johnson Johnson & Johnson

20100004259 - Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine: The present invention provides a tartrate salt of Formula (I), Formula I is also known as (7S)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2R)-2-methylpiperazin-1-yl]-6,7-dihydro-5H-cyclopenta[b]pyridine. The tartrate salt is preferably crystalline. The tartrate salt of Formula I of the invention is useful in the treatment of diseases linked to activation of the 5HT2c receptor in animals including humans,... Agent: Pfizer Inc. Patent Department

20100004261 - Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase: Certain piperazinyl and piperidinyl urea compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation,... Agent: Philip S. Johnson Johnson & Johnson

20100004262 - Pharmaceutical compositions of aripiprazole: An orally deliverable pharmaceutical composition provides controlled release of aripiprazole. The composition includes a therapeutically effective amount of aripiprazole and at least one pharmaceutically acceptable excipient. The compositions of the invention may exhibit one or more of the release profiles defined in the specification.... Agent: Panitch Schwarze Belisario & Nadel LLP

20100004263 - Mtp inhibiting aryl piperidines or peperazines substituted with5-membered heterocycles:

20100004258 - Novel heterocyclic nf-kb inhibitors:

20100004265 - 1,2,3-triazole derivatives as sigma receptor inhibitors: The invention relates to compounds having pharmacological activity towards the sigma receptor, and more particularly to 1,2,3-triazole derivatives of formula (I) and to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and prophylaxis, in particular for the treatment of psychosis or... Agent: Hoffmann & Baron, LLP

20100004264 - Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto: Pyrazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the serotonin 5HT2A receptor. Formula (Ia). Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina,... Agent: Fish & Richardson P.C.

20100004267 - Liquid preparation: r

20100004266 - Salt or solvate of 5-methyl-2(piperazin-1-yl)benzenesulfonic acid:

20100004268 - Optically pure dihydropyrimidine compounds and their uses for the preparation of a medicament for treatment and prevention of viral diseases: The present invention relates to an optically pure compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof, a process for preparing the optically pure compound of formula (I), and use of the optically pure compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof as... Agent: Macmillan Sobanski & Todd, LLC

20100004269 - 5-anilinoimidazopyridines and methods of use: The invention relates to imidazopyridines of formula I with anti-cancer and/or anti-inflammatory activity and more specifically to imidazopyridines which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention... Agent: Genentech, Inc.

20100004270 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Wilson, Sonsini, Goodrich & Rosati

20100004271 - Heterocyclic compounds as aganist for the thyroid receptor: The invention provides Compounds of formula (I) or pharmaceutically acceptable esters, amides, solvates or salts thereof, including salts of such esters or amides, and solvates of such esters, amides or salts, wherein R3, R4, G, Y, W and R5 are as defined in the specification. The invention also provides the... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20100004272 - Modulators of metabolism and the treatment of disorders related thereto: The present invention relates to 4-[6-(6-methanesulfonyl-2-methyl-pyridin-3-ylamino)-5-methyl-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester, pharmaceutically acceptable salts, solvates and hydrates thereof that are modulators of glucose metabolism. Accordingly, compounds of the present invention are useful in the treatment of metabolic-related disorders and complications thereof, such as, diabetes and obesity.... Agent: Fish & Richardson P.C.

20100004273 - Compounds and methods for treating disorders related to glucose metabolism: The present invention relates to compounds and pharmaceutically acceptable salts thereof, and compositions comprising the same, that are useful in modulating lyn kinase activity, treating obesity, type II diabetes, metabolic syndrome, and in reducing blood glucose level, weight gain, or fat depot level, or treating a disease or condition associated... Agent: Pepper Hamilton LLP

20100004274 - Stable pharmaceutical compositions comprising a pyrimidine-sulfamide: Stable pharmaceutical compositions include the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof:... Agent: Hoxie & Associates LLC

20100004275 - Agent for suppressing development of tolerance to narcotic analgesics: A medicament for suppressing development of tolerance to analgesic effect induced by administration of a narcotic analgesic such as morphine, which comprises an antagonist of the vasopressin receptor 1b as an active ingredient.... Agent: Greenblum & Bernstein, P.L.C

20100004276 - Vitamin receptor binding drug delivery conjugates: The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety includes vitamins, and vitamin receptor binding analogs and derivatives thereof, and the drug includes... Agent: Barnes & Thornburg LLP

20100004277 - Compounds and methods for modulating protein trafficking: Disclosed are compositions and methods for modulating protein trafficking and treating or preventing disorders characterized by impaired protein trafficking. Also disclosed are methods for identification of compounds that rescue protein trafficking defects and methods of enhancing protein production.... Agent: Fish & Richardson P.C.

20100004278 - Dextromethorphan hydrochloride: The present invention provides pharmaceutical compositions comprising dextromethorphan hydrochloride.... Agent: Reed Smith LLP

20100004279 - Solid medicinal preparation containing mannitol or lactose: e

20100004280 - Substituted imidazoles as bombesin receptor subtype-3 modulators: Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.... Agent: Merck And Co., Inc

20100004281 - Viral inhibitors: The present invention relates to imidazo[4,5-c]pyridine compounds and pharmaceutical compositions for the treatment or prevention of viral infections, wherein the imidazo[4,5-c]pyridine compounds have the formula:... Agent: Clark & Elbing LLP

20100004282 - Treatment of antibiotic-resistant bacteria infection: This invention relates to a method of treating infection by methicillin-nonsusceptibale bacteria, vancomycin-nonsusceptibale bacteria, penicillin-nonsusceptibale bacteria, clarithromycin-nonsusceptibale bacteria, or metronidazole-nonsusceptibale bacteria by administering to a subject in need thereof an effective amount of a compound of the following formula:... Agent: Occhiuti Rohlicek & Tsao, LLP

20100004283 - 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions: The present patent application is directed to 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonic acid salt (formula I), its synthesis and use in the manufacture of a medicament for the treatment and/or prevention of a serotonine and/or norepinephrine mediated disease or condition. The present invention is also directed to pharmaceutical compositions comprising the same.... Agent: Intellectual Property / Technology Law

20100004284 - Novel heterocyclic compounds as positive allosteric modulators of metabotropic glutamate receptors: The present invention relates to new compounds which are Heterocyclic derivatives of formula (I) wherein A, B, P, X, Y, Q, W, R1 and R2 are defined in the description. Invention compounds are useful for treating central or peripheral nervous system disorders and other disorders which are affected by the... Agent: Edwards Angell Palmer & Dodge LLP

20100004285 - Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-yl]-1-piperidinyl]ethyl]-alpha alpha-dimethyl-benzeneacetic acid: Crystalline form 1 4-[2-[4-[1 -(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]-ethyl]-αα-dimethyl-benzeneacetic acid of formula (I) is described, procedures for its preparation, pharmaceutical formulae containing crystalline form 1 and the use of crystalline form 1 to treat allergic reactions and pathological processes mediated by histamine in mammals such as man.... Agent: Ostrolenk Faber Gerb & Soffen

20100004286 - Novel isoindolinone derivatives having inhibitory activity against t-type calcium channel and method for preparation thereof: y

20100004287 - Cyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase: Cyclic amine derivatives of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity;... Agent: Merck And Co., Inc

20100004288 - Fungicidal amides: c

20100004289 - Substituted butyrophenone derivatives: The present invention relates to a central nervous system-acting substituted butyrophenones. These compounds are useful in antipsychotic medications for psychosis, including schizophrenia, but especially for L-DOPA-induced psychosis, while having low or no risk of eliciting extrapyramidal side effects, hyperprolactinemia or tardive dyskinesia.... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20100004290 - Insecticidal n-substituted (heteroaryl)cycloalkyl sulfoximines: N-Substituted (heteroaryl)cycloalkyl sulfoximines are effective at controlling insects.... Agent: Dow Agrosciences LLC

20100004291 - Liquid dosage forms of non-enterically coated acid-labile drugs: Provided herein are formulations of acid labile drugs, such as proton pump inhibitors (PPI). The formulations comprise a PPI and a liquid vehicle typically having a pH greater than 6.5 and a viscosity sufficient to maintain a uniform suspension of the PPI for 15 minutes.... Agent: Steven F. Weinstock Abbott Laboratories

20100004292 - Iminooxazolidine derivatives and their use: The present application relates to novel iminooxazolidine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular thromboembolic disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100004293 - Crystalline forms of aryl-substituted pyrazole-amide compounds: The present invention provides novel crystals of Compound I, pharmaceutical compositions containing such novel form and a method of treating p38 kinase associated conditions, including rheumatoid arthritis, using such novel form.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100004294 - Stable lozenge compositions providing rapid release of nicotine: Compositions comprising nicotine, which compositions provide a rapid release of nicotine. Nicotine is present in the form of a nicotine-cellulose combination. The compositions are designed for administration to the oral cavity where the nicotine is rapidly released from the composition and available for absorption through the oral mucosa. The compositions... Agent: Edwards Angell Palmer & Dodge LLP

20100004295 - Hydrazine amide derivative: m

20100004296 - Waterborne topical compositions for the delivery of azelaic acid: A waterborne topical composition is designed specifically to address the treatment of acne vulgaris, rosacea, seborrheic dermatitis and other skin conditions. The composition contains effective amounts of essential components azelaic acid, niacinamide, and glycerin to create a rapidly penetrating and non-irritating compound.... Agent: Blynn L. Shideler The Blk Law Group

20100004297 - Novel hexafluoroisopropanol derivatives: w

20100004298 - P-38 inhibitors: Provided are 5-membered heterocycle-based p38 kinase, including p38α and p38β kinase, inhibitors. Pharmaceutical compositions containing the compounds are also provided. Methods of use of the compounds and compositions are also provided, including methods of treatment, prevention, or amelioration of one or more symptoms of p38 kinase mediated diseases and disorders,... Agent: Novartis Institutes For Biomedical Research, Inc.

20100004299 - Imidazo[2,1-b]thiazoles and their use as pharmaceuticals: in which R, R1 to R3 and n have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100004300 - Heterocyclic derivatives as modulators of ion channels: The present invention relates to heterocyclic derivatives useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Inc.

20100004301 - Benzoxazoles useful in the treatment of inflammation: wherein Y, W1 to W4, Z1 to Z4 and R have meanings given in the description, and pharmaceutically-acceptable salts thereof, for the manufacture of a medicament for the treatment of a disease in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and... Agent: Morgan Lewis & Bockius LLP

20100004302 - Methods for treating degenerative diseases/injuries: Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100004303 - Treatment of endocrine dysfunction using iron chelators: The invention relates to the use of an iron chelator for the treatment or prevention of pathologies due to iron loading, e.g. related to a dysfunction, in particular a reduction or inhibition, of the secretory function of cells from endocrine glands, in the human or animal body.... Agent: Novartis Corporate Intellectual Property

20100004304 - Methods and compositions for the treatment of malignant melanoma, breast, prostate, colon, papillary thyroid and pancreatic cancer: It is now recognized that chronic inflammation is an important risk factor for the development of cancer. The proinflammatory cytokine IL-6 is implicated in cancer because it is important for the activation of STAT, a key regulator of cancer growth, survival, metastasis, immune evasion and angiogenesis. Increased IL-6 and Stat-3... Agent: Reed Smith LLP

20100004305 - Naphthylmethylimidizoles as therapeutic agents: Disclosed herein is a compound of the formula (a): Therapeutic methods, compositions and medicaments related thereto are also disclosed.... Agent: Allergan, Inc.

20100004306 - Pigf-1 assay and kits and components thereof: The present disclosure relates to, among other things, methods for determining whether a subject receiving treatment with a drug has obtained an efficacious blood level of the drug. Moreover, the present disclosure also relates to methods of determining whether a subject predisposed to or suffering from a disease will benefit... Agent: Paul D. Yasger Abbott Laboratories

20100004307 - Process for the sulfinylation of a pyrazole derivative: The present invention relates to a process for the sulfinylation of a pyrazole derivative, characterized in that 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazole-3-carbonitrile (II) is reacted with a sulfinylating agent S in the presence of at least one amine acid complex wherein the amine(s) are selected from secondary and/or tertiary amines and the acid(s) are... Agent: Brinks, Hofer, Gilson & Lione

20100004308 - Benzofuran-3-yl(indol-3-yl) maleimides as potent gsk3 inhibitors: Pharmaceutically compositions and medicaments containing a compound of the invention are provided. The invention provides methods of treatment of protein kinase-related disease, disorders or conditions. The invention provides methods of treatment of GSK-3-related diseases, disorders or conditions. More specifically, methods of treatment of bipolar disorder, including mania, schizophrenia, stroke, epilepsy,... Agent: Greenlee Winner And Sullivan P C

20100004309 - Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging: The present invention relates to dietary compositions comprising reduced level of methionine, tryptophan, all amino acids, or protein, dietary compositions comprising glycerol as a substitute for monosaccharides, disaccharides, and polysaccharides, and hypocaloric or calorie free diets with reduced level of energy, carbohydrates, or protein. Also disclosed are methods of using... Agent: Hogan & Hartson L.L.P.

20100004310 - Pharmaceutical formulations for the treatment of alzheimer's disease: The present invention relate to pharmaceutical formulations that include a CPHPC component and a delivery agent compound.... Agent: Emisphere Technologies, Inc

20100004311 - Excitatory amino acid inhibitors for treating sensitive skins: Sensitive human skin/scalp/mucous membrane conditions, for example skin irritation and/or dry patches and/or erythemas and/or dysaesthesic sensations and/or sensations of heating and/or pruritus, are therapeutically treated by topically applying thereto an effective condition-alleviating amount of at least one inhibitor of at least one excitatory amino acid.... Agent: Buchanan, Ingersoll & Rooney PC

20100004312 - Fused cyclic compounds: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof. The compound or a salt thereof or a prodrug thereof has a GPR40 receptor function modulating action and is useful as an insulin secretagogue or an... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100004324 - Antimicrobial compounds and methods of use thereof: In one aspect, the invention relates to compounds and methods useful for activating heme sensor systems; for decreasing virulence of bacteria, for example, Staphylococcus aureus; pharmaceutical compositions comprising the compounds; and methods of treating microbial-related disorders. This abstract is intended as a scanning tool for purposes of searching in the... Agent: Ballard Spahr LLP

20100004325 - Use of baicalein as prolyl hydroxylase 2 inhibitor: The present invention is to prove a new molecular and cellular effect of baicalein, which is selected by a prolyl hydroxylase 2 (PHD2) inhibitor screening method using a compound library. Specifically, the present invention quantitatively analyzed the inhibitory effect of the baicalein against PHD2, confirmed the inhibitory effect against FIH... Agent: Sughrue Mion, PLLC

20100004326 - Metabolites of selective androgen receptor modulators and methods of use thereof: This invention provides metabolites of SARM compounds including inter alia glucuronidated metabolites and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, muscle wasting disease and/or disorder, a bone related disease and/or disorder, metabolic syndrome, diabetes and associated diseases, and others.... Agent: Pearl Cohen Zedek Latzer, LLP

20100004327 - Novel use of ansamycin antibiotics and method of screening novel angiogenesis inhibitor: The present invention provides novel angiogenesis inhibitors effective, safe and highly practical for inhibition of angiogenesis in various diseases, and a method for screening the same. The active ingredients of the angiogenesis inhibitors of the present invention comprise ansamycin antibiotics such as rifampicin, rifamycin SV and 3-formyl rifamycin, which have... Agent: Locke Lord Bissell & Liddell LLP Attn:IPDocketing

20100004328 - Compound, alpha1 adrenergic receptor antagonistic agent, and composition: A novel compound, a novel α1 adrenergic receptor antagonistic agent, and a novel composition are provided which are capable of exerting a therapeutic effect on treatment of hypertension as well as treatment of prostatic hypertrophy and the like. The compound is represented by the following formula (1):... Agent: Drinker Biddle & Reath (dc)

20100004329 - Alcohol metabolism enhancer and alcoholic beverage: An alcohol metabolism enhancer is made from safe plant extracts and an alcoholic beverage and causes a reduced sick feeling and hangover from drinking alcohol without causing hemolysis using safe materials derived from plants. The alcohol metabolism enhancer and the alcoholic beverage include proanthocyanidins, such as pine bark extracts.... Agent: Okada C/o Keating & Bennett, LLP

20100004330 - Anti-oxidative content material used in drink and food manufacturing method: The present invention relates to a food or drink which provides anti-ageing, anti-cancer, anti-heart disease, vision-enhancing effects of antioxidant substances. This method contains the following anti-oxidative supplements, and is added in food or drink in certain ratio. The method is as follows: adding into a fixed quantity of food or... Agent: Sinorica, LLC

20100004331 - Antagonists of prostaglandin d2 receptors: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100004332 - Levodopa prodrugs, and compositions and uses thereof: Prodrugs of levodopa, methods of making prodrugs of levodopa, methods of using prodrugs of levodopa, and compositions of prodrugs of levodopa are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100004333 - Compositions and methods for treating cardiovascular disorders: The present invention relates to compounds and methods for the treatment of cardiovascular diseases and disorders. Compounds according to the present invention may comprise an optionally substituted phenyl ring linked to an aromatic or alkyl group by a spacer, wherein the spacer comprises two groups selected from selenium, sulfur, S(O)... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100004334 - Nutritional compositions containing punicalagins: The present invention relates generally to a nutritional composition comprising punicalagins.... Agent: Waddey & Patterson, P.C.

20100004335 - Oral preparation for preventing or improving skin dryness: An oral preparation for the prophylaxis or improvement of dry skin accompanied by atopic dermatitis, xeroderma, chapped hand, chapped skin and the like is provided. The present invention can provide an oral preparation for the prophylaxis or improvement of dry skin, which comprises citrulline or a salt thereof as an... Agent: Leydig Voit & Mayer, Ltd

20100004336 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20100004337 - Electrostatically charged multi-acting nasal application, product, and method: A product to reduce and method of reducing the risk of inhalation of harmful substances by applying a formulation composition to a substrate or the skin in close proximity of one or more nostrils. This formulation, when applied creates an electrostatic field having a charge. The electrostatic field attracts airborne... Agent: Stanley H. Kremen

20100004338 - Topical gel composition comprising azelaic acid: The present invention discloses a novel azelaic acid topical pharmaceutical gel composition that does not contain lecithin and a process for its preparation.... Agent: Glenmark Pharmaceuticals Inc Usa

20100004339 - Somatostatin receptor 1 and/or 4 selective agonists and antagonists: The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein R1, R2, R3, A, B, D, Q, k and n are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes SSTR1 and/or SSTR4... Agent: Oliff & Berridge, PLC

20100004340 - Naphthyl(ethyl) acetamides: This disclosure relates to novel melatonin analogues or naphthyl(ethyl)acetamides, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a dual... Agent: Fish & Richardson P.C.

20100004341 - C-(2-phenyl-cyclohexyl)-methylamine compounds for therapy of fibromyalgia: Pharmaceutical formulations of [2-(3-methoxyphenyl)-cyclohexylmethyl]-dimethylamine and the metabolites thereof suitable for treating fibromyalgia or chronic pain due to fibromyalgia, and related methods of treating fibromyalgia or chronic pain due to fibromyalgia are described.... Agent: Crowell & Moring LLP Intellectual Property Group

20100004342 - Lfa-1 inhibitors and use thereof: The present invention provides an LFA-1 inhibitor comprising at least one member selected from the group consisting of polyamines represented by general formula (I) and pharmaceutical acceptable salts thereof: NH2—(CH2)m1-(NH)p1-(CH2)m2-(NH)p2-(CH2)m3-(NH)p3-(CH2)m4-(NH)p4-(Cl2)m5-NH2 (1), wherein at least two of m1 to m5 exceed 0, each of m1 to m5 is independently an integer... Agent: Steptoe & Johnson LLP

20100004343 - Disinfectant and sanitizer for cosmetics and cosmetic tools: The present invention provides a disinfectant and sanitizer composition for application to cosmetics and cosmetic tools, which composition comprises: ethyl alcohol; and one or more conditioners selected from the group consisting of isopropyl palmitate, caprylic triglyceride, capric triglyceride, isopropyl myristate, and alkylbenzoate.... Agent: Riches, Mckenzie & Herbert, LLP

20100004344 - Anti-oxidant dietary composition containing fruits and vegetables, method for preparing the same and use of the composition: The invention relates to a dietary composition containing at least polyphenols and cartenoids. It is advantageously obtained from a mixture of vegetal species containing at least red and/or white grapes (Vitis vinfera), blueberries (Vaccinium myrtillus), tomatoes (Solanum lycopersicum), carrots (Daucus carrota), and green tea (Camelia sinensis). The invention also relates... Agent: The Nath Law Group

20100004345 - High gloss non-stick film coating compositions: The invention generally relates to film coating compositions and processes for film coating pharmaceutical, nutraceutical, and food products. One film coating composition includes a shellac in an aqueous solution; a hydrolyzed starch product; an optional plasticizer; and a coating resin. The coating resin may be one or more of polyvinyl... Agent: William D. Hare

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141113: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 3.82956 seconds

PATENT INFO